Lactam-derivatives as SOS1 inhibitors

Lactam compounds targeting the RAS-SOS1 interaction provide a novel solution to address the limitations of current therapies for RAS-dependent tumors, effectively inhibiting RAS-SOS1 and offering therapeutic potential for hyperproliferative disorders like cancer.

WO2026234145A1PCT designated stage Publication Date: 2026-11-12BAYER AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063192
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies for RAS-dependent tumors are limited in efficacy, and there is a need for effective inhibitors that target RAS directly, particularly for hyperproliferative and genetic disorders such as cancer, as existing approaches have shown limited success in clinical trials.

Method used

Development of lactam compounds that inhibit the RAS-SOS1 interaction, represented by compounds of general formula (I), which effectively target the RAS-SOS1 interaction, providing a novel approach to treat or prevent hyperproliferative disorders.

Benefits of technology

The lactam compounds demonstrate surprising effectiveness in inhibiting the RAS-SOS1 interaction, offering potential therapeutic benefits for hyperproliferative and genetic disorders, including cancer, with data supporting their biological activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026063192_12112026_PF_FP_ABST
    Figure EP2026063192_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention includes lactame compounds of general formula (I) in which R1, R2, R3, R4a, R4b, R5, R6, R7a, R7b, R8a, R8b, R9, X and Y are as defined herein, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative or genetic disorders, as a sole agent or in combination with other active ingredients.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] LACTAM-DERIVATIVES AS S0S1 INHIBITORS

[0002] The present invention includes lactam compounds of general formula (I) as described and defined herein, pharmaceutical compositions comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and genetic disorders, as a sole agent or in combination with other active ingredients.

[0003] BACKGROUND

[0004] RAS proteins play an important role in human cancer. Mutations in RAS proteins can be found in 20-30% of all human tumors and are recognized as tumorigenic drivers especially in lung, colorectal and pancreatic cancers. Three human Ras genes are known to encode four different RAS proteins of 21 kDa size: H-RAS, N-RAS, and two splice variants of K-RAS, namely K-RAS 4A and K-RAS-4B. All RAS isoforms are highly conserved within the GTP-binding domain and differ mainly in the hypervariable C-terminal region. The C-termini of the different Ras-isoforms are posttranslationally modified by lipidation (farnesylation, palmitoylation) to facilitate membrane anchorage. The localization of RAS-proteins at the cytoplasmic membrane provides vicinity to transmembrane growth receptors and has been shown to be essential for transmitting growth signals from extracellular growth factor binding to intracellular downstream pathways. A variety of upstream signals may activate RAS proteins depending on the cellular context, such as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), nerve growth factor receptor (NGFR) and others. Activated RAS can signal through various downstream pathways, e.g. the RAF-MEK-ERK or the PI3K-PDK1-AKT pathways.

[0005] On the molecular level, RAS proteins function as molecular switches. By binding GTP and GDP they exist in an active (GTP-bound) and inactive (GDP-bound) state in the cell respectively. Active GTP-loaded RAS recruits other proteins by binding of their cognate RAS-binding domains (RBDs) resulting in activation of the effector protein followed by downstream signaling events of diverse functions, e.g. cytoskeletal rearrangements, cell proliferation and differentiation. The activity status of RAS is tightly regulated by guanine nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). GEFs function as activators of RAS by promoting the nucleotide exchange from GDP to GTP. GAPs deactivate RAS-GTP by catalyzing the hydrolysis of the bound GTP to GDP. In a cancer cell, point mutations, typically within the GTP-binding region at codon 12, eliminate the ability of RAS to efficiently hydrolyse bound GTP, even in the presence of a GAP.Therefore, cancer cells comprise increased levels of active mutated RAS-GTP, which is thought to be a key factor for driving cancer cell proliferation.

[0006] Three main families of RAS-specific GEFs have been identified so far. There are two son of sevenless (SOS) proteins, SOS1 and SOS2, four different isoforms of RAS guanine nucleotide releasing proteins (RAS-GRP1-4) and two RAS guanine nucleotide releasing factors (RAS-GRF1 and 2). The SOS proteins are ubiquitously expressed and are recruited to sites of activated growth factors. RAS-GRFs are expressed mainly in the nervous system, where they are involved in calcium-dependent activation of RAS. In contrast, RAS GRP proteins are expressed in hematopoietic cells and act in concert with non-receptor tyrosine kinases. In the context of cancer, mainly SOS proteins have been found to be involved.

[0007] Targeting RAS for cancer therapy has been a dream since the 1990s. Due to the compact nature, the high affinity towards GDP and GTP in combination with high intracellular GTP concentrations, the RAS protein itself has long been considered been considered to be undruggable, i.e. the chance to identify small chemical molecules that would bind to and inhibit active RAS was rated extremely low. Alternative approaches have been undertaken to reduce RAS signaling, e.g. by addressing more promising drug targets such as enzymes involved in the posttranslational modification of RAS proteins, especially farnesyltransferase and geranylgeranyltransferase. Inhibitors of farnesyltransferase (FTIs) were identified and developed with promising antitumor effects in preclinical models. Unexpectedly, in clinical trials these inhibitors have been of limited efficacy. Targeting upstream and downstream kinases involved in RAS signaling pathways has been more successful. Several drugs are and have been in clinical trials that inhibit different kinases, e.g. EGFR, RAF, MEK, AKT, and PI3K. Marketed cancer drugs are available that inhibit RAF, EGFR or MEK.

[0008] Nevertheless, there is still a large unmet need for the treatment of RAS-dependent tumors that are resistant against current therapies. Many research groups have been active to identify small molecules that target RAS directly. One group of inhibitors comprises small molecules that inhibit the interaction of RAS with its effectors RAF or PI3K. Another group of compounds acts as covalent inhibitors of a specific cysteine mutant form of K-RAS (glycine to cysteine point mutation G12C). The specific targeting of the K-RAS-G12C mutant might have the benefit of reduced side effects, as the wildtype K-RAS proteins are not affected. Furthermore, several reports show small molecules and peptides that interrupt the GEF assisted activation of RAS. There seem to be several different binding sites possible that result in this mode of action. Inhibitors may bind to RAS or to the GEF in an allosteric or orthosteric fashion. All these approaches of direct RAS-targeting are inpreclinical research or early development stage. Stabilized peptides have been shown to be active in the nanomolar range. Their usefulness as drugs in a clinical setting has to be awaited.

[0009] WO2022 / 219035 (Bayer) describes compounds having phosphinoxides or phosphinothioxide attached to the bicyclic core, which have the following formula

[0010]

[0011] as SOS1-inhibitors.

[0012] WO 2023 / 205701 (Kumquat Biosciences) discloses macrocyclic SOS1 inhibitors having the general formula

[0013]

[0014] The recently filed international patent application PCT / EP2025 / 057645 (Bayer) also describes macrocyclic SOS1 inhibitors of the general formula

[0015]

[0016] SUMMARY

[0017] However, the state of the art does not describe the first aspect of the present invention that includes compounds of general formula (I)

[0018]

[0019] in which,

[0020] X represents N or C-R10, in which

[0021] R10represents -H, -F, -Cl, -Br,

[0022]

[0023] optionally substituted with

[0024] 1 or 2 -F; C1-3 alkyl optionally substituted with 1 to 3 -F; C1-3 alkoxy, -OCHF2, -OCF3, -OCH2CHF2, or -OCH2CF3; and

[0025] Y represents C-H, N, or C-F; and

[0026] R1represents

[0027] -H; or

[0028] -F, -Cl, -Br, or -I; or

[0029] C1-4 alkyl optionally substituted with 1 to 6 -F, or 1 to 2 -OH; or

[0030] C1-6 alkoxy optionally substituted with 1 to 6 -F, or 1 to 2 -OCH3; or

[0031] -OCD3; or

[0032] -OR11a, in which

[0033] R11arepresents C3-7 cycloalkyl, C3-6 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the followingsubstituents -F, -CH3, -OCH3, or mixtures thereof; or C3-5 heteroaryl optionally substituted with 1 or 2 of the following

[0034] substituents -F,

[0035]

[0036] , C1-3 alkyl, or mixtures thereof, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or

[0037] -O-CH2-R11b, in which

[0038] R11brepresents C3-7 cycloalkyl, or C3-6 heterocyclyl, both optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or

[0039] -P(=O)R12aR12b, -S(=O)2R12a, in which

[0040] R12aand R12bindependently from each other represent C1-3 alkyl,

[0041]

[0042] which R12aand R12bin -P(=O)R12aR12btogether with the phosphor atom they are attached to form a 5 or 6 membered ring which can be saturated or unsaturated; or

[0043]

[0044] each R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CI, -CH2I, or -CH2OH; and

[0045] W represents O, or NR14, in which

[0046] R14represents -H, or C1-3 alkyl optionally substituted with 1 to 3 -F; or

[0047]

[0048]

[0049] , in which Z represents C(=O), or S(=O)2; and

[0050] R15a, R15b, R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15a, R15b, R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15a, R15b, R15c, R15d, R15eand R15frepresent -H; or

[0051]

[0052] orin which

[0053] T represents C=O, or S(=O)2; and

[0054] R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and

[0055] R17represents

[0056]

[0057] -CH2-CF3, -CH2-CHF2, -C(=O)O-C(CH3)3; or

[0058] -NR18aR18b, in which

[0059] R18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3, or -C(=O)O-C(CH3)3; or

[0060]

[0061] in which

[0062] R19represents -H, -CH3, -CH2-CHF2, -CH2-CF3, or -C(=O)O-C(CH3)3; or

[0063]

[0064]

[0065] independently from each other represent -H, -CH3, -CHF2, or -CF3; and

[0066] R2represents -H, -F, -Cl, -CD3, -CHD2, C1-4 alkyl optionally substituted with 1 to 3

[0067]

[0068] R3represents Ci-3alkyl optionally substituted with 1 or 2 -F; -C=CH, or

[0069]

[0070] and

[0071] p4a p4b independently from each other represent -H, or -F; and

[0072] R5represents -H, -F, -Cl, -Br, or -CH3; and

[0073] R6represents -H, -F, -Cl, -Br, Ci-3alkyl optionally substituted with 1 to 3

[0074] -F;

[0075]

[0076] optionally substituted with 1 to 2 -F; -OCHF2, -OCF3, -C=CH, or -C=C-CH3; and

[0077] R7a, R7bindependently from each other represent -H, -F, or -CH3; and / orR8a, R8brepresent independently from each other -H, or -CH3; and / or

[0078] R7aand R8arepresent both -H and R7band R8btogether form a double bond; and

[0079] R9represents -H, C1-4 alkyl optionally substituted with 1 -OH, -CD3, -CHF2,

[0080] -CF3, -CH2-CHF2, or -CH2-CF3;

[0081] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0082] It has now been found, and this partially constitutes the basis of the present invention, that the compounds of the present invention have surprising and advantageous properties.

[0083] In particular, the compounds of the present invention have surprisingly been found to effectively inhibit the RAS-SOS1 interaction for which data are given in biological experimental section and may therefore be used for the treatment or prophylaxis of hyperproliferative or genetic disorders, such as cancer, for example.

[0084] DETAILED DESCRIPTION

[0085] DEFINITIONS

[0086] It will be understood that the description of compounds herein is limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be “substituted” by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding with regard to valencies, etc. and to give compounds which are not inherently unstable in a chemical and a biological environment. For example, any carbon atom will be bonded to two, three, or four other atoms, consistent with the four valence electrons of carbon. Combinations of substituents and / or variables are permissible.

[0087] “Not being inherently unstable in a chemical and a biological environment" means that the compounds maintain their structural integrity under typical conditions encountered during synthesis, purification, and in vivo applications. This includes stability in common solvents and buffers used in these processes. However, this definition excludes extreme conditions such as temperatures above 200 °C, exposure to highly reactive chemical reagents, or metabolic enzymes in biological systems. Essentially, the compounds should remain stable under normal laboratory and physiological conditions.The term “optionally substituted” means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon, nitrogen, oxygen, sulfur or phosphor atom. Commonly, it is possible for the number of optional substituents, when present, to be 1, 2, 3, 4, 5, or 6 in particular 1, 2 or 3.

[0088] As used herein, the term “one or more”, e.g. in the definition of the substituents of the compounds of general formula (I) of the present invention, means “1, 2, 3, 4 or 5, particularly 1, 2, 3 or 4, more particularly 1, 2 or 3, even more particularly 1 or 2”.

[0089] The term “Ci-Ce”, as used throughout this text, e.g., in the context of the definition of “Ci-Ce-alkyl-”, “Ci-Ce-haloalkyl-”, “Ci-Ce-alkoxy-” or “Ci-Ce-haloalkoxy-” is to be understood as meaning an alkyl group having a whole number of carbon atoms from 1 to 6, i.e., 1, 2, 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term “Ci-Ce” is to be interpreted as disclosing any sub-range comprised therein, e.g. Ci-Ce, C2-C5, C3-C4, Ci-02, C1-C3, C1-C4, C1-C5, Ci-Ce; preferably C1-C2, C1-C3, C1-C4, C1-C5, Ci-Ce; more preferably C1-C4; in the case of “Ci-Ce-haloalkyl-” or “Ci-Ce-haloalkoxy-” even more particularly C1-C2.

[0090] Similarly, as used herein, the term “C2-C6”, as used throughout this text, e.g., in the context of the definitions of “C2-C6-alkenyl-” and “C2-C6-alkynyl-”, is to be understood as meaning an alkenyl- group or an alkynyl group having a whole number of carbon atoms from 2 to 6, i.e., 2, 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term “C2-C6” is to be interpreted as disclosing any sub-range comprised therein, e.g., C2-C6, C3-C5, C3-C4, C2-C3, C2-C4, C2-C5; particularly C2-C3.

[0091] Further, as used herein, the term “C3-C7”, as used throughout this text, e.g., in the context of the definition of “Cs-Cy-cycloalkyl-”, is to be understood as meaning a cycloalkyl- group having a whole number of carbon atoms of 3 to 7, i.e., 3, 4, 5, 6 or 7 carbon atoms. It is to be understood further that said term “C3-C7” is to be interpreted as disclosing any subrange comprised therein, e.g., C3-C6, C4-C5, C3-C5, C3-C4, C4-C6, C5-C7; particularly C3-C6.

[0092] Further, as used herein, the term “Cs-Ce”, as used throughout this text, e.g., in the context of the definition of “C3-6 heterocyclyl-”, is to be understood as meaning a heterocyclyl-group having a whole number of carbon atoms of 3 to 7, i.e., 3, 4, 5, or 6 carbon atoms and one or more hetero atom. It is to be understood further that said term “Cs-Ce” is to be interpreted as disclosing any sub-range comprised therein, e.g., C3-C6, C4-C5, C3-C5, C3-C4, C4-C6, Cs-Ce; particularly C3-C6.As used herein, the term “leaving group” means an atom or a group of atoms that is displaced in a chemical reaction as stable species taking with it the bonding electrons. In particular, such a leaving group is selected from the group comprising: halide, in particular a chloro-, bromo- or a iodo group, a (methylsulfonyl)oxy-, [(4-methylphenyl)sulfonyl] oxy-, [(trifluoromethyl)sulfonyl]oxy-, [(nonafluorobutyl)sulfonyl]oxy-, [(4-bromophenyl)sulfonyl]oxy-, [(4-nitrophenyl)sulfonyl]oxy-, [(2-nitrophenyl)sulfonyl]oxy-, [(4-isopropylphenyl)sulfonyl]oxy-, [(2,4,6-triisopropylphenyl)sulfonyl]oxy-, [(2,4,6-trimethylphenyl)sulfonyl]oxy-, [(4-tert-butylphenyl)sulfonyl]oxy-, (phenylsulfonyl)oxy- and a [(4-methoxyphenyl)sulfonyl]oxy group.

[0093] The terms “oxo”, “an oxo group” or “an oxo substituent” mean an oxygen atom, which is bound to a carbon atom, to a sulfur atom or to a phosphor atom via a double bond. For example, but without limitation, one oxo group can be attached to a carbon atom, resulting in the formation of a carbonyl group C(=O), or two oxo groups can be attached to one sulfur atom, resulting in the formation of a sulfonyl group –S(=O)2.

[0094] As used herein, the term “protective group” is a protective group attached to an oxygen or nitrogen atom in intermediates used for the preparation of compounds of the general formula (I). Such groups are introduced e.g., by chemical modification of the respective hydroxy or amino group in order to obtain chemoselectivity in a subsequent chemical reaction. Protective groups for hydroxy and amino groups are descibed for example in T. W. Greene and P. G. M. Wuts in Protective Groups in Organic Synthesis, 4thedition, Wiley 2006; more specifically, protective groups for amino groups can be selected from substituted sulfonyl groups, such as a mesyl-, tosyl- or a phenylsulfonyl group, acyl groups such as a benzoyl-, acetyl- or a tetrahydropyranoyl group, or carbamate based groups, such as a tert-butoxycarbonyl group (Boc). Protective groups for hydroxy groups can be selected from acyl groups such as a benzoyl-, acetyl, pivaloyl- or a tetrahydropyranoyl group, or can include silicon, as in e.g., a tert-butyldimethylsilyl-, tert-butyldiphenylsilyl-, triethylsilyl- or a triisopropylsilyl group.

[0095] By "subject" is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, rodent, orfeline.

[0096] Should a composite substituent be composed of more than one parts, e.g. (Ci-C4-alkoxy)-(Ci-C4-alkyl)-, it is possible for the position of a given part to be at any suitable position of said composite substituent, i.e. the Ci-C4-alkoxy part can be attached to any carbon atom of the Ci-C4-alkyl part of said (Ci-C4-alkoxy)-(Ci-C4-alkyl)- group. A hyphen at the beginning or at the end of such a composite substituent indicates the point of attachment of said composite substituent to the rest of the molecule. Should a ring,comprising carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulfur atoms for example, be substituted with a substituent, it is possible for said substituent to be bound at any suitable position of said ring, be it bound to a suitable carbon atom and / or to a suitable heteroatom.

[0097] The term “comprising” when used in the specification includes “consisting of” but does not have to be the scope indicated by “consisting of”.

[0098] If within the present text any item is referred to as “as mentioned herein”, it means that it may be mentioned anywhere in the present text.

[0099] If within the present text any item is referred to as “supra" within the description it indicates any of the respective disclosures made within the specification in any of the preceding pages, or above on the same page.

[0100] If within the present text any item is referred to as “infra" within the description it indicates any of the respective disclosures made within the specification in any of the subsequent pages, or below on the same page.

[0101] The terms as mentioned in the present text have the following meanings:

[0102] The term “halogen atom” means a fluorine, chlorine, bromine or iodine atom, particularly a fluorine, chlorine or bromine atom.

[0103] The term “Ci-Ce-alkyl-” means a linear or branched, saturated hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms, such as, for example, a methyl-, ethyl-, propyl-, / so-propyl-, n-butyl-, / so-butyl-, sec-butyl-, tert-butyl-, n-pentyl-, / so-pentyl-, 2-methylbutyl-, 1 -methylbutyl-, 1 -ethylpropyl-, 1,2-dimethylpropyl-, neo-pentyl-, 1, 1-dimethylpropyl-, n-hexyl-, 4-methylpentyl-, 3-methylpentyl-, 2-methylpentyl-, 1 -methylpentyl-, 2-ethylbutyl-, 1 -ethylbutyl-, 3,3-dimethylbutyl-, 2,2-dimethylbutyl-, 1, 1-dimethylbutyl-, 2,3-dimethylbutyl-, 1,3-dimethylbutyl-, or a 1,2-dimethylbutyl-, or an isomer thereof. Preferably, said group has 1, 2, 3, or 4 carbon atoms (“Ci-C4-alkyl-”), e.g., a methyl-, ethyl-, n-propyl-, / so-propyl-, n-butyl-, / so-butyl-, sec-butyl-, or tert-butyl-, or an isomer thereof. More preferably, said group 1, 2 or 3 carbon atoms (“Ci-Cs-alkyl-”), e.g., a methyl-, ethyl-, n-propyl- or a / so-propyl group, or 1 or 2 carbon atoms (“Ci-C2-alkyl-”), e.g., a methyl group or an ethyl group.

[0104] The same definitions can be applied should the alkyl group be placed within a chain as a bivalent “Ci-Ce-alkylene” moiety. All names as mentioned above then will bear an “ene” added to the end, thus e.g., a “pentyl” becomes a bivalent “pentylene” group. In addition, the term “Ci-Ce-heteroalkyl” refers to a Ci-Ce-alkyl group in which one or more of thecarbon atoms have been replaced with an atom selected from N, O, or S, which are substituted as mentioned herein to satisfy atom valency requirements.

[0105] The term “Ci-Ce-haloalkyl” means a linear or branched, saturated, monovalent hydrocarbon group in which the term “Ci-Ce-alkyl” is as defined supra, and in which one or more of the hydrogen atoms are replaced, identically or differently, with a halogen atom. Particularly, said halogen atom is a fluorine atom. Said Ci-Ce-haloalkyl group is, for example, a fluoromethyl-, difluoromethyl-, trifluoromethyl-, 2-fluoroethyl-, 2.2-difluoroethyl-, 2,2,2-trifluoroethyl-, pentafluoroethyl-, 3,3,3-trifluoropropyl- or a 1.3-difluoropropan-2-yl group.

[0106] The term “Ci-Ce-alkoxy” means a linear or branched, saturated, monovalent group of formula (Ci-Ce-alkyl)-O-, in which the term “Ci-Ce-alkyl” is as defined supra, such as, for example, a methoxy-, ethoxy-, n-propoxy-, isopropoxy-, n-butoxy-, sec-butoxy-, isobutoxy-, tert- butoxy-, pentyloxy-, isopentyloxy or a n-hexyloxy group, or an isomer thereof.

[0107] The term “Cs-Cy-cycloalkyl” means a saturated, monovalent, mono- or bicyclic hydrocarbon ring which contains 3, 4, 5, 6, or 7 carbon atoms (“Cs-Cy-cycloalkyl”). Said Cs-Cycycloalkyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclopropyl-, cyclobutyl-, cyclopentyl-, cyclohexyl-, or a cycloheptyl- group.

[0108] The term “aryl” means a phenyl-, naphthyl-, 5,6-dihydronaphthyl-, 7,8-dihydronaphthyl-, 5,6,7,8-tetrahydronaphthyl-, an indanyl-, or an indenyl group, which is unsubstituted or substituted with one, two, three, four or five substituents, each substituent independently selected from a halogen atom, a cyano group, a Ci-Cs-alkyl group, aCi-Cs-haloalkyl group, a Ci-Cs-alkoxy group, a Ci-Cs-thioalkyl group, a Ci-Cs-haloalkoxy group, a C1-C3-halothioalkyl group, a Cs-Cs-cycloalkyl group, particularly a halogen atom, a Ci-Cs-alkyl group, a Ci-Cs-haloalkyl group, a Ci-Cs-alkoxy group, and a Ci-Cs-haloalkoxy group. The term “heteroaryl” means a monovalent, monocyclic, aromatic ring having 4, 5, 6, or ring atoms (a “4- to 6-membered heteroaryl” group), particularly 5, or 6 ring atoms, which contains at least one ring heteroatom and optionally one, two or three further ring heteroatoms from the series: N, O and / or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency).

[0109] Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, a thienyl-, furanyl-, pyrrolyl-, oxazolyl-, thiazolyl-, imidazolyl-, pyrazolyl-, isoxazolyl-, isothiazolyl-, oxadiazolyl-, triazolyl-, thiadiazolyl- or a tetrazolyl group; or a 6-membered heteroaryl group, such as, for example, a pyridyl-, pyridazinyl-, pyrimidyl-, pyrazinyl- or a triazinyl group; or a benzo-fused 5-membered heteroaryl- group, such as, for example, abenzofuranyl-, benzothienyl-, benzoxazolyl-, benzisoxazolyl-, benzimidazolyl-, benzothiazolyl-, benzotriazolyl-, indazolyl-, indolyl- ora isoindolyl group; or a benzo-fused 6-membered heteroaryl group, such as, for example, a quinolinyl-, quinazolinyl-, isoquinolinyl-, cinnolinyl-, phthalazinyl- or quinoxalinyl-; or another bicyclic group, such as, for example, indolizinyl-, purinyl- or a pteridinyl group; or a tricyclic heteroaryl group, such as, for example, a carbazolyl-, acridinyl- or a phenazinyl group.

[0110] In general, and unless otherwise mentioned, the heteroaryl or heteroarylene groups include all possible isomeric forms thereof, for example tautomers and positional isomers with respect to the point of linkage to the rest of the molecule. Thus, for some illustrative non-restricting examples, the term pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.

[0111] It is possible for the compounds of general formula (I) to exist as isotopic variants. The invention therefore includes one or more isotopic variant(s) of the compounds of general formula (I), particularly deuterium-containing compounds of general formula (I).

[0112] The term “Isotopic variant” of a compound or a reagent is defined as a compound exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound.

[0113] The term “Isotopic variant of the compound of general formula (I)” is defined as a compound of general formula (I) exhibiting an unnatural proportion of one or more of the isotopes that constitute such a compound.

[0114] The expression “unnatural proportion” means a proportion of such isotope which is higher than its natural abundance. The natural abundances of isotopes to be applied in this context are described in “Isotopic Compositions of the Elements 1997”, Pure Appl. Chem., 70(1), 217-235, 1998.

[0115] Examples of such isotopes include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as2H (deuterium presented as “D”),3H (tritium),11C,13C,14C,15N,17O,18O,32P,33P,33S,34S,35S,36S,18F,36CI,82Br,123l,124l,125l,129l and131I, respectively.

[0116] With respect to the treatment and / or prophylaxis of the disorders specified herein the isotopic variant(s) of the compounds of general formula (I) preferably contain deuterium (“deuterium-containing compounds of general formula (I)”). Isotopic variants of the compounds of general formula (I) in which one or more radioactive isotopes, such as3H or14C, are incorporated are useful e.g. in drug and / or substrate tissue distribution studies. These isotopes are particularly preferred for the ease of their incorporation anddetectability. Positron emitting isotopes such as18F or11C may be incorporated into a compound of general formula (I). These isotopic variants of the compounds of general formula (I) are useful for in vivo imaging applications. Deuterium-containing and13C-containing compounds of general formula (I) can be used in mass spectrometry analyses in the context of preclinical or clinical studies.

[0117] Isotopic variants of the compounds of general formula (I) can generally be prepared by methods known to a person skilled in the art, such as those described in the schemes and / or examples herein, by substituting a reagent for an isotopic variant of said reagent, preferably for a deuterium-containing reagent. Depending on the desired sites of deuteration, in some cases deuterium from D2O can be incorporated either directly into the compounds or into reagents that are useful for synthesizing such compounds. Deuterium gas is also a useful reagent for incorporating deuterium into molecules. Catalytic deuteration of olefinic bonds and acetylenic bonds is a rapid route for incorporation of deuterium. Metal catalysts (i.e. Pd, Pt, and Rh) in the presence of deuterium gas can be used to directly exchange deuterium for hydrogen in functional groups containing hydrocarbons. A variety of deuterated reagents and synthetic building blocks are commercially available from companies such as for example C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA.

[0118] The term “deuterium-containing compound of general formula (I)” is defined as a compound of general formula (I), in which one or more hydrogen atom(s) is / are replaced by one or more deuterium atom(s) and in which the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than the natural abundance of deuterium, which is about 0.015%. Particularly, in a deuterium-containing compound of general formula (I) the abundance of deuterium at each deuterated position of the compound of general formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70% or 80%, preferably higher than 90%, 95%, 96% or 97%, even more preferably higher than 98% or 99% at said position(s). It is understood that the abundance of deuterium at each deuterated position is independent of the abundance of deuterium at other deuterated position(s).

[0119] The selective incorporation of one or more deuterium atom(s) into a compound of general formula (I) may alter the physicochemical properties (such as for example acidity, basicity, lipophilicity) and / or the metabolic profile of the molecule and may result in changes in the ratio of parent compound to metabolites or in the amounts of metabolites formed. Such changes may result in certain therapeutic advantages and hence may bepreferred in some circumstances. Reduced rates of metabolism and metabolic switching, where the ratio of metabolites is changed, have been reported. These changes in the exposure to parent drug and metabolites can have important consequences with respect to the pharmacodynamics, tolerability and efficacy of a deuterium-containing compound of general formula (I). In some cases deuterium substitution reduces or eliminates the formation of an undesired or toxic metabolite and enhances the formation of a desired metabolite. In other cases the major effect of deuteration is to reduce the rate of systemic clearance. As a result, the biological half-life of the compound is increased. The potential clinical benefits would include the ability to maintain similar systemic exposure with decreased peak levels and increased trough levels. This could result in lower side effects and enhanced efficacy, depending on the particular compound’s pharmacokinetic / pharmacodynamic relationship. ML-337 (C. J. Wenthur et al., J. Med. Chem., 2013, 56, 5208) and Odanacatib (K. Kassahun et al., WO2012 / 112363) are examples for this deuterium effect. Still other cases have been reported in which reduced rates of metabolism result in an increase in exposure of the drug without changing the rate of systemic clearance. Deuterated drugs showing this effect may have reduced dosing requirements (e.g. lower number of doses or lower dosage to achieve the desired effect) and / or may produce lower metabolite loads.

[0120] A compound of general formula (I) may have multiple potential sites of attack for metabolism. To optimize the above-described effects on physicochemical properties and metabolic profile, deuterium-containing compounds of general formula (I) having a certain pattern of one or more deuterium-hydrogen exchange(s) can be selected. Particularly, the deuterium atom(s) of deuterium-containing compound(s) of general formula (I) is / are attached to a carbon atom and / or is / are located at those positions of the compound of general formula (I), which are sites of attack for metabolizing enzymes such as e.g. cytochrome P450.

[0121] Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like.

[0122] By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0123] The compounds of the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S)configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.

[0124] One embodiment includes those compounds which produce the more desirable biological activity. Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.

[0125] One embodiment includes those isomers which produce the more desirable biological activity. These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.

[0126] The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and / or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.

[0127] In order to distinguish different types of isomers from each other reference is made to IIIPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).

[0128] The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g.(R)- or (S)- isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention is achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.

[0129] Further, it is possible for the compounds of the present invention to exist as tautomers. The present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.

[0130] Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.

[0131] The present invention also includes useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and / or co-precipitates.

[0132] The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates. Further, it is possible for the compounds of the present invention to exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention.

[0133] The term “pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention.

[0134] A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or “mineral acid”, such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as hydrochloric acid, hydrobromic acid, hydroiodicacid, sulfuric acid, bisulfuric acid, phosphoric acid, and nitric acid or with an organic acid, such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl)-benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectinic acid, persulfuric acid, 3-phenylpropionic acid, picric acid, pivalic acid, 2-hydroxyethanesulfonate acid, itaconic acid, sulfamic acid, trifluoromethanesulfonic acid, dodecylsulfuric acid, ethansulfonic acid, benzenesulfonic acid, para-toluenesulfonic acid, methansulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphorsulfonic acid acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerophosphoric acid, aspartic acid, sulfosalicylic acid, hemisulfuric acid and thiocyanic acid, for example.

[0135] A “pharmaceutically acceptable anion” refers to the deprotonated form of a conventional acid, such as, for example, a hydroxide, a carboxylate, a sulfate, a halide, a phosphate, or a nitrate.

[0136] Physiologically acceptable salts of the compounds according to the invention also comprise salts of conventional bases, such as, by way of example and by preference, alkali metal salts (for example lithium, sodium and potassium salts), alkaline earth metal salts (for example calcium, strontium and magnesium salts) or an aluminium salt or a zinc salt, or an ammonium salt derived from ammonia or from an organic primary, secondary or tertiary amine having 1 to 20 carbon atoms, such as by way of example ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, / V-methylmorpholine, arginine, lysine, 1,2-ethylenediamine, / V-methylpiperidine, / V-methyl-glucamine, N, N-dimethyl-glucamine, / V-ethyl-glucamine, 1,6-hexanediamine, glucosamine, sarcosine, serinol, 2-amino-1,3-propanediol, 3-amino-1,2-propanediol, 4-amino-1,2,3-butanetriol. Additionally, the compounds according to the invention may form salts with a quaternary ammonium ion obtainable, e.g., by quaternisation of a basic nitrogen-containing group with agents such as lower alkylhalides, such as alkylchlorides, e.g. methylchloride, ethylchloride, propylchloride and butylchloride; such as alkylbromides, e.g. methylbromide, ethylbromide, propylbromide and butylbromide; and such as alkyliodides; e.g. methyliodide, ethyliodide, propyliodide and butyliodide; dialkylsulfatessuch as dimethylsulfate, diethylsulfate, dibutylsulfate and diamylsulfates, long chain halides such as e.g. decylchloride, laurylchloride, myristylchloride and stearylchloride, decylbromide, laurylbromide, myristylbromide and stearylbromide, decyliodide, lauryliodide, myristyliodide and stearyliodide, aralkylhalides such as benzylchloride, benzylbromide, benzyliodide and phenethylbromides and others. Examples of suitable quaternary ammonium ions are tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra (n-butyl)ammonium, or / V-benzyl- / V, / V, / V-trimethylammonium. Those skilled in the art will further recognise that it is possible for acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods.

[0137] The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.

[0138] In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and / or purification process, is, in most cases, unknown.

[0139] Unless specified otherwise, suffixes to chemical names or structural formulae relating to salts, such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HCI", "x CF3COOH", "x Na+", for example, mean a salt form, the stoichiometry of which salt form not being specified.

[0140] This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and / or purification processes described, as solvates, such as hydrates, with (if defined) unknown stoichiometric composition.

[0141] Solvates and hydrates of disclosed intermediates or example compounds, or salts thereof, which have been obtained, by the preparation and / or purification processes described herein, may be formed in any ratio.

[0142] Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio.Moreover, the present invention also includes prodrugs of the compounds according to the invention. The term “prodrugs” designates compounds which themselves can be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body. For example, a prodrug may be in the form of an in vivo hydrolysable ester of the specified compound. Derivatives of the compounds of formula (I) and the salts thereof which are converted into a compound of formula (I) or a salt thereof in a biological system (bioprecursors or pro-drugs) are covered by the invention. Said biological system may be, for example, a mammalian organism, particularly a human subject. The bioprecursor is, for example, converted into the compound of formula (I) or a salt thereof by metabolic processes.

[0143] DESCRIPTION

[0144] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0145] X represents N or C-R10, in which

[0146] R10represents -H, -F, -Cl, -Br,

[0147]

[0148] optionally substituted with 1 or 2 -F; C1-3 alkyl optionally substituted with 1 to 3 -F; C1-3 alkoxy, -OCHF2, -OCF3, -OCH2CHF2, or -OCH2CF3; and

[0149] Y represents C-H, N, or C-F; and

[0150] R1represents

[0151] -F, -Cl, -Br, -I; or

[0152] C1-3 alkyl optionally substituted with 1 to 6 -F; or

[0153] C1-6 alkoxy optionally substituted with 1 to 6 -F, or 1 to 2 -OCH3; or

[0154] -OCD3

[0155] -OR11a, in which

[0156] R11arepresents C3-6 cycloalkyl, C3-5 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; orCs-sheteroaryl optionally substituted with 1 or 2 C1-3 alkyl, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or

[0157] -O-CH2-R11b, in which

[0158] R11brepresents C3-7 cycloalkyl, or C3-6 heterocyclyl; or

[0159] -P(=O)R12aR12b, -S(=O)2R12a, in which

[0160] R12aand R12bindependently from each other represent -CH3, -CH2-CH3; or in which R12aand R12bin -P(=O)R12aR12btogether with the phosphor atom they are attached to form a 5 or 6 membered ring which can be saturated or unsaturated; or

[0161]

[0162] Z represents C(=O), or S(=O)2; and

[0163] R15a, R15b, R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15a, R15b, R15c, R15d, R15eandR15frepresent -CH3 and all remaining of R15a, R15b, R15c, R15d, R15eand R15frepresent -H; or

[0164]

[0165] T represents C=O, or S(=O)2; and

[0166] R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and

[0167] R17represents

[0168]

[0169] -CH2-CF3, -CH2-CHF2, -C(=O)O-C(CH3)3; or

[0170] -NR18aR18b, in which

[0171] R18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atomwhich is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3, -C(=O)O-C(CH3)3; specific

[0172]

[0173] R20a, R20band R20cindependently from each other represent -H, -CH3, -CHF2, or -CF3; andR2represents -H, -F, -Cl, -CD3, -CHD2, C1-4 alkyl optionally

[0174] substituted with 1 to 3 -F or with

[0175]

[0176] optionally

[0177] substituted with 1 to 2 -F;

[0178]

[0179] , -OCH3, -OCHF2, or

[0180] -OCF3, -C=C-R21in which R21represents

[0181]

[0182] and

[0183] R3represents C1-3 alkyl optionally substituted with 1 or 2 -F; -C=CH,

[0184]

[0185] R4a, R4bindependently from each other represent -H, or -F; and

[0186] R5represents -H, -F, -Cl, or -CH3; and

[0187] R6represents -H, -F, -Cl, C1-3 alkyl optionally substituted with 1 to 3

[0188] -F;

[0189]

[0190] optionally substituted with 1 to 2 -F; -OCHF2, -OCF3, -C=CH, or -C=C-CH3; and

[0191] R7a, R7bindependently from each other represent -H, -F, or -CH3; and

[0192] R8a, R8brepresents independently from each other -H, or -CH3; and

[0193] R9represents -H, C1-4 alkyl optionally substituted with 1 -OH,

[0194] -CD3, -CH2-CHF2, or -CH2-CF3;

[0195] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0196] X represents N or C-R10, in which

[0197] R10represents -H, -F, or C1-3 alkyl optionally substituted with 1 to 3 -F; and

[0198] Y represents C-H; and

[0199] R1represents

[0200] -Br, -I; or

[0201] C1-3 alkyl optionally substituted with 1 to 3 -F; or

[0202] C1-4 alkoxy optionally substituted with 1 to 4 -F, or 1 -OCH3; or

[0203] -OCD3

[0204] -OR11a, in which

[0205] R11arepresents C3-5 cycloalkyl, C3-4 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; orCs-s heteroaryl optionally substituted with 1 or 2 C1-3 alkyl, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or

[0206] -O-CH2-R11b, in which

[0207] R11brepresents C3-4 cycloalkyl, or C3-4 heterocyclyl; or

[0208]

[0209] each R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CI, -CH2I, or -CH2OH; or

[0210]

[0211] R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15c, R15d, R15eand R15frepresent -H; or

[0212]

[0213] R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and R17represents -H, -CH3, -CH2-CH3,

[0214]

[0215] -NR18aR18b, in which

[0216] R18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3; specific examples of such rings

[0217]

[0218] R20a, R20band R20cindependently from each other represent -H, -CH3, -CHF2, or -CF3; andR2represents -H, -CD3, -CHD2, C1-4 alkyl optionally substituted with

[0219] 1 to 3 -F or with 1

[0220]

[0221] optionally substituted with 1 to 2 -F; -OCH3, -OCHF2, -OCF3’, -C=CH, or -C C-R21in which

[0222] R21represents

[0223]

[0224] R3represents C1-2 alkyl optionally substituted with 1 or 2 -F; or -C=CH; and

[0225] R4a, R4brepresent -H; and

[0226] R5represents -H, or -F; and

[0227] R6represents -Cl, C1-3 alkyl optionally substituted with 1 to 3 -F;

[0228] -OCHF2, or -OCF3; and

[0229] R7a, R7brepresent -H; and

[0230] R8a, R8brepresents -H; and

[0231] R9represents -H, -CD3, -CH2-CHF2;

[0232] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0233] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0234] X represents N; and

[0235] Y represents C-H;

[0236] R1represents

[0237] C1-3 alkyl optionally substituted with 1 to 3 -F; or

[0238] C1-4 alkoxy optionally substituted with 1 to 4 -F; or-OCD3

[0239] -OR11a, in which

[0240] R11arepresents C3-4 cycloalkyl, or C3-4 heterocyclyl, both optionally substituted with 1 to 2 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or C3-4 heteroaryl optionally substituted with 1 or 2 of the following substituents -CH3, -CHF2, -CF3, -CH2-CHF2, -CH2-CF3; or

[0241] -O-CH2-R11b, in which

[0242]

[0243] each R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, or -CH2OH; or

[0244]

[0245] R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15c, R15d, R15eand R15frepresent -H; or

[0246]

[0247] R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and

[0248] R17represents

[0249]

[0250] -CH2-CF3, -CH2-CHF2; or

[0251] -NR18aR18b, in which

[0252] R18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3,; specific examples of such rings

[0253]

[0254]

[0255] her represent -H, -CH3, -CHF2, or -CF3; and

[0256] R2represents -H, -CD3, Ci-3alkyl optionally substituted with 1 to 3

[0257]

[0258] R3represents C1-2 alkyl optionally substituted with 1 or 2 -F; or -C≡CH; and

[0259] R4a, R4brepresent -H; andR5represents -H, or -F; and

[0260] R6represents C1-2 alkyl optionally substituted with 1 to 3 -F;

[0261] -OCHF2, or -OCF3; and

[0262] R7a, R7brepresent -H; and

[0263] R8a, R8brepresents -H; and

[0264] R9represents -H;

[0265] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0266] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0267] Y represents C-H

[0268] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0269] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0270] R7a, R7brepresent -H; and

[0271] R8a, R8brepresent -H; and

[0272] R9represents -H;

[0273] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0274] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:represents C1-3 alkyl optionally substituted with 1 to 3 -F; or

[0275] C1-4 alkoxy optionally substituted with 1 to 4 -F; or

[0276] -OCD3

[0277] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0278] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0279] R1represents -OR11a, in which

[0280] R11arepresents C3-4 cycloalkyl, or C3-4 heterocyclyl, both optionally substituted with 1 to 2 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or C3-4 heteroaryl optionally substituted with 1 or 2 of the following substituents -CH3, -CHF2, -CF3, -CH2-CHF2, -CH2-CF3; or

[0281] -O-CH2-R11b, in which

[0282] R11brepresents C3-4 cycloalkyl,

[0283]

[0284] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0285] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0286]

[0287] , in whicheach R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, or -CH2OH

[0288] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0289] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0290]

[0291] R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15c, R15d, R15eand R15frepresent -H; or

[0292]

[0293] R16a, Ri6b, RI6C, pi6djRi6e, Ri6f Ri6g anc| ^i6h represent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and

[0294] R17represents -H, -CH3, -CH2-CH3, -CH(CH3)2,

[0295]

[0296] -CH2-CF3, -CH2-CHF2;or

[0297] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0298] According to further embodiments of the first aspect, the present invention includes compounds of general formula (I), supra, in which:

[0299] R1represents -NR18aR18b, in which

[0300] R18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3; specific

[0301] examples of such rings include

[0302]

[0303]

[0304] independently from each other represent -H, -CH3, -CHF2, or -CF3;

[0305] and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

[0306] In accordance with a second aspect, the present invention includes the compounds of the first aspect of the invention of general formula (I) or any of its further embodiments disclosed supra for use in the treatment or prophylaxis of a disease.

[0307] In accordance with a third aspect, the present invention includes a composition comprising a compound of the first aspect of the invention of general formula (I) or any of its further embodiments disclosed supra and one or more phamryceutically acceptable excipients.

[0308] In accordance with a fourth aspect, the present invention includes the use of a compound of the first aspect of the invention of general formula (I) or any of its further embodiments disclosed supra for the treatment or prophylaxis of a disease.In accordance with a fifth aspect, the present invention includes the use of any of the second, fourth, or sixth aspect of the invention wherein the disease is a hyperproliferative or genetic disorder, such as cancer, for example.

[0309] In accordance with a sixth aspect, the present invention includes the use of a compound of the first aspect of the invention of general formula (I) or any of its further embodiments disclosed supra for the preparation of a medicament for the treatment or prophylaxis of a disease.

[0310] Methods and Administration

[0311] Compounds of general formula (I) of the present invention demonstrate a valuable pharmacological spectrum of action and pharmacokinetic profile, both of which could not have been predicted. Compounds of the present invention have surprisingly been found to effectively inhibit SOS1 / KRAS interaction and it is possible therefore that said compounds be used for the treatment or prophylaxis of diseases, preferably hyperproliferative and genetic disorders in humans and animals.

[0312] Compounds of the present invention can be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and / or cell division, and / or produce apoptosis. This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of general formula (I) of the present invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, or solvate thereof, which is effective to treat the disorder.

[0313] Hyperproliferative disorders include, but are not limited to, for example: hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.

[0314] Examples of breast cancers include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.Examples of brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.

[0315] Tumours of the male reproductive organs include, but are not limited to, prostate and testicular cancer.

[0316] Tumours of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.

[0317] Tumours of the digestive tract include, but are not limited to, anal, colon, colorectal, oesophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.

[0318] Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.

[0319] Head-and-neck cancers include, but are not limited to, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell. Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.

[0320] The present invention also provides methods of treating angiogenic disorders including diseases associated with excessive and / or abnormal angiogenesis.

[0321] Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism. A number of pathological conditions are associated with the growth of extraneous blood vessels. These include, for example, diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity, age-related macular degeneration (AMD), neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc. In addition, the increased blood supply associated with cancerous and neoplastic tissue, encourages growth, leading to rapid tumour enlargement and metastasis. Moreover, the growth of new blood and lymph vessels in a tumour provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer. Thus, compounds of general formula (I) of the present invention can be utilized to treat and / or prevent any of the aforementioned angiogenesis disorders, for example by inhibiting and / or reducing blood vessel formation; by inhibiting, blocking, reducing, decreasing, etc. endothelial cellproliferation, or other types involved in angiogenesis, as well as causing cell death or apoptosis of such cell types.

[0322] These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.

[0323] The term “treating” or “treatment” as stated throughout this document is used conventionally, for example the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as a carcinoma.

[0324] The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.

[0325] Generally, the use of chemotherapeutic agents and / or anti-cancer agents like e.g. inhibitors targeting mutated KRAS enzyme in combination with a compound or pharmaceutical composition of the present invention will serve to:

[0326] 1. yield better efficacy in reducing the growth of a tumour or even eliminate the tumour as compared to administration of either agent alone,

[0327] 2. provide for the administration of lesser amounts of the administered chemotherapeutic agents,

[0328] 3. provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent chemotherapies and certain other combined therapies,

[0329] 4. provide for treating a broader spectrum of different cancer types in mammals, especially humans,

[0330] 5. provide for a higher response rate among treated patients,

[0331] 6. provide for a longer survival time among treated patients compared to standard chemotherapy treatments,

[0332] 7. provide a longer time for tumour progression, and / or

[0333] 8. yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.In addition, the compounds of general formula (I) of the present invention can also be used in combination with radiotherapy and / or surgical intervention.

[0334] In a further embodiment of the present invention, the compounds of general formula (I) of the present invention may be used to sensitize a cell to radiation, i.e. treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the present invention. In one aspect, the cell is treated with at least one compound of general formula (I) of the present invention.

[0335] Thus, the present invention also provides a method of killing a cell, wherein a cell is administered one or more compounds of the present invention in combination with conventional radiation therapy.

[0336] The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of general formula (I) of the present invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of general formula (I) of the present invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.

[0337] In other embodiments of the present invention, a cell is killed by treating the cell with at least one DNA damaging agent, i.e. after treating a cell with one or more compounds of general formula (I) of the present invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g. cis platin), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents.

[0338] In other embodiments, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non-limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell.In one aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.

[0339] In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo.

[0340] Leukemias include, but are not limited to acute lymphoblastic leukemia, acute myeloid leukemia, (acute) T-cell leukemia, acute lymphoblastic leukemia, acute lymphocytic leukemia (ALL), acute monocytic leukemia (AML), acute promyelocytic leukemia (APL), bisphenotypic B myelomonocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), large granular lymphocytic leukemia, plasma cell leukemia and also myelodysplastic syndrome (MDS), which can develop into an acute myeloid leukemia. Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin’s lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin’s disease, and lymphoma of the central nervous system.

[0341] Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.

[0342] The term “treating” or “treatment” as stated throughout this document is used conventionally, for example the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as a carcinoma.

[0343] The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.

[0344] Thus in some embodiments, the present invention includes a method of inhibiting proliferation of a cell and / or the induction of apoptosis in a cell, comprising contacting the cell with a compound of formula (I) according to any one of claims 1-11.

[0345] Compounds of the present invention can be utilized to inhibit, block, reduce, decrease, etc., SOS1-KRAS interaction and therefore support to disrupt the downstream signalling of the RAS / MAPK pathway. This method comprises administering to a mammal in needthereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder.

[0346] The present invention also includes methods of treating hyperproliferative and genetic disorders, for example cancer. Some of the diseases that can be treated with the compounds of formula (I) are, without being limited to, for example:

[0347] 1. Non-Small Cell Lung Cancer (NSCLC): Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancers. It is defined as a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. NSCLC differs from small cell lung cancer in terms of its cell size, appearance, and behavior. The main subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma and large cell carcinoma. NSCLC typically grows and spreads more slowly than small cell lung cancer, though it can still be aggressive. The disease often develops in the outer parts of the lungs and can grow quite large before causing symptoms, which can make early detection challenging. The treatment approach for NSCLC depends on various factors including the stage of the cancer, specific genetic changes in the tumor cells, and the patient's overall health.

[0348] 2. Colorectal Cancer (CRC): Colorectal cancer (CRC) is a type of cancer that begins in the large intestine (colon) or the rectum. It typically starts as small, benign clumps of cells called polyps that form on the inner lining of the colon or rectum. Overtime, some of these polyps can develop into cancerous tumors. Key characteristics of colorectal cancer include that it is the third most common cancer diagnosed in both men and women, that it typically develops slowly over several years, starting from non-cancerous polyps, that the cancer can affect either the large intestine or the rectum and that it is often preventable through regular screening and removal of precancerous polyps. The disease is influenced by both genetic and environmental factors, including family history, diet, physical activity, and other lifestyle factors. Early detection through screening is crucial as it significantly improves treatment outcomes and survival rates.

[0349] 3. Pancreatic Cancer: Pancreatic cancer is a disease that occurs when abnormal cells develop and grow uncontrollably in the pancreas, an organ located behind the stomach that produces hormones and digestive enzymes. The most common type (about 95% of cases) is pancreatic ductal adenocarcinoma (PDAC), whichbegins in the cells that line the ducts of the pancreas. Less common types include neuroendocrine tumors, which form in hormone-producing cells. Pancreatic cancer is one of the most aggressive forms of cancer. It often has poor prognosis because it is typically diagnosed at late stages, as early-stage disease rarely causes symptoms. It has one of the highest rates of KRAS mutations among all cancers (approximately 90% of cases). The disease is particularly challenging to treat due to its aggressive nature, late detection, and high rate of resistance to conventional therapies.

[0350] 4. Acute Myeloid Leukemia (AML): Acute Myeloid Leukemia (AML) is a type of aggressive blood cancer that starts in the bone marrow (the soft inner part of bones where new blood cells are made) and quickly moves into the blood. It occurs when immature blood cells, specifically myeloid cells that normally develop into different types of blood cells, become cancerous. These abnormal cells multiply rapidly, interfere with normal blood cell production, and accumulate in the bone marrow and blood. " Acute" means the disease progresses rapidly. It affects the myeloid line of blood cells (which normally develop into red blood cells, white blood cells, and platelets). AML is the most common type of acute leukemia in adults, which - without treatment - can be fatal within months of diagnosis. The disease typically requires immediate treatment due to its aggressive nature and rapid progression.

[0351] These diseases are often interconnected in terms of their molecular pathways and treatment approaches, particularly when it comes to targeting the RAS signaling pathway, which is why SOS1 inhibitors show promise in their treatment.

[0352] These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.

[0353] The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of hyperproliferative and genetic disorders, for example cancer.

[0354] Another aspect of the invention is a method for controlling cancer (e.g., through treatment and / or prophylaxis) in a subject (e.g., human, other mammal, such as rat, etc.) by administering an effective amount of at least one compound of general formula (I), or a pharmaceutically acceptable salt, polymorph, metabolite, hydrate, solvate or ester thereof to the subject.Particularly in some embodiments, the present invention includes a method of treating a hyperproliferative or genetic disorder, more particularly cancer, comprising administering an effective amount of at lest one compound of general formula (I) according to any one of claims 1-11.

[0355] A method of inhibiting SOS1-KRAS interaction in a cancer cell is also provided, wherein the method comprises contacting a cancer cell with a compound of general formula (I). The cancer cell may be in vitro or in vivo.

[0356] In accordance with a further aspect, the present invention includes a method of treatment or prophylaxis of diseases, in particular hyperproliferative and genetic disorders, particularly cancer, using an effective amount of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same. In some embodiments, the method of treatment and / or prophylaxis of a hyperproliferative or genetic disorder in a subject may comprise administering to the subject an effective amount of a compound of general formula (I). The hyperproliferative or genetic disorder may be, for example, cancer (such as e.g., NSCLC, CRC, pancreatic cancer, AML etc.). Furthermore in some embodiments, the present invention includes a method of treating cancer, particularly NSCLC, CRC, pancreatic cancer, AML comprising administering an effective amount of at least one compound of formula (I) according to any one of claims 1-11.

[0357] In accordance with a further aspect, the present invention includes compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for use in the treatment or prophylaxis of diseases, in particular hyperproliferative or genetic disorders.

[0358] In some embodiments, the present invention includes a method of using a compound of general formula (I) for the treatment of cancer, e.g. NSCLC, CRC, pancreatic cancer, or AML.

[0359] The pharmaceutical activity of the compounds according to the invention can be explained by their activity as SOS1 inhibitors that block the interaction between SOS1 and RAS proteins. In particular, the compounds according to formula (I) disrupt the RAS-GTP / GDP cycle by interrupting the SOS1-KRAS interaction and thereby blocking the GEF activity of SOS1, which prevents RAS proteins from switching to their active (GTP-bound) state. As a result, they suppress RAS-dependent signaling pathways.In accordance with a further aspect, the present invention includes the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the treatment or prophylaxis of diseases, in particular hyperproliferative or genetic disorders, particularly cancer.

[0360] In accordance with a further aspect, the present invention includes the use of a compound of formula (I), described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of same, for the prophylaxis or treatment of diseases, in particular hyperproliferative or genetic disorders, particularly cancer.

[0361] In accordance with a further aspect, the present invention includes the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, in a method of treatment or prophylaxis of diseases, in particular hyperproliferative or genetic disorders, particularly cancer.

[0362] In some embodiments, the present invention includes use of the compounds of general formula (I) for the manufacture of a medicament for the treatment of a hyperproliferative or genetic disease, particularly cancer and more particularly e.g. NSCLC, CRC, pancreatic cancer, or AML.

[0363] In some embodiments, the present invention includes a compound of general formula (I) for use in a method of inhibiting proliferation of a cell and / or the induction of apoptosis in a cell, comprising contacting the cell with a compound of formula (I) according to any one of claims 1-11.

[0364] Particularly in some embodiments, the present invention includes compounds of general formula (I) for use in a method of treating a hyperproliferative or genetic disease, more particularly wherein the hyperproliferative or genetic disease is cancer, and yet even more particularly wherein the cancer disease is NSCLC, CRC, pancreatic cancer, or AML. In accordance with a further aspect, the present invention includes use of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the preparation of a pharmaceutical composition, preferably a medicament, for the prophylaxis or treatment of diseases, in particular hyperproliferative or genetic disorders, particularly cancer.In accordance with a further aspect, the present invention includes pharmaceutical compositions, in particular a medicament, comprising a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture of same, and one or more excipients), in particular one or more pharmaceutically acceptable excipient(s). Conventional procedures for preparing such pharmaceutical compositions in appropriate dosage forms can be utilized.

[0365] The present invention furthermore includes pharmaceutical compositions, in particular medicaments, which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipients, and to their use for the above mentioned purposes.

[0366] It is possible for the compounds according to the invention to have systemic and / or local activity. For this purpose, they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.

[0367] For these administration routes, it is possible for the compounds according to the invention to be administered in suitable administration forms.

[0368] For oral administration, it is possible to formulate the compounds according to the invention to dosage forms known in the art that deliver the compounds of the invention rapidly and / or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, films / wafers, films / lyophylisates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds according to the invention in crystalline and / or amorphised and / or dissolved form into said dosage forms.

[0369] Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Administration forms which are suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophylisates or sterile powders.

[0370] Examples which are suitable for other administration routes are pharmaceutical forms for inhalation, nasal drops, nasal solutions, nasal sprays; tablets / films / wafers / capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eyebaths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents.

[0371] The compounds according to the invention can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, inter alia,

[0372] • fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel®), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos®)),

[0373] • ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols), • bases for suppositories (for example polyethylene glycols, cacao butter, hard fat), • solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins), • surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette®), sorbitan fatty acid esters (such as, for example, Span®), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, for example, Pluronic®),

[0374] • buffers, acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine),

[0375] • isotonicity agents (for example glucose, sodium chloride),

[0376] • adsorbents (for example highly-disperse silicas),

[0377] • viscosity-increasing agents, gel formers, thickeners and / or binders (for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®); alginates, gelatine),• disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab®), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol®)), • flow regulators, lubricants, glidants and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)),

[0378] • coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®), • capsule materials (for example gelatine, hydroxypropylmethylcellulose),

[0379] • synthetic polymers (for example polylactides, polyglycolides, polyacrylates, polymethacrylates (such as, for example, Eudragit®), polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers),

[0380] • plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate),

[0381] • penetration enhancers,

[0382] • stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate),

[0383] • preservatives (for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate),

[0384] • colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide),

[0385] • flavourings, sweeteners, flavour- and / or odour-masking agents.

[0386] The present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.In accordance with another aspect, the present invention includes pharmaceutical combinations, in particular medicaments, comprising at least one compound of general formula (I) of the present invention and at least one or more further active ingredients, in particular for the treatment and / or prophylaxis of a hyperproliferative or genetic disorder, particularly cancer.

[0387] Particularly, the present invention includes a pharmaceutical combination, which comprises:

[0388] • one or more first active ingredients, in particular compounds of general formula (I) as defined supra, and

[0389] • one or more further active ingredients, in particular inhibitors that target the MAPK pathway including those that inhibit EGFR, RAS, RAF, MEK and ERK.

[0390] The term “combination” in the present invention is used as known to persons skilled in the art, it being possible for said combination to be a fixed combination, a non-fixed combination or a kit-of-parts.

[0391] A “fixed combination” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein, for example, a first active ingredient, such as one or more compounds of general formula (I) of the present invention, and a further active ingredient are present together in one unit dosage or in one single entity. One example of a “fixed combination” is a pharmaceutical composition wherein a first active ingredient and a further active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a “fixed combination” is a pharmaceutical combination wherein a first active ingredient and a further active ingredient are present in one unit without being in admixture.

[0392] A non-fixed combination or “kit-of-parts” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein a first active ingredient and a further active ingredient are present in more than one unit. One example of a nonfixed combination or kit-of-parts is a combination wherein the first active ingredient and the further active ingredient are present separately. It is possible for the components of the non-fixed combination or kit-of-parts to be administered separately, sequentially, simultaneously, concurrently or chronologically staggered.

[0393] The compounds of the present invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutically active ingredients where the combination causes no unacceptable adverse effects. The present invention alsoincludes such pharmaceutical combinations. For example, the compounds of the present invention can be combined with known KRAS G12C, and KRAS G12Dinhibitors.

[0394] EXPERIMENTAL SECTION

[0395] NMR peak forms are stated as they appear in the spectra, possible higher order effects may have not been considered.

[0396] The1H-NMR data of selected compounds are listed in the form of1H-NMR peak lists. Therein, for each signal peak the 5 value in ppm is given, followed by the signal intensity, reported in round brackets. The 5 value-signal intensity pairs from different peaks are separated by commas. Therefore, a peaklist is described by the general form: δ₁ (intensity₁), δ₂ (intensity₂), ... , δᵢ (intensityᵢ), ... , δn(intensityₙ).

[0397] The intensity of a sharp signal correlates with the height (in cm) of the signal in a printed NMR spectrum. When compared with other signals, this data can be correlated to the real ratios of the signal intensities. In the case of broad signals, more than one peak, or the center of the signal along with their relative intensity, compared to the most intense signal displayed in the spectrum, are shown. A1H-NMR peaklist is similar to a classical1H-NMR readout, and thus usually contains all the peaks listed in a classical NMR interpretation. Moreover, similar to classical1H-NMR printouts, peaklists can show solvent signals, signals derived from stereoisomers of the particular target compound, peaks of impurities,13C satellite peaks, and / or spinning sidebands. The peaks of stereoisomers, and / or peaks of impurities are typically displayed with a lower intensity compared to the peaks of the target compound (e.g., with a purity of >90%). Such stereoisomers and / or impurities may be typical for the particular manufacturing process, and therefore their peaks may help to identify a reproduction of the manufacturing process on the basis of "by-product fingerprints". An expert who calculates the peaks of the target compound by known methods (ACD spectrus, ACD simulation, or by use of empirically evaluated expectation values), can isolate the peaks of the target compound as required, optionally using additional intensity filters. Such an operation would be similar to peak-picking in classical1H-NMR interpretation. A detailed description of the reporting of NMR data in the form of peaklists can be found in the publication " Citation of NMR Peaklist Data within Patent Applications" (cf. http: / / www.researchdisclosure.com / searching-disclosures, Research Disclosure Database Number 605005, 2014, 01 Aug 2014). In the peak picking routine, as described in the Research Disclosure Database Number 605005, the parameter " MinimumHeight"can be adjusted between 1% and 4%. However, depending on the chemical structure and / or depending on the concentration of the measured compound it may be reasonable to set the parameter " MinimumHeight" <1 %.

[0398] Chemical names were generated using the ACD / Name software from ACD / Labs or ChemDraw by PerkinElmer. In some cases generally accepted names of commercially available reagents were used in place of ACD / Name or ChemDraw generated names. The following table 1 lists the abbreviations used in this paragraph and in the Examples section as far as they are not explained within the text body. Other abbreviations have their meanings customary perse to the skilled person.

[0399] Table 1: Abbreviations

[0400] The following table lists the abbreviations used herein.

[0401]

[0402]

[0403]

[0404] Other abbreviations have their meanings customary per se to the skilled person.

[0405] The various aspects of the invention described in this application are illustrated by the following examples which are not meant to limit the invention in any way.

[0406] The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.

[0407] EXPERIMENTAL SECTION - GENERAL PART

[0408] All reagents, for which the synthesis is not described in the experimental part, are either commercially available, or are known compounds or may be formed from known compounds by known methods by a person skilled in the art. Reactions were set up and started, e.g. by the addition of reagents, at temperatures as specified in the protocols; if no temperature is specified, the respective working step was performed at ambient temperature, i.e. between 18 and 25 °C.

[0409] The compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In somecases, no purification may be necessary. In some cases, the compounds may be purified by crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash column chromatography, using for example prepacked silica gel cartridges, e.g. Biotage SNAP cartidges KP-Sil® or KP-NH® in combination with a Biotage autopurifier system (SP4® or Isolera Four®) and eluents such as gradients of hexane / ethyl acetate or DCM / methanol.

[0410] In some cases, the compounds may be purified by preparative HPLC using for example a Waters autopurifier equipped with a diode array detector and / or on-line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.

[0411] In some cases, purification methods as described above can provide those compounds of the present invention which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. A salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base etc.) of a compound of the present invention as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.

[0412] UPLC-MS Standard Procedures

[0413] Analytical UPLC-MS was performed as described below. The masses (m / z) are reported from the positive mode electrospray ionisation unless the negative mode is indicated (ESIneg). In most of the cases method 1 is used. If not, it is indicated.

[0414] Analytical LC-MS

[0415] Method 1:

[0416] Instrument: Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1.7 pm, 50x2.1 mm; eluent A: water + 0.1 vol. -% formic acid (99%), eluent B: acetonitrile;gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL / min; temperature: 60 °C; DAD scan: 210-400 nm.

[0417] Method 2:

[0418] Instrument: Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1.7 µm, 50x2.1 mm; eluent A: water + 0.2 vol.-% aqueous ammonia (32%), eluent B: acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 mL / min; temperature: 60 °C; DAD scan: 210-400 nm.

[0419] Method 3

[0420] Instrument: SHIMADZU LCMS-2020 SingleQuad; Column: Chromolith@Flash RP-18E 25*2 mm; eluent A: water + 0.0375 vol.-% trifluoroacetic acid, eluent B: acetonitrile + 0.01875 vol.-% trifluoroacetic acid; gradient: 0-0.8 min 5-95% B, 0.8-1.2 min 95% B; flow 1.5 mL / min; temperature: 50 °C; PDA: 220 nm &254 nm.

[0421] Preparative HPLC

[0422] a) Autopurifier: acidic method

[0423] System: Waters Autopurification system: Pump 2545, Sample Manager 2767,

[0424] CFO, DAD 2996, ELSD 2424, SQD

[0425] Column: XBrigde C185.0 pm 100x30 mm

[0426] Solvent: A = H2O + 0.1%vol. HCOOH (99%)

[0427] B = acetonitrile

[0428] Gradient: 0-0.5 min 5% B 25 mL / min, 0.51-5.5 min 10-100% B 70 mL / min, 5.51-6.5 min, 100% B, 70 mL / min

[0429] Temperature: RT

[0430] Solution: max. 250 mg I max. 2.5 mL DMSO or DMF

[0431] Injection: 1 x 2.5 mL

[0432] Detection: DAD scan range 210-400 nm, MS ESI+, ESI-, scan range 160-1000 m / z b) Autopurifier: basic method

[0433] System: Waters Autopurification system: Pump 2545, Sample Manager 2767,

[0434] CFO, DAD 2996, ELSD 2424, SQD

[0435] Column: XBrigde C185.0 pm 100x30 mmSolvent: A = H2O + 0.2%vol. NH3(32%)

[0436] B = acetonitrile

[0437] Gradient: 0-0.5 min 5% B 25 mL / min, 0.51-5.5 min 10-100% B 70 mL / min, 5.51-6.5 min, 100% B, 70 mL / min

[0438] Temperature: RT

[0439] Solution: max. 250 mg I max. 2.5 mL DMSO or DMF

[0440] Injection: 1 x 2.5 mL

[0441] Detection: DAD scan range 210-400 nm, MS ESI+, ESI-, scan range 160-1000 m / z c) chiral SFC: method cSFC-1

[0442] Instrument: Sepiatec: Prep SFC100; column: Chiral Art Cellulose-SB 5 pm 250x30 mm; mobile phase A: carbon dioxide; mobile phase B: methanol; isocratic: 80% A + 20% B; flow: 100 mL / min; temperature: 40 °C; backpressure: 150 bar; wavelength: 254 nm d) chiral SFC: method cSFC-2

[0443] Instrument: Sepiatec: Prep SFC100; column: Chiral Art Cellulose-SC 5 pm 250x30 mm; mobile phase A: carbon dioxide; mobile phase B: methanol; isocratic: 65% A + 35% B; flow: 100 mL / min; temperature: 40°C; backpressure: 150 bar; wavelength: 325 nm

[0444] EXPERIMENTAL SECTION - GENERAL PROCEDURES

[0445] The compounds of the present invention can be prepared as described in the following section. The schemes and the procedures described below illustrate general synthetic routes to the compounds of general formula (I) of the invention and are not intended to be limiting. It is clear to the person skilled in the art that the order of transformations as exemplified in the schemes can be modified in various ways. The order of transformations exemplified in the schemes is therefore not intended to be limiting. In addition, interconversion of any of the substituents can be achieved before and / or after the exemplified transformations. These modifications can be such as the introduction of protecting groups, cleavage of protecting groups, exchange, reduction or oxidation of functional groups, halogenation, metalation, substitution or other reactions known to the person skilled in the art. These transformations include those which introduce a functionality which allows for further interconversion of substituents. Appropriate protecting groups and their introduction and cleavage are well-known to the person skilled in the art. Specific examples are described in the subsequent paragraphs. Further, it ispossible that two or more successive steps may be performed without work-up being performed between said steps, e.g. a "one-pot" reaction, as is well known to the person skilled in the art.

[0446] The syntheses of the compounds of the present invention are preferably carried out according to the general synthetic sequences, shown in schemes 1-2.

[0447] Scheme 1

[0448]

[0449] (I) or (II); R9is H (I) or (II); R9is not H Scheme 1: General synthesis route for the preparation of compounds of general formula (I), wherein R1to R9are defined as for general formula (I), RNis H or Boc, and HX represents an acid, which is typically used for Boc-deprotection and leads to the respective salt of the deprotected amine.Compounds of general formula (I) as well as compound of formula [II], which is a subset of formula [I], can be prepared by lactam formation starting from amino carboxylic acid derivatives of general formula (III) by using dehydrative conjugation methods. Such methods are known using coupling reagents like 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and benzotriazol- 1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP), or other well-known reagents usually used for amide couplings, which are described in the public domain. Typically, general method D is used, which is described below.

[0450] Compounds of general formula (III) can be prepared by subsequent deprotection of the / V-Boc group and saponification of the alkyl ester of compounds of general formula (IV). These methods are known to the person skilled in the art and employ acids like TFA or HCI in dioxane for the removal of the Boc-group and alkali hydroxide, e.g. lithium hydroxide or sodium hydroxide in suitable solvents like THF, methanol, acetonitrile, water, or mixtures thereof. Typically, the compounds of this invention were synthesized by hydrolysis of the ester followed by removal of the Boc group, as described in general procedures B and C, respectively.

[0451] Compounds of general formula (IV) can be prepared by coupling of hydroxypyrimidine derivatives (V) and amines of general formula (VI) by using dehydrative conjugation methods. Such methods are known using coupling reagents like benzotriazol- 1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) and benzotriazol- 1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP), see the teachings of J. Org. Chem., 2007, 72, 10194; Advanced Synthesis & Catalysis, 2018, 360, 4764; Bioorg. Med. Chem., 2019, 27, 931; WO 2011028741 A1; are in the public domain.

[0452] In certain instances, the substituents R1and R2in the compounds of general formula (V), are identical with the substituents R1and R2in the compounds of general formula (I). In other instances, for certain compounds of general formula (I), R1is installed at a later stage using halide substituted compounds of general formula (II), as shown in scheme 2. In these cases, R1in the compounds of general formula (V), formula (IV), formula (III) is a halide atom, preferably chloride, bromide, or iodide, leading to compounds of formula (II). In certain cases, the compounds of formula (I) and compounds of formula (II) are identical.

[0453] In further instances, the substituent R2which is present in compounds of formula (V) is identical with the substituent R2which is present in compounds of formula (I). In other further instances, the substituent R2in compounds of formula (V) is hydrogen, and different substituent R2is introduced at a later stage, preferably after the synthesis ofcompounds of formula (II) or after the synthesis of compounds of formula (I), to obtain other compounds of formula (I), e.g. by introduction of alkyl substituents according to general method E.Scheme 2

[0454]

[0455] Scheme 2: Synthesis route for the preparation of compounds of general formula (I) by introduction of R1, wherein Hal is a halogen atom, R1’ is identical to R1or is a suitable precursor of R1.

[0456] Compounds of general formula (I) can generally be prepared by transition metal catalyzed coupling of the aryl halide (Hal) of (II) with nucleophiles like alcohols, amines, lactams, sultams, phosphinoxides, or suitable organometal derivatives. Typically, R1can be introduced by the general procedures F - R, which are described below. In some cases, R1’ is introduced, which is subsequently converted to R1by protecting group manipulations and / or derivatization of R1’. For example, R1’ can contain a protected amine, which is then deprotected and further substituted by alkylation or acylation, using methods known to the person skilled in the art. An alkyl group as R2can be introduced at this stage using general procedure E, which is described below.

[0457] General synthetic procedures

[0458] General Procedure A

[0459] Bicyclic starting material (1 eq.) and PyBop (1.5 eq.) were dissolved in DMF (0.1 M), then amine (1 eq.), base (DIPEA and / or DBU, 2-3 eq.) were added and stirred at room temperature for 16-24 hours. The reaction mixture was diluted with EtOAc and washed with water (x2), and brine. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography affords the desired product.

[0460] General Procedure B

[0461] The ester (1 eq.) was dissolved in THF (0.2 M) and 1 M (sodium / potassium / lithium) hydroxide (2-5 eq.) was added at 0 °C and stirred at room temperature for 1-24 hours.The reaction mixture was diluted with water and acidified to ~pH 3, and the resulting precipitate was isolated by filtration. Alternatively, the mixture was acidified to ~pH 3 and extracted into EtOAc (x3), and the combined org. phases were filtered through hydrophobic filter paper and concentrated under reduced pressure to afford the desired compound. The obtained material was used directly in the next step without further purification.

[0462] General Procedure C

[0463] / V-Boc protected amine (1 eq.) was dissolved in one of DCM / THF / 1,4-dioxane / MeCN (0.05 - 0.2 M), then, 4 M HCI in 1,4-dioxane (5-20 eq.) was added and the reaction was stirred at room temperature for 2-24 hours. The reaction mixture was concentrated under reduced pressure to afford the desired compound. The obtained material was used directly in the next step without further purification.

[0464] General Procedure D - Macrocyclisation slow addition

[0465] The starting material (1 eq.) and DIPEA (3 equiv.) were dissolved in a DCM I DMF mixture (~4: 1, 0.01 M) and added dropwise to a DCM and / or DMF solution (0.015 M) of HATU (1.1 - 3 eq.) over 0.5 - 6 hours, then stirred at room temperature for 16-24 hours. The reaction mixture was concentrated under reduced pressure and purification by flash column chromatography and / or HPLC afforded the desired compound.

[0466] General Procedure E

[0467] Pyridopyrimidine substrate (1 eq.) was dissolved in DMSO at RT. The respective nitroalkane (5 eq.) was added, followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (2 eq.). The mixture was stirred at RT to 80 °C for 1-5 days until conversion was sufficient as monitored by LCMS. The nitroalkane was removed under reduced pressure and the crude reaction mixture was purified by preparative HPLC (acidic or basic method) to give the desired compound.

[0468] General Procedure F

[0469] To a solution of halide (1.0 eq.) and dimethylphosphinoxide (1.0 - 1.1 eq.) in MeCN was added triethylamine (3.5 eq.) and palladium catalyst (Pd(PPh3)4 or Pd(dppf)Cl2*CH2Cl2, 0.2 eq.). The reaction mixture was purged with argon and stirred at 100 °C overnight. The mixture was filtered and concentrated. Purification by HPLC and / or prep. TLC yielded the desired compound.

[0470] General Procedure GTo a solution of an aromatic halide (1.0 eq.) and nucleophile (1.5 -5.0 eq.) in 1,4-dioxane was added potassium carbonate (2.0 - 5.0 eq.), trans-N, N'-dimethylcyclohexane-1,2-diamine (0.4 - 1.5 eq.) and copper(l) iodide (0.25 - 1.0 eq.). The reaction mixture was purged with argon and stirred at 100 °C to 110 °C overnight. The mixture was filtered and concentrated under reduced pressure. The residue was purified by HPLC (afterwards in some cases preparative TLC was used) yielding the desired compound.

[0471] General Procedure H

[0472] To a solution of pyridopyrimidine halide (1.0 eq.) and dialkylphosphinoxide (1.0- 1.1 eq.) in MeCN was added triethylamine (3.5 eq.) and palladium catalyst (Pd(PPh3)4or Pd(dppf)Cl2*CH2Cl2, 0.2 eq.). The reaction mixture was purged with argon and stirred at 100 °C overnight. The mixture was filtered and concentrated. Purification by HPLC and prep. TLC yielded the desired compound.

[0473] General Procedure I

[0474] To a solution of halide (1.0 eq.) and amine (1.2-2.0 eq.) in 1,4-dioxane was added sodium tert-butoxide (2.0 - 4.0 eq.), Pd2(dba)3(0.05 - 0.5 eq), and XPhos (0.1 - 1 eq.). The reaction was purged with argon and stirred at 100 °C for 3 hours. The mixture was filtered and concentrated. Purification by HPLC yielded the desired compound.

[0475] General Procedure J

[0476] To a solution of cyclic amide (1.0 eq.) in tetrahydrofuran was added sodium hydride (2.0 eq.), and the mixture was stirred at room temperature for 30 minutes. Alkyl halide (2.0 eq.) was added, and the mixture was stirred at room temperature for 10 - 24 hours. The mixture was diluted with either 0.5 M aqueous citric acid or water and ethyl acetate, the organic phase was washed with saturated aqueous sodium chloride and concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain the desired N-alkyl derivative.

[0477] General Procedure K

[0478] To a solution of an aromatic halide (1.0 eq.) in 1,4-dioxane and water (4.5: 1), the respective boronic acid or boronic ester (1.0 - 5.0 eq.), caesium carbonate (3.0 eq.) or potassium carbonate (3.0 eq.) were added under argon, followed by 1,1-bis(diphenylphosphino)ferrocenedichloropalladium(ll) (0.2 eq.), and the mixture was stirred at 80 °C for 10 -20 hours. The mixture was cooled, diluted with dichloromethane and methanol, and filtered. To the filtrate was added a small amount of citric acid and the mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC to obtain the desired product.General Procedure L

[0479] To a solution of aryl halide (1.0 eq.) and caesium carbonate (1.2 -3.5 eq.) in 1,4-dioxane was added tBuBrettPhos Pd G3 (0.1 - 0.5 eq.), and tBuBrettPhos (0.1 - 0.5 eq.), and the mixture was purged with argon. The respective alcohol (5 - 20 eq.) was added, and the mixture was stirred at 80 °C overnight. The mixture was cooled, diluted with dichloromethane, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC, respectively, to obtain the desired aryl ether.

[0480] General Procedure M

[0481] To a solution of aryl halide (1.0 eq.), the respective boronic acid (5- 10 eq.), and caesium carbonate (3.0 - 6.0 eq.) in 1,4-dioxane under argon was added palladium(II)acetate (0.1 - 0.2 eq.) and XPhos (0.2 - 0.4 eq.), and the mixture was stirred at 80 °C overnight. The mixture was cooled, diluted with dichloromethane, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC, respectively, to obtain the desired product. Alternatively, Pd(dppf)Cl2(0.2 eq.) was used instead of palladium(II)acetate and XPhos. In some cases, THF was used instead 1,4-dioxane.

[0482] General Procedure N

[0483] To a solution of an aromatic halide (1.0 eq.) and nucleophile (1.5 -5.0 eq.) in 1,4-dioxane was added potassium carbonate (3.0 eq.), Xantphos (1.5 eq.), and tris(dibenzylideneacetone)-dipalladium (0.5 eq.), and the mixture was stirred at 120 °C for 1 hour. After cooling to room temperature, ethyl acetate and aqueous ammonium chloride solution were added, the phases were separated and the organic phase was extracted with saturated aqueous sodium chloride, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC to obtain the desired product.

[0484] General Procedure O

[0485] To a solution of the respective alkyl iodide (5.0 eq.) in / V, / V-dimethylacetamide was added zinc (5.1 eq), and the reaction was stirred at 65 °C for 20 minutes. In parallel, to a solution of aryl halide (1.0 eq.) in / V, / V-dimethylacetamide was added Pd(dppf)Cl2(0.4 eq.), and copper(l)iodide (0.2 eq.), and the mixture was stirred at 85 °C for 5 minutes. After cooling, both mixtures were combined and stirred at 85 °C overnight. The mixture was cooled to room temperature, diluted with ethyl acetate, filtered, and the filtrate was consecutively washed with water and saturated aqueous sodium chloride solution, then dried oversodium sulfate and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC to obtain the desired product.

[0486] General Procedure P

[0487] To a suspension of an aryl halide (1.0 eq.), copper(l)iodide (0.6 eq.), and PdCh(PPh3)2 (0.3 eq.) in 1,4-dioxane was added triethylamine (10 eq.), the respective TMS-acetylene derivative (5.0 eq.), and tetra-n-butylammonium fluoride (1 M in tetrahydrofuran, 5.0 eq.), and the mixture was stirred at 80 °C under argon overnight. The mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC to obtain the desired product.

[0488] General Procedure Q

[0489] To a solution of an aryl halide (1.0 eq.) and the respective amine (5.0 eq.) in / V, / V-dimethylacetamide was added potassium carbonate (2.0 eq.), and the mixture was stirred at 125 °C for 1-5 days. The mixture was cooled to room temperature, diluted with dichloromethane, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC to obtain the desired product.

[0490] General Procedure R

[0491] To a solution of an aryl halide (1.0 eq.) and the respective sulfinate salt (2.0 eq.) in DMSO was added potassium carbonate (2.0 eq.), copper(l)iodide (0.4 eq.), and L-prolinamide (0.5 eq.), and the mixture was stirred under argon at 110 °C overnight. The mixture was cooled to room temperature, diluted with dichloromethane, filtered, and concentrated under reduced pressure. The residue was purified by preparative HPLC, flash column chromatography, or preparative TLC to obtain the desired product.EXPERIMENTAL SECTION - INTERMEDIATES

[0492] Intermediate 1

[0493] 2-Amino-5-methoxybenzamide

[0494]

[0495] To a solution of 2-amino-5-methoxybenzoic acid (1.00 g, 5.98 mmol) in CH2Cl2(80 mL) was added ammonia (10 mL, 7.0 M in MeOH, 72 mmol). PyBop (3.27 g, 6.28 mmol) was added, and the reaction mixture was stirred for 5 min. N, N-Diisopropylethylamine (1.3 mL, 7.2 mmol) and MeOH (10 mL) were added. The reaction mixture was stirred overnight at room temperature. Sat. aq. NaHCO3sol. was added and the phases were separated. The aq. phase was extracted with CH2Cl2 / iPrOH. The combined org. phases were concentrated under reduced pressure to afford the title compound (3.00 g, quantitative yield). The obtained material was used directly in the next step without further purification.

[0496] LC-MS (method 2): Rt= 0.61 min; MS (ESIpos): m / z = 167 [M+H]+

[0497] Intermediate 2

[0498] Ethyl 6-methoxy-4-oxo-3,4-dihydroquinazoline-2-carboxylate

[0499]

[0500] To a solution of 2-amino-5-methoxybenzamide (45.1 g, 33 % purity, 89.6 mmol) in pyridine (80 mL) was added ethyl chloro(oxo)acetate (10 mL, 90 mmol). The reaction mixture was stirred overnight at room temperature. Additional ethyl chloro(oxo)acetate (4 mL, 36 mmol) was added and the reaction mixture was stirred for 2 h. The reaction mixture was concentrated under reduced pressure. AcOH (256 mL) and Ac2O (25 mL) were added. The reaction mixture was stirred overnight at 125 °C. The reaction mixture was concentrated under reduced pressure and triturated with EtOAc / MTBE / MeCN to yield the title compound (11.5 g, 52 % yield).

[0501] LC-MS (method 2): Rt= 0.50 min; MS (ESIpos): m / z = 249 [M+H]+Intermediate 3

[0502] Ethyl 6,7-dimethoxy-4-oxo-3,4-dihydroquinazoline-2-carboxylate

[0503]

[0504] To a solution of 2-amino-4,5-dimethoxybenzamide (2.00 g, 10.2 mmol) in pyridine (10 mL) was added ethyl chloro(oxo)acetate (1.4 mL, 12 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. AcOH (29 mL) and Ac2O (2.9 mL) were added. The reaction mixture was stirred overnight at 125 °C. The reaction mixture was concentrated under reduced pressure and triturated with EtOAc / MTBE / MeCN to yield the title compound (1.70 g, 60 % yield).

[0505] LC-MS (method 2): Rt= 0.47 min; MS (ESIpos): m / z = 279 [M+H]+

[0506] Intermediate 4

[0507] Methyl 5-bromo-2-hydroxypyridine-4-carboxylate

[0508]

[0509] To a stirred solution of sulfuric acid (25 mL, 470 mmol) in water (250 mL) was added methyl 2-amino-5-bromopyridine-4-carboxylate (25.0 g, 108 mmol). The reaction mixture was cooled to 0 °C. Sodium nitrite (22.4 g, 325 mmol) in water (125 mL) was added dropwise at 0 °C and stirred at room temperature until completion (as monitored by TLC). The reaction mixture was filtered and washed with petroleum ether to give the title compound as yellow solid (25.0 g, 97 % purity, 97 % yield) which was used in the next step without further purification.

[0510] LC-MS (method 3): Rt= 0.36 min; MS (ESIpos): m / z = 232 [M+H]+

[0511] Intermediate 5

[0512] Methyl 5-bromo-2-(trifluoromethoxy)pyridine-4-carboxylate

[0513]

[0514] To a solution of methyl 5-bromo-2-hydroxypyridine-4-carboxylate (25.0 g, 97 % purity, 105 mmol) in nitromethane (250 mL) was added 1 -(trifluoromethyl)- 1lambda3,2-benziodoxol-3(1H)-one (66.1 g, 209 mmol). The reaction mixture was stirred at 100 °C for 16 hours. The reaction mixture was cooled to room temperature, quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound as a colorless oil (15.0 g, 60 % purity, 29 % yield).

[0515] LC-MS (method 3): Rt= 0.60 min; MS (ESIpos): m / z = 300 [M+H]+

[0516] Intermediate 6

[0517] 5-Amino-2-(trifluoromethoxy)pyridine-4-carboxamide

[0518]

[0519] Methyl 5-bromo-2-(trifluoromethoxy)pyridine-4-carboxylate (15.0 g, 60 % purity, 30.0 mmol) was dissolved in DMSO (150 mL), then, ammonium hydroxide (42.1 g, 25 % in water, 300 mmol), Cu2O (215 mg, 1.50 mmol), and water (150 mL) were added. The reaction mixture was heated at 110 °C for 16 hours. The reaction mixture was cooled to room temperature and diluted with water and extracted into EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (3.30 g, 24 % purity, 12 % yield).

[0520] LC-MS (method 3): Rt= 0.40 min; MS (ESIpos): m / z = 222 [M+H]+

[0521] Intermediate 7

[0522] Ethyl 4-oxo-6-(trifluoromethoxy)-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate

[0523]

[0524] To a solution of 5-amino-2-(trifluoromethoxy)pyridine-4-carboxamide (500 mg, 2.26 mmol) in pyridine (4.6 mL) was added ethyl chloro(oxo)acetate (320 pL, 98 % purity, 2.8 mmol) at 0 °C. After 3 h at rt, more ethyl chloro(oxo)acetate (25 pL, 230 pmol) was added. The reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. AcOH (6.5 mL) and Ac2O (0.64 mL) were added. The reaction mixture was stirred overnight at 125 °C. The reaction mixture was concentrated under reduced pressure and triturated with MeCN to yield the title compound (296 mg, 43 % yield) which was used without further purification in the next step.

[0525] LC-MS (method 2): Rt= 0.54 min; MS (ESIpos): m / z = 304 [M+H]

[0526] Intermediate 8

[0527] 3-Amino-6-chloropyridine-2-carboxamide

[0528]

[0529] To a solution of 3-amino-6-chloropyridine-2-carboxylic acid (1.47 g, 8.54 mmol) in CH2Cl2(63 mL) was added ammonia (15 mL, 7.0 M in MeOH, 100 mmol). PyBop (4.89 g, 9.40 mmol) was added, and the reaction mixture was stirred for 10 min. N, N-Diisopropylethylamine (1.8 mL, 10 mmol) was added. The reaction mixture was stirred for 4 h at room temperature. Sat. aq. NaHCOs sol. was added and the phases were separated. The aq. phase was extracted with CH2Cl2 / iPrOH. The combined org. phases were concentrated under reduced pressure. Purification by flash column chromatography (CH2Cl2 / MeOH) afforded the desired compound as an orange oil (1.23 g, 84 % yield). LC-MS (method 2): Rt= 0.71 min; MS (ESIpos): m / z = 172 [M+H]+

[0530] Intermediate 9

[0531] Ethyl 6-chloro-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidine-2-carboxylate

[0532]

[0533] To a solution of 3-amino-6-chloropyridine-2-carboxamide (830 mg, 4.84 mmol) in CH2Cl2 / THF (12.2 mL, 1:1 mixture) was added triethylamine (1.7 mL). Ethyl chloro(oxo)acetate (991 mg, 7.26 mmol) was slowly added. The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered and concentrated under reduced pressure. Purification by flash column chromatography (CH2Cl2 / MeOH) afforded the desired compound as an orange oil (632 mg, 52 % yield).

[0534] LC-MS (method 2): Rt= 0.45 min; MS (ESIpos): m / z = 254 [M+H]+

[0535] Intermediate 10

[0536] Ethyl 4,6-dichloropyrido[3,2-d]pyrimidine-2-carboxylate

[0537]

[0538] To a mixture of ethyl 6-chloro-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidine-2-carboxylate (632 mg, 2.49 mmol) and 1,2-dichloroethane (7.3 mL) was added one drop of DMF. Phosphorus(V) oxychloride (580 pL, 6.2 mmol) was slowly added and the reaction mixture was stirred overnight at room temperature. Water was added and the reaction mixture was extracted with 1,2-dichloroethane. The org. phase was dried and concentrated under reduced pressure. The obtained material (369 mg) was used directly in the next step without further purification.

[0539] LC-MS (method 1): Rt= 1.00 min; MS (ESIpos): m / z = 272 [M+H]+

[0540] Intermediate 11

[0541] 2-Bromo-6-(trifluoromethyl)pyridin-3-amine

[0542]

[0543] To a solution of 6-(trifluoromethyl)pyridin-3-amine (5.00 g, 30.8 mmol) in 1,2-dichloroethane (50 mL) was added NBS (5.49 g, 30.8 mmol) at 0 °C under argon. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a solid (7.3 g, 98 % yield).

[0544] LC-MS (method 2): Rt= 1.01 min; MS (ESIpos): m / z = 241 [M+H]+

[0545] Intermediate 12

[0546] Methyl 3-amino-6-(trifluoromethyl)picolinate

[0547]

[0548] To a solution of 2-bromo-6-(trifluoromethyl)pyridin-3-amine (13.0 g, 53.9 mmol) in MeOH (260 mL) and THF (26 mL) in an autoclave was added Pd(dppf)Cl2'CH2Cl2 (4.40 g, 5.39 mmol) and triethylamine (30 mL, 220 mmol). The reaction mixture was stirred at 80 °C for 4 h under CO atmosphere (15 bar). The pressure was released and the reaction mixture was filtered and concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a solid (12.5 g, quantitative yield).

[0549] LC-MS (method 2): Rt= 0.93 min; MS (ESIpos): m / z = 221 [M+H]+

[0550] Intermediate 13

[0551] 3-Amino-6-(trifluoromethyl)pyridine-2-carboxylic acid

[0552]

[0553] To a solution of methyl 3-amino-6-(trifluoromethyl)picolinate (1.00 g, 4.54 mmol) in THF (200 mL) was added aq. LiOH solution (27 mL, 1.0 M, 27 mmol). The reaction mixture was stirred for two days at room temperature. The reaction mixture was concentrated under reduced pressure. Water was added and the pH was adjusted with citric acid to be acidic. The aq. phase was extracted with EtOAc. The combined org. phase was concentrated under reduced pressure to yield 1.1 g of the title compound which was used directly in the next step without further purification.

[0554] LC-MS (method 1): Rt= 0.81 min; MS (ESIpos): m / z = 207 [M+H]+

[0555] Intermediate 14

[0556] 3-Amino-6-(trifluoromethyl)pyridine-2-carboxamide

[0557]

[0558] To a solution of 3-amino-6-(trifluoromethyl)pyridine-2-carboxylic acid (100 mg, 485 pmol) in CH2CI2 (8.0 mL) was added ammonia (830 pL, 7.0 M in MeOH, 5.8 mmol). PyBop (265 mg, 509 pmol) was added, and the reaction mixture was stirred for 10 min. N, N-Diisopropylethylamine (100 pL, 0.58 mmol) and MeOH (1 mL) were added. The reaction mixture was stirred overnight at room temperature. Sat. aq. NaHCOs solution was added and the phases were separated. The aq. phase was extracted with CH2CI2. The combined org. phases were concentrated under reduced pressure. The residue was triturated with MTBE. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a solid (50.0 mg, 50 % yield).

[0559] LC-MS (method 2): Rt= 0.86 min; MS (ESIneg): m / z = 204 [M-H]’

[0560] Intermediate 15

[0561] Ethyl {[2-carbamoyl-6-(trifluoromethyl)pyridin-3-yl]amino}(oxo)acetate

[0562]

[0563] To a solution of 3-amino-6-(tnfluoromethyl)pyndine-2-carboxamide (500 mg, 2.44 mmol) in CH2CI2 (3.0 mL) was added pyridine (390 pL, 4.88 mmol). The reaction mixture was stirred for 10 min and cooled to 0 °C. Ethyl chloro(oxo)acetate (410 pL, 3.7 mmol) was added and the reaction mixture was stirred overnight. Water and CH2CI2 were added. The layers were separated and the org. phase was washed with water, dried and concentrated under reduced pressure affording 760 mg (quant.) of the title compound which was used directly in the next step without further purification.

[0564] LC-MS (method 1): Rt= 1.02 min; MS (ESIpos): m / z = 306 [M+H]+

[0565] Intermediate 16

[0566] Ethyl 4-hydroxy-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylate

[0567]

[0568] Ethyl {[2-carbamoyl-6-(trifluoromethyl)pyridin-3-yl]amino}(oxo)acetate (200 mg, 655 pmol) was suspended in AcOH (1.9 mL) and Ac2O (190 pL, 2.0 mmol). The reaction mixture was stirred for two days at 125 °C. The reaction mixture was allowed to cool down and the precipitate was filtered off. The filter cake was washed with water and CH2CI2 to obtain the title product (86.0 mg, 46 % yield) which was used in the next step without further purification.

[0569] LC-MS (method 1): Rt= 0.80 min; MS (ESIpos): m / z = 288 [M+H]+

[0570] Intermediate 17

[0571] 5-Amino-2-methoxypyridine-4-carboxamide

[0572]

[0573] To a solution of 5-amino-2-methoxypyridine-4-carboxylic acid (11.5 g, 68.4 mmol) in CH2CI2 (860 mL) was added ammonia (120 mL, 7.0 M in MeOH, 820 mmol). PyBop (37.4 g, 71.8 mmol) was added, and the reaction mixture was stirred for 10 min. N, N-Diisopropylethylamine (14.3 mL, 82 mmol) and MeOH (120 mL) were added. The reaction mixture was stirred overnight at room temperature. Sat. aq. NaHCOs sol. wasadded and the phases were separated. The aq. phase was extracted with CH2Cl2 / iPrOH. The combined org. phases were concentrated under reduced pressure and triturated with CH2CI2 to give the title product (4.50 g, 90 % purity, 35 % yield) which was used without further purification in the next step.

[0574] LC-MS (method 2): Rt= 0.47 min; MS (ESIpos): m / z = 168 [M+H]+

[0575] Intermediate 18

[0576] Ethyl 6-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate

[0577]

[0578] To a solution of 5-amino-2-methoxypyridine-4-carboxamide (11.2 g, 67.0 mmol) in pyridine (140 mL) was added ethyl chloro(oxo)acetate (9.3 mL, 82 mmol). The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was filtered and the filter cake was washed with CH2CI2. The solid was added to AcOH (190 mL) and Ac2O (19 mL, 200 mmol). The reaction mixture was stirred overnight at 125 °C. The reaction mixture was concentrated under reduced pressure and dissolved in EtOAc. The org. phase was washed with sat. aq. NaHCOs sol. and brine and concentrated under reduced pressure. The residue was triturated with MeCN to yield the title compound (5.15 g, 28 % yield) which was used in the next step without further purification.

[0579] LC-MS (method 1): Rt= 0.76 min; MS (ESIpos): m / z = 250 [M+H]+

[0580] Intermediate 19

[0581] Ethyl 6-bromo-4-oxo-3,4-dihydroquinazoline-2-carboxylate

[0582]

[0583] To a solution of 2-amino-5-bromobenzoic acid (5.00 g, 23.1 mmol), HCI (29 mL, 4.0 M in 1,4-dioxane, 120 mmol), dioxane (30 mL) was added ethyl carbonocyanidate (2.3 mL, 23 mmol). The reaction mixture was stirred at 90 °C for 5 h, allowed to cool down and concentrated under reduced pressure. The residue was triturated with water to give thetitle compound (6.49 g, 94 % yield) which was used in the next step without further purification.

[0584] LC-MS (method 1): Rt= 0.93 min; MS (ESIpos): m / z = 297 [M+H]+

[0585] Intermediate 20

[0586] Ethyl 6-bromo-7-fluoro-4-oxo-3,4-dihydroquinazoline-2-carboxylate

[0587]

[0588] To a solution of 2-amino-5-bromo-4-fluorobenzamide (10.0 g, 42.9 mmol) in pyridine (50 mL) was added ethyl chloro(oxo)acetate (5.8 mL, 51 mmol). The reaction mixture was stirred for 2 h at room temperature ands concentrated under reduced pressure. AcOH (120 mL) and Ac2O (12 mL, 130 mmol) were added. The reaction mixture was stirred overnight at 125 °C. The reaction mixture was allowed to cool down, concentrated under reduced pressure and triturated with MTBE to yield the title compound (10.5 g, 78 % yield) which was used without further purification in the next step.

[0589] LC-MS (method 2): Rt= 0.55 min; MS (ESIpos): m / z = 315 [M+H]+

[0590] Intermediate 21

[0591] 5-Amino-2-bromopyridine-4-carboxamide

[0592]

[0593] To a suspension of 5-amino-2-bromopyridine-4-carboxylic acid (3.00 g, 13.8 mmol) in THF (24 mL) was added 1,1'-carbonyldiimidazole (2.64 g, 16.3 mmol). The reaction mixture was stirred for 3 h at room temperature and 1 h at 40 °C. The reaction mixture was added to ammonia (69 mL, 0.4 M in THF, 28 mmol). The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc. The org. phase was washed with sat. aq. NaHCO3solution and brine. The combined aq. phase was extracted with EtOAc. The combined org. phases were dried, filtered and concentrated underreduced pressure. Purification by recrystallization (EtOH, 25 mL) gave the desired compound (1.80 g, 60 % yield).

[0594] LC-MS (method 2): Rt= 0.51 min; MS (ESIpos): m / z = 216 [M+H]+

[0595] Intermediate 22

[0596] Ethyl [(6-bromo-4-carbamoylpyridin-3-yl)amino](oxo)acetate

[0597]

[0598] To a suspension of 5-amino-2-bromopyridine-4-carboxamide (1.00 g, 4.63 mmol) in CH2CI2 (6.7 mL) was added pyridine (750 pL). The reaction mixture was cooled to 0 °C and ethyl chloro(oxo)acetate (780 pL, 6.9 mmol) was added and stirred at room temperature overnight. Upon completion, DOM and water were added to the reaction mixture and stirred until a precipitate formed. The solids were isolated by filtration to afford the title compound (1.29 g, 83 % purity, 73 % yield) which was used without further purification in the next step.

[0599] LC-MS (method 1): Rt= 0.80 min; MS (ESIpos): m / z = 316 [M+H]+

[0600] Intermediate 23

[0601] Ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate

[0602]

[0603] To a suspension of ethyl [(6-bromo-4-carbamoylpyridin-3-yl)amino](oxo)acetate (17.0 g, 53.8 mmol) in EtOH (1.2 L) under argon was added NaOEt (24.1 mL, 64.5 mmol, 21 % in EtOH). The reaction mixture was stirred for 30 min at room temperature. Additional, NaOEt (4.0 mL, 11 mmol, 21 % in EtOH) was added and the reaction mixture was stirred for 2 h at room temperature. The reaction mixture was quenched with aq. HOI sol. (2 M) and the resulting precipitate was filtered off. The filter cake was dissolved in EtOAc andwas washed with water and brine, dried, filtered and concentrated under reduced pressure to give the desired compound (12.2 g, 76 % yield) which was used without further purification in the next step.

[0604] LC-MS (method 1): Rt= 0.81 min; MS (ESIpos): m / z = 298 [M+H]+

[0605] Intermediate 24

[0606] 5-Amino-2-chloropyridine-4-carboxamide

[0607]

[0608] To a solution of 5-amino-2-chloropyridine-4-carboxylic acid (12.3 g, 71.2 mmol) in DMF (200 mL) was added triethylamine (15 mL, 110 mmol) and 1H-benzotriazol-1-ol — ammonia (1 / 1) (13.0 g, 85.4 mmol). The reaction mixture was stirred for 4 days. Water was added and the reaction mixture was extracted with EtOAc. The combined org. phase was washed with sat. aq. NaHCO3sol. and brine, dried, filtered and concentrated under reduced pressure to give the desired compound (9.15 g, 96 % purity, 72 % yield) which was used in the next step without further purification.

[0609] LC-MS (method 1): Rt= 0.51 min; MS (ESIpos): m / z = 172 [M+H]+

[0610] Intermediate 25

[0611] Ethyl 6-chloro-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate

[0612]

[0613] To a solution of 5-amino-2-chloropyridine-4-carboxamide (3.80 g, 22.1 mmol) in pyridine (23 mL) was added ethyl chloro(oxo)acetate (3.0 mL, 27 mmol). The reaction mixture was stirred for 3 days at room temperature and concentrated under reduced pressure. AcOH (75 mL) and Ac2O (7.5 mL, 80 mmol) were added. The reaction mixture was stirred overnight at 125 °C and allowed to cool down. The reaction mixture was concentrated under reduced pressure and triturated with EtOH. The resulting solid was washed with MTBE to yield the title compound (2.42 g, 90 % purity, 39 % yield) which was used in the next step without further purification.LC-MS (method 1): Rt= 0.77 min; MS (ESIpos): m / z = 254 [M+H]+

[0614] Intermediate 26

[0615] T ert-butyl [6-(trifluoromethyl)pyridin-3-yl]carbamate

[0616]

[0617] To a solution of 6-(trifluoromethyl)pyridin-3-amine (5.00 g, 30.8 mmol) in 1,4-dioxane (15 mL) was added di-tert-butyldicarbonate (11 mL, 46 mmol) and N, N-diisopropylethylamine (11 mL, 62 mmol). The reaction mixture was stirred at 100 °C overnight. The reaction mixture was allowed to cool down and concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a colorless oil (5.50 g, 68 % yield).

[0618] LC-MS (method 2): Rt= 1.23 min; MS (ESIpos): m / z = 263 [M+H]+

[0619] Intermediate 27

[0620] T ert-butyl [4-iodo-6-(trifluoromethyl)pyridin-3-yl]carbamate

[0621]

[0622] A solution of tert-butyl [6-(trifluoromethyl)pyridin-3-yl]carbamate (5.50 g, 21.0 mmol) and N, N, N', N'-tetramethylethylenediamine (7.9 mL, 52 mmol) in THF (140 mL) was cooled to -78 °C under argon. N-Butyllithium sol. (33 mL, 1.6 M in hexane, 52 mmol) was added. The reaction mixture was stirred for 30 min at -10 °C. Then, the reaction mixture was cooled to -78 °C and iodine (6.92 g, 27.3 mmol) in THF (25 mL) was added and stirred at room temperature for 18 hours. The reaction mixture was quenched with water and the aq. phase was extracted with EtOAc. The org. phase was dried and concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a colorless oil (1.24 g, 15 % yield).

[0623] LC-MS (method 2): Rt= 1.36 min; MS (ESIpos): m / z = 389 [M+H]+

[0624] Intermediate 28Methyl 5-[(tert-butoxycarbonyl)amino]-2-(tnfluoromethyl)pyridine-4-carboxylate

[0625]

[0626] To a solution of tert-butyl [4-iodo-6-(trifluoromethyl)pyridin-3-yl]carbamate (2.07 g, 5.33 mmol) in MeOH (55 mL) and THF (5.4 mL) in an autoclave was added Pd(dppf)Cl2'CH2Cl2 (436 mg, 533 pmol) and triethylamine (3.0 mL, 21 mmol). The reaction mixture was stirred at 80 °C for 5 h under CO atmosphere (16 bar). The pressure was released and the reaction mixture was filtered and concentrated. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound as a solid (1.59 g, 93 % yield).

[0627] LC-MS (method 2): Rt= 1.44 min; MS (ESIpos): m / z = 321 [M+H]+

[0628] Intermediate 29

[0629] 5-[(Tert-butoxycarbonyl)amino]-2-(trifluoromethyl)pyridine-4-carboxylic acid

[0630]

[0631] Methyl 5-[(tert-butoxycarbonyl)amino]-2-(trifluoromethyl)pyridine-4-carboxylate (100 mg, 312 pmol) was dissolved in THF (14 mL), then aq. LiOH sol. (1.9 mL, 1.0 M, 1.9 mmol) was added and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was acidified with aq. citric acid solution and extracted into EtOAc (3x). The combined org. phases were filtered through a hydrophobic filter and concentrated under reduced pressure to afford the title compound (100 mg, quantitative yield). The obtained material was used directly in the next step without further purification.

[0632] LC-MS (method 2): Rt= 0.64 min; MS (ESIneg): m / z = 305 [M-H]’Intermediate 30

[0633] 5-Amino-2-(trifluoromethyl)pyridine-4-carboxylic acid

[0634]

[0635] 5-[(Tert-butoxycarbonyl)amino]-2-(trifluoromethyl)pyridine-4-carboxylic acid (1.38 g, 4.51 mmol) was dissolved in 1,4-dioxane (14 mL), then 4M HCI in 1,4-dioxane (23 mL) was added and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure to afford the title compound (1.10 g, quantitative yield) which was used directly in the next step without further purification.

[0636] LC-MS (method 1): Rt= 0.78 min; MS (ESIpos): m / z = 207 [M+H]+

[0637] Intermediate 31

[0638] 5-Amino-2-(trifluoromethyl)pyridine-4-carboxamide

[0639]

[0640] 5-Amino-2-(trifluoromethyl)pyridine-4-carboxylic acid (70.0 mg, 340 pmol) was dissolved in DCM (5.6 mL), then 7 M NH3in MeOH (0.58 mL, 4.1 mmol) and PyBOP (186 mg, 357 pmol) were added. The reaction mixture was stirred for 10 min and then DIPEA (120 pL, 0.68 mmol) and methanol (0.7 mL) were added and stirred at room temperature for 18 hours. The mixture was washed with aq. sat. NaHCO3sol., and the aqueous phase was extracted with DCM (2x). The combined org. phases were washed with brine, dried over Na2SC>4, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound (45.0 mg, 65 % yield).

[0641] LC-MS (method 1): Rt= 0.64 min; MS (ESIneg): m / z = 204 [M-H]’

[0642] Intermediate 32

[0643] Ethyl {[4-carbamoyl-6-(trifluoromethyl)pyridin-3-yl]amino}(oxo)acetate

[0644]

[0645] 5-Amino-2-(trifluoromethyl)pyridine-4-carboxamide (45.0 mg, 219 pmol) was dissolved in DCM (270 pL) and pyridine (35 pL, 0.44 mmol), cooled to 0 °C and ethyl chloro(oxo)acetate (37 pL, 330 pmol) was added. The reaction mixture was warmed to room temperature and stirred for 18 hours. The reaction mixture was quenched with water and extracted into DCM (3x). The combined org. phases were washed with brine, dried over Na2SC>4, filtered, and concentrated under reduced pressure to afford the title compound (60.0 mg, 90% yield). The obtained material was used directly in the next step without further purification.

[0646] LC-MS (method 1): Rt= 0.90 min; MS (ESIpos): m / z = 306 [M+H]

[0647] Intermediate 33

[0648] Ethyl 4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate

[0649]

[0650] Ethyl {[4-carbamoyl-6-(trifluoromethyl)pyridin-3-yl]amino}(oxo)acetate (750 mg, 2.46 mmol) was dissolved in acetic acid (7.0 mL) and acetic acid anhydride (0.7 mL, 7.4 mmol) and heated at 125 °C for 18 hours. The reaction mixture was cooled to room temperature. Then, a small amount of DCM was added and the resulting precipitate was isolated by filtration to afford the title compound (100 mg, 14% yield). The obtained material was used directly in the next step without further purification.

[0651] LC-MS (method 1): Rt= 0.90 min; MS (ESIpos): m / z = 288 [M+H]

[0652] Intermediate 34

[0653] Tert-butyl 2-bromo-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate

[0654]

[0655] A solution of tert-butyl 2-bromo-5-fluoropyridine-4-carboxylate (32.0 g, 116 mmol), 1-(4-methoxyphenyl)methanamine (23.8 g, 174 mmol) and DIPEA (61 mL, 350 mmol) in DMSO (300 mL) was stirred at 80 °C for 16 h. The reaction mixture was diluted with water and was extracted (2x) with EtOAc and washed with brine. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired product (45.0 g, 97% yield).

[0656] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.93 (s, 1H), 7.81-7.71 (m, 2H), 7.28 (d, 2H), 6.90 (d, 2H), 4.40 (d, 2H), 3.82 (s, 3H), 1.59 (s, 9H).

[0657] Intermediate 35

[0658] Tert-butyl 2-[1-(methoxycarbonyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate

[0659]

[0660] Preparation of the Reformatski reagent:

[0661] Zinc (46.9 g, 718 mmol) was suspended in THF (840 mL), 1,2-dibromoethane (10 mL, 120 mmol) was added and the mixture was stirred at 70 °C for 1 minute, then cooled to room temperature. Chlorotrimethylsilane (5.7 mL, 45 mmol) was added and stirred at room temperature for 15 minutes. A solution of methyl 1 -bromocyclopropane- 1-carboxylate (107 g, 598 mmol) in THF (150 mL) was added dropwise, maintaining an internal temperature of 65 °C. Upon completion of addition, the mixture was cooled to room temperature.

[0662] A solution of tert-butyl 2-bromo-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate (30.0 g, 98 % purity, 74.8 mmol), QPhos (10.6 g, 15.0 mmol), and Pd2(dba)3(6.85 g, 7.48 mmol) was added to the freshly prepared solution of the Reformatskireagent at room temperature and stirred at room temperature for 16 hours. The reaction mixture was quenched with water and extracted into EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (25.9 g, 95% purity, 80 % yield).

[0663] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 8.13 (s, 1H), 7.71 (t, 1H), 7.65 (s, 1H), 7.30 (d, 2H), 6.89 (d, 2H), 4.42 (d, 2H), 3.81 (s, 3H), 3.65 (s, 3H), 1.64-1.61 (m, 2H), 1.58 (s, 9H), 1.34-1.26 (m, 2H).

[0664] Intermediate 36

[0665] Tert-butyl 2-[1-(hydroxymethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate

[0666]

[0667] To a solution of tert-butyl 2-[1-(methoxycarbonyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate (25.9 g, 95 % purity, 59.6 mmol) in THF (350 mL) was added hydrido(diisobutyl)aluminium in toluene (180 mL, 1.0 M, 180 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 1h under nitrogen atmosphere. The mixture was quenched with sodium potassium tartrate solution, extracted into EtOAc (x2) and washed with brine. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired product (12.0 g, 43% yield).

[0668] LC-MS (method 3): Rt = 0.50 min; MS (ESIpos): m / z = 385 [M+H]+

[0669] Intermediate 37

[0670] Tert-butyl 2-(1-formylcyclopropyl)-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate

[0671]

[0672] To a solution of tert-butyl 2-[1-(hydroxymethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate (2.41 g, 95 % purity, 5.95 mmol) in DCM (50 mL) was added 1, 1,1 -triacetoxy- 1lambda5,2-benziodoxol-3(1H)-one (3.79 g, 8.93 mmol) at 0 °C. The reaction mixture was stirred at rt for 2 hours. The reaction mixture was quenched with sat. aq. sodium bicarbonate sol., extracted with DCM (2x) and washed with brine. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired product (2.10 g, 87% yield).

[0673] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 9.40 (s, 1H), 8.14 (s, 1H), 7.77 (t, 1H), 7.73 (s, 1H), 7.29 (d, 2H), 6.89 (d, 2H), 4.43 (d, 2H), 3.81 (s, 3H), 1.59 (s, 9H), 1.58-1.55 (m, 4H).

[0674] Intermediate 38

[0675] Tert-butyl 2-[1-(difluoromethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate

[0676]

[0677] To a solution of tert-butyl 2-(1-formylcyclopropyl)-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate (13.5 g, 73 % purity, 25.8 mmol) in DCM (300 mL) was added diethylaminosulfur trifluoride (17 mL, 130 mmol) dropwise at 0 °C. The reaction mixture was stirred at rt for 16 hours. The reaction mixture was quenched with saturated aq. sodium bicarbonate solution, extracted with DCM (2x) and washed with brine. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired product (2.60 g, 91% yield).1H NMR (400 MHz, CDCl3) 6 [ppm] = 8.13 (s, 1H), 7.79-7.70 (m, 1H), 7.64 (s, 1H), 7.29 (d, 2H), 6.89 (d, 2H), 6.07 (t, 1H), 4.42 (d, 2H), 3.81 (s, 3H), 1.59 (s, 9H), 1.23-1.16 (m, 2H), 1.12-1.05 (m, 2H).

[0678] Intermediate 39

[0679] 5-Amino-2-[1-(difluoromethyl)cyclopropyl]pyridine-4-carboxylic acid — hydrogen chloride (1 / 1)

[0680]

[0681] Tert-butyl 2-[1-(difluoromethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxylate (2.60 g, 91 % purity, 5.85 mmol) was dissolved in trifluoroacetic acid (20 mL, 260 mmol) and DCM (20 mL) and stirred for 16 hours at room temperature. The reaction mixture was adjusted to pH = 9 with saturated aq. sodium bicarbonate solution and extracted with EtOAc. The aqueous phase was adjusted to pH = 4 with aq. HCI sol. (1 M) and extracted with EtOAc. The org. phase was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by trituration (petroleum ether / EtOAc, 10:1) afforded the title compound (1.46 g, 96 % purity, 91 % yield).

[0682] 1H NMR (400 MHz, DMSO-d6) 6 [ppm] = 8.22 (s, 1H), 7.65 (s, 1H), 6.12 (t, 1H), 1.12 (s, 4H).

[0683] Intermediate 40

[0684] Ethyl 6-[1-(difluoromethyl)cyclopropyl]-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate

[0685]

[0686] 5-Amino-2-[1-(difluoromethyl)cyclopropyl]pyridine-4-carboxylic acid — hydrogen chloride (1 / 1) (685 mg, 2.59 mmol) and ethyl carbonocyanidate (260 pL, 2.6 mmol) were dissolved in 1,4-dioxane (32 mL), then HCI (3.2 mL, 4.0 M in 1,4-dioxane, 13 mmol) was added, and the reaction mixture was stirred for 48 h at 60 °C. The reaction mixture wasdiluted with toluene and concentrated under reduced pressure (3x). Purification by preparative HPLC (acidic method) afforded the title compound (427 mg, 53% yield). LC-MS (method 1): Rt= 0.94 min; MS (ESIpos): m / z = 310 [M+H]+

[0687] Intermediate 41

[0688] Methyl 2-(2,2-difluoroethoxy)-5-nitropyridine-4-carboxylate

[0689]

[0690] 2,2-Difluoroethan-1-ol (72 mL, 1.2 mol) was cooled to 0 °C, then NaH (7.39 g, 60 % in mineral oil, 185 mmol) was added portionwise and stirred for 30 minutes. The reaction mixture was warmed to room temperature and methyl 2-chloro-5-nitropyridine-4-carboxylate (20.0 g, 92.3 mmol) was added and stirred for 16 hours. The reaction mixture was poured into water and extracted with EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (22.0 g, 77 % purity, 70 % yield).

[0691] LC-MS (method 3): Rt = 0.53 min; MS (ESIpos): m / z = 263 [M+H]+

[0692] Intermediate 42

[0693] 2-(2,2-Difluoroethoxy)-5-nitropyridine-4-carboxylic acid

[0694]

[0695] Methyl 2-(2,2-difluoroethoxy)-5-nitropyridine-4-carboxylate (22.0 g, 77 % purity, 64.6 mmol) was dissolved in THF (240 mL) and water (60 mL), then lithium hydroxide monohydrate (5.42 g, 129 mmol) was added and stirred at room temperature for 2 hours. The reaction mixture was acidified with aq. HCI sol. to pH = 3 and extracted into EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (18.0 g, 85 % purity, 95 % yield).1H NMR (400 MHz, CDCl3) 6 [ppm] = 8.95 (s, 1 H), 7.09 (s, 1 H), 6.14 (m, 1H), 4.69 (d, 2H).

[0696] Intermediate 43

[0697] 5-Amino-2-(2,2-difluoroethoxy)pyridine-4-carboxylic acid

[0698]

[0699] Performed in a flow reactor.

[0700] Solution 1: 2-(2,2-difluoroethoxy)-5-nitropyridine-4-carboxylic acid (8.00 g, 85 % purity, 27.4 mmol) in MeOH (50 mL) and THF (50 mL).

[0701] Solution 1 was pumped (flowrate = 0.30 mL / min) to the flow reactor (stainless steel, fixed bed, 6.35 mm [1 / 4”], 5 mL volume, packed with 1 % Pt / C, 26 g, heated at 45 °C) under hydrogen atmosphere (flowrate = 30 mL / min, 1.5 MPa backpressure). The output solution was concentrated under reduced pressure and purified by prep. HPLC (acidic method) to afford the title compound (3.09 g, 97 % purity, 50 % yield).

[0702] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 8.55 (br s, 2H), 7.83 (s, 1H), 7.02 (s, 1H), 6.33 (m, 1H), 4.41 (d, 2H).

[0703] Intermediate 44

[0704] Ethyl 6-(2,2-difluoroethoxy)-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate

[0705]

[0706] 5-Amino-2-(2,2-difluoroethoxy)pyridine-4-carboxylic acid (250 mg, 1.15 mmol) and ethyl carbonocyanidate (114 mg, 1.15 mmol) were dissolved in 1,4-dioxane (4.0 mL), then 4 M HCI in 1,4-dioxane (1.4 mL, 5.7 mmol) was added and stirred at 60 °C for 1 hour. The reaction mixture was cooled to room temperature, diluted with toluene and concentrated under reduced pressure. The residue was triturated with MeCN and dried under reduced pressure to afford the title compound (219 mg, 64 % yield).

[0707] LC-MS (method 2): Rt= 0.50 min; MS (ESIpos): m / z = 300 [M+H]+Intermediate 45

[0708] Methyl 5-bromo-2-(difluoromethoxy)pyridine-4-carboxylate

[0709]

[0710] Methyl 5-bromo-2-hydroxypyridine-4-carboxylate (10.0 g, 90 % purity, 38.8 mmol) and sodium chloro(difluoro)acetate (20.0 g, 131 mmol) were dissolved in MeCN (1.0 L) and stirred at 90 °C for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by flash column chromatography (petroleum ether / EtOAc) to afford the title compound (6.4 g, 53% yield).

[0711] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 8.47 (s, 1H), 7.40 (t, 1H), 7.26 (s, 1H), 3.98 (s, 3H).

[0712] Intermediate 46

[0713] 5-Amino-2-(difluoromethoxy)pyridine-4-carboxamide

[0714]

[0715] Methyl 5-bromo-2-(difluoromethoxy)pyridine-4-carboxylate (6.00 g, 90 % purity, 19.1 mmol), ammonium hydroxide (30 mL, 28 % in water, 190 mmol) and copper(l) oxide (822 mg, 5.74 mmol) were dissolved in 1-methyl-2-pyrrolidinone (60 mL) and stirred at 110 °C for 16 hours. The mixture was diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The crude product was triturated with TBME to afford the desired product (310 mg, 8 % yield).

[0716] 1H NMR (400 MHz, DMSO-d6) 5 [ppm] = 8.10 (s, 1H), 7.79 (s, 1H), 7.61 (s, 1H), 7.43 (t, 1H), 7.20 (s, 1H), 6.34 (s, 2H).

[0717] Intermediate 47

[0718] 2-Amino-4-fluoro-5-methoxybenzamide

[0719]

[0720] 2-Amino-4-fluoro-5-methoxybenzoic acid (2.00 g, 10.8 mmol), DIPEA (7.9 mL, 45 mmol), ammonia solution (9.7 mL, 2.0 M in EtOH, 19 mmol) and HATU (5.75 g, 15.1 mmol) were dissolved in DCM (13 mL) and stirred at room temperature for 18 hours. The reaction mixture was diluted with DCM and washed water. The org. phase was concentrated under reduced pressure. The crude material was triturated with water and DCM to afford the desired product (462 mg, 90 % purity, 21% yield).

[0721] LC-MS (method 2): Rt= 0.63 min; MS (ESIpos): m / z = 185 [M+H]+

[0722] Intermediate 48

[0723] Ethyl 7-fluoro-6-methoxy-4-oxo-3,4-dihydroquinazoline-2-carboxylate

[0724]

[0725] 2-Amino-4-fluoro-5-methoxybenzamide (720 mg, 3.91 mmol) was dissolved in pyridine (7.9 mL) at 0 °C and ethyl chloro(oxo)acetate (540 pL, 98 % purity, 4.8 mmol) was added dropwise and stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in acetic acid (11 mL) and acetic anhydride (1.1 mL, 12 mmol) and heated at reflux for 18 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was suspended in MTBE / EtOAc (1:1), stirred and filtered to afford the title compound (184 mg, 18 % yield).

[0726] LC-MS (method 2): Rt= 0.48 min; MS (ESIpos): m / z = 267 [M+H]+

[0727] Intermediate 49

[0728] 1-Bromo-2-(bromomethyl)-3-(trifluoromethyl)benzene

[0729]

[0730] To a solution of 1-bromo-2-methyl-3-(trifluoromethyl)benzene (500 g, 2.09 mol) in acetonitrile (5.0 L) was added NBS (410 g, 2.30 mol) at room temperature. The reaction mixture was stirred at 40 °C for 4 hours under light (450 nm, 600 W). The reaction mixture was quenched with sat. aq. sodium thiosulfate sol. and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (petroleum ether / EtOAc) afforded the title compound (600 g, 86 % yield) as a colorless oil.

[0731] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 4.75 (s, 2 H) 7.24 - 7.38 (m, 1 H) 7.66 (d, 1 H) 7.83 (d, 1 H).

[0732] Intermediate 50

[0733] [2-Bromo-6-(trifluoromethyl)phenyl]acetonitrile

[0734]

[0735] To a solution of 1-bromo-2-(bromomethyl)-3-(trifluoromethyl)benzene (200 g, 598 mmol) in DMSO (1.5 L) was added sodium cyanide (44.0 g, 898 mmol) at room temperature and stirred for 32 hours at room temperature. The reaction mixture was diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (145 g, 83 % yield).

[0736] 1H NMR (400 MHz, DMSO-d6) 6 [ppm] = 4.11 (s, 2 H) 7.54 (t, 1 H) 7.84 (d, 1 H) 8.07 (d, 1 H).

[0737] Intermediate 51

[0738] Tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}carbamate

[0739]

[0740] This reaction was performed in a flow reactor: [2-bromo-6-(trifluoromethyl)phenyl]acetonitrile (50.0 g, 170 mmol) and BOC2O (112 g, 511 mmol) were dissolved in THF (1000 mL) and MeOH (200 mL). The fixed bed (volume 5 mL) was completely packed with granular catalyst 14% Co / Al2O3(270 g). The H2 back pressure regulator was adjusted to 3 MPa and the flow rate of H2 was 30 mL / min. Then the solution was pumped (0.303 mL / min) to the fixed bed (6.350 (1 / 4") mm, 5 mL, 100 °C). The reaction mixture was collected from the reactor output. The fixed bed was washed with MeOH (100 mL). The reaction mixture was concentrated under reduced pressure. Purification by flash column chromatography on silica gel (petroleum ether / EtOAc) afforded the title compound (63.0 g, 72 % yield).

[0741] LC-MS (method 3): Rt= 0.59 min; MS (ESIpos): m / z = 312 [M-C4H9+2H]+

[0742] Intermediate 52

[0743] Tert-butyl (2-{2-[(1R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-6- (trifluoromethyl)phenyl}ethyl)carbamate

[0744]

[0745] The reaction was performed in a flow reactor.

[0746] Solution 1: tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}carbamate (50.0 g, 134 mmol) in THF (1000 mL).

[0747] Solution 2: n-BuLi (1.6 M in hexane, 210 mL, 336 mmol).Solution 3: (S2S)- / V-[(1E)-ethylidene]-2-methylpropane-2-sulfinamide (29.7 g, 202 mmol) in THF (1000 mL).

[0748] Solution 1 (flowrate = 13.6 mL / min) and solution 2 (flowrate = 2.3 mL / min) were pumped to the flow reactor (coils reactor, PFA, 1.588 mm [1 / 16”], -40 °C, residence time = 0.04 min). Then, solution 3 (flowrate = 13.2 mL / min) was pumped to the flow reactor (-40 °C, residence time = 0.022 min). The output mixture was quenched with sat. aq. NH4CI sol. and extracted into EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (4.30 g, 7 % yield).

[0749] LC-MS (method 3): Rt= 0.58 min; MS (ESIpos): m / z = 437 [M+H]+

[0750] Intermediate 53

[0751] Tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate

[0752]

[0753] To a mixture of tert-butyl (2-{2-[(1R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (4.3 g, 9.8 mmol) in water (10 mL) and THF (20 mL) was added iodine (0.74 g, 2.9 mmol) at room temperature. Then, the reaction mixture was stirred at 50 °C for 16 hours. The reaction mixture was diluted with sat. aq. NaHCOs sol. and extracted with EtOAc. The org. phase was washed with sat. aq. sodium thiosulfate sol., dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (2.4 g, 70 % yield).

[0754] LC-MS (method 2): Rt= 1.21 min; MS (ESIpos): m / z = 333 [M+H]+

[0755] Intermediate 54

[0756] 1-Bromo-2-iodo-3-(trifluoromethyl)benzene

[0757]

[0758] A solution of 2-bromo-6-(trifluoromethyl)aniline (50.0 g, 208 mmol) in 20% aq. sulfuric acid (250 mL) and MeCN (250 mL) was cooled to 0 °C and a solution of sodium nitrite (18.7 g, 271 mmol) in water (50 mL) was added dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour, then a solution of KI (45.0 g, 271 mmol) in water (150 mL) was added dropwise while keeping the temperature at 0-5 °C. Then, the reaction mixture was warmed to room temperature and stirred for 16 hours. The reaction mixture was quenched with sat. aq. sodium thiosulfate sol. and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (52.0 g, 57 % yield).

[0759] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.32 (m, 1 H) 7.58 (d, 1 H) 7.84 (d, 1 H).

[0760] Intermediate 55

[0761] Ethyl [2-bromo-6-(trifluoromethyl)phenyl](difluoro)acetate

[0762]

[0763] To a solution of 1-bromo-2-iodo-3-(trifluoromethyl)benzene (52.0 g, 119 mmol) in DMSO (500 mL) were added ethyl bromo(difluoro)acetate (72.2 g, 356 mmol) and copper (22.6 g, 356 mmol) and the reaction mixture was stirred at 60 °C for 16 hours. The reaction mixture was extracted with petroleum ether and the org. phase was concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (19.0 g, 42 % yield).

[0764] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 1.34 (t, 3 H) 4.38 (q, 2 H) 7.46 (m, 1 H) 7.87 (m, 2 H).

[0765] Intermediate 56

[0766] 2-[2-Bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethan-1-ol

[0767]

[0768] To a solution of ethyl [2-bromo-6-(trifluoromethyl)phenyl](difluoro)acetate (15.0 g, 90 % purity, 38.9 mmol) in THF (150 mL) was added lithium borohydride (2 M in THF, 39.0 mL, 78.0 mmol) at 0 °C and stirred at that temperature for 2 hours. The reaction mixture was quenched with sat. aq. ammonium chloride sol. and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (11.5 g, 78 % yield).

[0769] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 4.29 (m, 2 H) 7.40 (m, 1 H) 7.83 (d, 1 H) 7.91 (d, 1 H).

[0770] Intermediate 57

[0771] 2-[2-Bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl trifluoromethanesulfonate

[0772]

[0773] To a solution of 2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethan-1-ol (3.00 g, 7.87 mmol) in DCM (30 mL) were added trifluoromethanesulfonic anhydride (2.66 g, 9.44 mmol) and pyridine (1.9 mL, 23.6 mmol) at 0 °C and stirred at rt for 2 hours. The reaction mixture was poured into water and extracted with DCM. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (2.70 g, 63 % yield).

[0774] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 5.07 (t, 2 H) 7.50 (m, 1 H) 7.89 (d, 1 H) 7.97 (d, 1 H).

[0775] Intermediate 582-(2-Azido-1,1-difluoroethyl)-1-bromo-3-(tnfluoromethyl)benzene

[0776]

[0777] To a solution of 2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl trifluoromethanesulfonate (8.00 g, 14.6 mmol) in DMF (80 mL) was added sodium azide (1.33 g, 20.5 mmol) at 0 °C, then stirred at 25 °C for 16 hours. The mixture was quenched with sat. aq. sodium bicarbonate sol. and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (4.83 g, quantitative). The obtained material was used directly in the next step without further purification.

[0778] LC-MS (method 3): Rt= 0.62 min; MS (ESIpos): m / z = 681.0 [2M+Na]+.

[0779] Intermediate 59

[0780] Tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl}carbamate

[0781]

[0782] The reaction was performed in a flow reactor.

[0783] Solution 1: 2-(2-azido-1,1-difluoro-ethyl)-1-bromo-3-(trifluoromethyl)benzene (4.8 g, 14.6 mmol) and BOC2O (9.587 g, 44.0 mmol) in THF (160 mL).

[0784] The fixed bed (volume 5 mL) was completely packed with granular catalyst 14% Co / Al2O3(3.5 g). The H2 back pressure regulator was adjusted to 2.5 MPa and the flow rate of H2 to 30 mL / min. Then, solution 1 was pumped (0.3 mL / min) to the fixed bed (1 mL, 105 °C). The reaction mixture was diluted with water and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford the title compound (5.92 g, quantitative). The obtained material was used directly in the next step without further purification.LC-MS (method 3): Rt= 0.62 min; MS (ESIpos): m / z = 328 [M-CO2C4H9+H+Na]+

[0785] Intermediate 60

[0786] Di-tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl}-2-imidodicarbonate

[0787]

[0788] To a mixture of tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyljcarbamate (5.92 g, 14.6 mmol), triethylamine (6.1 mL, 44 mmol) and DMAP (358 mg, 2.93 mmol) in MeCN (50.0 mL) was added di-tert-butyl dicarbonate (6.39 g, 29.3 mmol) dropwise at 80 °C and stirred for 16 hours at 80 °C. The reaction mixture was allowed to cool down, diluted with water and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (8.20 g, 67 % yield).

[0789] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 1.43 (s, 18 H) 4.66 (t, 2 H) 7.37 (m, 1 H) 7.80 (d, 1 H) 7.90 (d, 1 H).

[0790] Intermediate 61

[0791] Di-tert-butyl {2-[2-ethenyl-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl}-2-imidodicarbonate

[0792]

[0793] To a mixture of di-tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl}-2-imidodicarbonate (8.20 g, 9.76 mmol), potassium trifluoro(vinyl)borate (1.96 g,14.6 mmol), Na2COs (3.10 g, 29.3 mmol) and water (20.0 mL) in 1,4-dioxane (60.0 mL) was added XPhos Pd G4 (839 mg, 0.97 mmol) and stirred under nitrogen at 80 °C for 16 hours. The reaction mixture was allowed to cool down, diluted with water and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (6.50 g, 89 % yield).

[0794] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 1.49 (s, 18 H) 4.43 - 4.55 (m, 2 H) 5.42 (d, 1 H) 5.57 (d, 1 H) 7.29 - 7.39 (m, 1 H) 7.49 - 7.55 (m, 1 H) 7.75 (m, 2 H).

[0795] Intermediate 62

[0796] Di-tert-butyl {2,2-difluoro-2-[2-formyl-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate

[0797]

[0798] Through a solution of di-tert-butyl {2-[2-ethenyl-6-(trifluoromethyl)phenyl]-2,2-difluoroethyl}-2-imidodicarbonate (6.50 g, 8.64 mmol) in DCM (80.0 mL) cooled to -78 °C was bubbled ozone. When the solution turned blue, ozone addition was stopped. Nitrogen was passed through the solution until the blue color disappeared. The mixture was warmed to room temperature and flushed with nitrogen for 15 min. Then, anhydrous (methylsulfanyl)methane (5.37 g, 86.4 mmol) was added, the reaction mixture warmed to room temperature and stirred for 5 hours. The reaction mixture was diluted with water and extracted with DCM. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (5.50 g, 98 % yield).

[0799] 1H NMR (400 MHz, CDCh) 6 [ppm] = 10.48 (m, 1H), 8.19 (d, 1H), 8.03 (d, 1H), 7.71 (m, 1H), 4.63 (t, 2H), 1.48 (s, 18H).

[0800] Intermediate 63Di-tert-butyl {2,2-difluoro-2-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6- (trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate

[0801]

[0802] To a solution of di-tert-butyl {2,2-difluoro-2-[2-formyl-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (1.50 g, 3.31 mmol) in DCM (30.0 mL) were added Cs2CO3(1.62 g, 4.96 mmol) and (S2R)-2-methylpropane-2-sulfinamide (601 mg, 4.96 mmol) in portions at room temperature and the reaction mixture was stirred at 40 °C for 16 hours. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (1.55 g, 83% yield).

[0803] 1H NMR (400 MHz, CDCI3) 5 [ppm] = 9.08 (m, 1H), 8.20 (d, 1H), 7.96 (d, 1H), 7.64 (m, 1H), 4.61 (t, 2H), 1.45 (s, 18H), 1.29 (s, 9H).

[0804] Intermediate 64

[0805] Tert-butyl (2,2-difluoro-2-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6- (trifluoromethyl)phenyl}ethyl)carbamate

[0806]

[0807] To a solution of di-tert-butyl {2,2-difluoro-2-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (1.55 g, 2.76 mmol) in DCM (20.0 mL) bromo(methyl)magnesium (3.0 M in 2-methyltetrahydrofuran, 4.6 mL, 14.0 mmol) was added dropwise at -50 °C. The reaction mixture was stirred at 25 °C for 1 hour under nitrogen atmosphere. The mixture was quenched with sat. aq. ammonium chloride sol. and extracted with EtOAc. The org. phasewas washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (856 mg, 64% yield).

[0808] LC-MS (method 3): Rt= 0.62 min; MS (ESIpos): m / z = 473 [M+H]+

[0809] Intermediate 65

[0810] Tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}-2,2-difluoroethyl) carbamate

[0811]

[0812] To a mixture of tert-butyl (2,2-difluoro-2-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (850 mg, 1.74 mmol) in water (10.0 mL) and THF (20.0 mL) was added iodine (133 mg, 0.52 mmol) at room temperature. Then, the reaction mixture was stirred at 50 °C for 3 hours. The reaction mixture was diluted with sat. aq. sodium bicarbonate sol. and extracted with EtOAc. The org. phase was washed with sat. aq. sodium thiosulfate sol., dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (456 mg, 70 % yield).

[0813] LC-MS (method 2): Rt= 1.21 min; MS (ESIneg): m / z = 367 [M-H]’

[0814] Intermediate 66

[0815] 1 -Bromo- 3-(1, 1 -difluoroethyl)-2-methylbenzene

[0816]

[0817] To a mixture of 1-(3-bromo-2-methylphenyl)ethan-1-one (100 g, 469 mmol) in 1,2-dichloroethane (1.0 L) was added bis(2-methoxyethyl)aminosulfur trifluoride (311 g, 1.41 mol) at 0 °C. Then, the reaction mixture was stirred at 80 °C for 48 hours. The reaction mixture was diluted with sat. aq. sodium bicarbonate sol. and extracted withEtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (68.0 g, 60 % yield).

[0818] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 1.96 (t, 3 H) 2.52 - 2.56 (m, 3 H) 7.06 - 7.14 (m, 1 H) 7.47 (d, 1 H) 7.64 (d, 1 H).

[0819] Intermediate 67

[0820] 1-Bromo-2-(bromomethyl)-3-(1,1-difluoroethyl)benzene

[0821]

[0822] To a solution of 1-bromo-3-(1,1-difluoroethyl)-2-methylbenzene (104 g, 434 mmol) in 1,2-dichloroethane (1.0 L) was added NBS (108 g, 607 mmol) and dibenzoyl peroxide (2.10 g, 8.67 mmol) at 25 °C. Then, the reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was allowed to cool down, diluted with sat. aq. sodium thiosulfate sol. and sat. aq. sodium bicarbonate sol. and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford a yellow oil which was dissolved in THF (1.7 L). DIPEA (150 mL, 867 mmol) and diethyl phosphite (112 mL, 867 mmol) were added and the reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was diluted with sat. aq. sodium thiosulfate and sat. aq. sodium bicarbonate sol. and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (117 g, 82 % yield).

[0823] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 2.12 (t, 3 H) 4.83 - 5.01 (m, 2 H) 7.24 - 7.30 (m, 1 H) 7.55 (d, 1 H) 7.75 (d, 1 H).

[0824] Intermediate 68

[0825] [2-Bromo-6-(1,1-difluoroethyl)phenyl]acetonitrile

[0826]

[0827] To a solution of 1-bromo-2-(bromomethyl)-3-(1,1-difluoroethyl)benzene (117 g, 354 mmol) in DMSO (1.0 L) sodium cyanide (26.2 g, 535 mmol) at 25 °C was added and stirred for 16 hours. The reaction mixture was diluted with saturated sodium bicarbonate sol. and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (83.0 g, 86 % yield).

[0828] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 2.06 (t, 3 H) 4.10 (s, 2 H) 7.27 - 7.34 (m, 1 H) 7.54 (d, 1 H) 7.76 (d, 1 H).

[0829] Intermediate 69

[0830] Tert-butyl {2-[2-bromo-6-(1,1-difluoroethyl)phenyl]ethyl}carbamate

[0831]

[0832] This reaction was performed in a flow reactor.

[0833] Solution 1: 2-[2-bromo-6-(1,1-difluoroethyl)phenyl]acetonitrile (83.0 g, 319 mmol) and tert-butoxycarbonyl tert-butyl carbonate (348 g, 1.60 mol) in MeOH (1.2 L) and THF (2.0 L).

[0834] The fixed bed (volume 5 mL) was completely packed with granular catalyst 14% Co / Al2O3(40 g). The H2 back pressure regulator was adjusted to 3 MPa and the flow rate of H2 to 30 mL / min. Then, solution 1 was pumped (0.3 mL / min) to the fixed bed (1 mL, 100 °C). The fixed bed was washed with MeOH (500 mL). The residue was concentrated underreduced pressure to afford the title compound (116 g, 78 % yield). The obtained material was used directly in the next step without further purification.

[0835] LC-MS (method 3): Rt= 0.61 min; MS (ESIpos): m / z = 364 [M+H]+

[0836] Intermediate 70

[0837] Di-tert-butyl {2-[2-bromo-6-(1,1-difluoroethyl)phenyl]ethyl}-2-imidodicarbonate

[0838]

[0839] To a solution of tert-butyl {2-[2-bromo-6-(1,1-difluoroethyl)phenyl]ethyl}carbamate (116 g, 249 mmol) and di-tert-butyl dicarbonate (163 g, 747 mmol) in MeCN (1.0 L) was added DMAP (45.6 g, 373 mmol) at 20 °C. Then, the reaction mixture was stirred at 80 °C for 16 hours. The reaction mixture was diluted with water and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (134 g, 93 % yield).

[0840] 1H NMR (400 MHz, CDCl3) 5 [ppm] = 7.65 (d, 1H), 7.46 (d, 1H), 7.13 (m, 1H), 3.97 (t, 2H), 3.26 (t, 2H), 1.97 (t, 3H),1.41-1.53 (m, 18H).

[0841] Intermediate 71

[0842] Di-tert-butyl {2-[2- ( 1, 1 -difluoroethyl)-6-formylphenyl]ethyl}-2-imidodicarbonate

[0843]

[0844] To a mixture of di-tert-butyl {2-[2-bromo-6-(1,1-difluoroethyl)phenyl]ethyl}-2-imidodicarbonate (58.5 g, 101 mmol) in DMF (1 L) were added Pd(dppf)Cl2(7.37 g,10.1 mmol), triethylsilane (48 mL, 300 mmol) and triethylamine (42 mL, 300 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 16 hours under carbon monoxide atmosphere (50 psi). The reaction mixture was allowed to cool down, diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (13.0 g, 26 % yield) as a yellow oil.

[0845] LC-MS (method 3): Rt= 0.65 min; MS (ESIpos): m / z = 436 [M+Na]+

[0846] Intermediate 72

[0847] Di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(1,1-difluoroethyl)phenyl]ethyl}-2-imidodicarbonate

[0848]

[0849] To a solution of di-tert-butyl {2-[2-(1,1-difluoroethyl)-6-formylphenyl]ethyl}-2-imidodicarbonate (26.0 g, 82 % purity, 51.6 mmol) in 1,2-dichloroethane (300 mL) were added cesium carbonate (25.2 g, 77.3 mmol) and (S2R)-2-methylpropane-2-sulfinamide (9.38 g, 77.3 mmol) in portions at room temperature. The reaction mixture was stirred at 50 °C for 16 hours. The reaction mixture was allowed to cool down, filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (20.0 g, 92 % purity, 69 % yield) as a yellow oil.

[0850] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 9.03 (s, 1H), 8.06 (d, 1H), 7.65 (d, 1H), 7.37 (m, 1H), 3.94-3.78 (m, 2H), 3.53-3.34 (m, 2H), 2.01 (t, 3H), 1.55-1.37 (m, 18H), 1.29 (s, 9H).

[0851] Intermediate 73

[0852] Di-tert-butyl (2-{2-[(1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6-(1,1-difluoroethyl)phenyl}ethyl)-2-imidodicarbonate

[0853]

[0854] To a solution of di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(1, 1-difluoroethyl)phenyl]ethyl}-2-imidodicarbonate (5.00 g, 92 % purity, 8.90 mmol) in dichloromethane (50 mL) methylmagnesium bromide (8.9 mL, 3.0 M in methyltetrahydrofuran, 27 mmol) was added dropwise at -50 °C. The reaction mixture was stirred at 25 °C for 1 hour under an atmosphere of nitrogen. The reaction mixture was quenched with saturated ammonium chloride sol. and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (2.80 g, 95 % purity, 56 % yield) as yellow oil.

[0855] LC-MS (method 3): Rt= 0.58 min; MS (ESIpos): m / z = 333 [M-(CO2C4H9)2+3H]+

[0856] Intermediate 74

[0857] Di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(1,1-difluoroethyl)phenyl}ethyl)-2-imidodicarbonate

[0858]

[0859] To a mixture of di-tert-butyl (2-{2-[(1 R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6-(1, 1-difluoroethyl)phenyl}ethyl)-2-imidodicarbonate (20.6 g, 95 % purity, 36.7 mmol) in tetrahydrofuran (600 mL) and water (100 mL) was added iodine (2.80 g, 11.0 mmol) at room temperature. The reaction mixture was stirred at 60 °C for 48 hours under an atmosphere of nitrogen. The reaction mixture was allowed to cool down and quenched with water and extracted with ethyl acetate. The combined organic phases were washedwith brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (9.55 g, 96 % purity, 58 % yield) as a yellow oil.

[0860] LC-MS (method 2): Rt= 1.46 min; MS (ESIpos): m / z = 429 [M+H]+

[0861] Intermediate 75

[0862] 2-Bromo-3-(1,3-dioxolan-2-yl)benzaldehyde

[0863]

[0864] 2-Bromobenzene-1,3-dicarbaldehyde (21.7 g, 102 mmol) and para-toluenesulfonic acid monohydrate (388 mg, 2.04 mmol) were dissolved in toluene (360 mL) and heated to 130 °C using a Dean-Stark apparatus. Then, 1,2-ethandiol (5.7 mL) was added over 3 hours and heated for an additional hour. The mixture was cooled to room temperature, washed with sat. aq. NaHCOs sol., and the aqueous solution was extracted with DCM. The combined org. phases were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (hexane I EtOAc) afforded the title compound (15.3 g, 58 % yield).

[0865] LC-MS (method 2): Rt= 0.99 min; MS (ESIpos): m / z = 301 [M+MeCN+H]+

[0866] Intermediate 76

[0867] 2-[2-Bromo-3-(difluoromethyl)phenyl]-1,3-dioxolane

[0868]

[0869] 2-Bromo-3-(1,3-dioxolan-2-yl)benzaldehyde (15.4 g, 59.9 mmol) was dissolved in DCM (150 mL) and cooled to 0 °C. Then, DAST (24 mL, 180 mmol) was added dropwise and stirred at room temperature for 2 hours. The reaction was quenched by pouring onto ice water, then neutralised with sat. aq. NaHCO3solution. The aqueous mixture was extracted with EtOAc, and the org. phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (hexane I EtOAc) afforded the title compound (13.6 g, 81 % yield).LC-MS (method 2): Rt= 1.18 min; MS (ESIpos): m / z = 279 [M+H]+

[0870] Intermediate 77

[0871] 2-Bromo-3-(difluoromethyl)benzaldehyde

[0872]

[0873] 2-[2-Bromo-3-(difluoromethyl)phenyl]-1,3-dioxolane (13.6 g, 48.7 mmol) was dissolved in 1,4-dioxane (140 mL), then aq. 6 M HCI (140 mL, 840 mmol) was added and stirred at 80 °C for 10 hours. The reaction mixture was diluted with water and extracted into EtOAc. The org. phase was washed with brine and concentrated under reduced pressure to afford the title compound (12.1 g, quantitative yield) which was used without further purification in the next step.

[0874] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 6.87 - 7.19 (m, 1 H) 7.57 (t, 1 H) 7.88 - 7.93 (m, 1 H) 8.00 - 8.06 (m, 1 H) 10.46 (m, 1 H).

[0875] Intermediate 78

[0876] (S2S)-N-{(E)-[2-Bromo-3-(difluoromethyl)phenyl]methylidene}-2-methylpropane-2-sulfinamide

[0877]

[0878] 2-Bromo-3-(difluoromethyl)benzaldehyde (11.1 g, 47.2 mmol) and (S2S)-2-methylpropane-2-sulfinamide (6.01 g, 49.6 mmol) were dissolved in THF (240 mL), then K3PO4 (20.0 g, 94.5 mmol) was added and stirred to room temperature for 1 hour. The mixture was diluted with DCM, filtered over celite and concentrated under reduced pressure. Purification by flash column chromatography (hexane I EtOAc) afforded the title compound (13.1 g, 82 % yield).

[0879] LC-MS (method 2): Rt= 1.33 min; MS (ESIpos): m / z = 338 [M+H]+

[0880] Intermediate 79

[0881] (S2S)-N-{(1R)-1-[2-Bromo-3-(difluoromethyl)phenyl]ethyl}-2-methylpropane-2-sulfinamide

[0882]

[0883] (S2S)-N-{(E)-[2-Bromo-3-(difluoromethyl)phenyl]methylidene}-2-methylpropane-2-sulfinamide (13.3 g, 39.3 mmol) was dissolved in DCM (530 mL), cooled to -78 °C and placed under argon. Then, bromido(methyl)magnesium (29 mL, 3.4 M in 2-methyltetrahydrofuran, 98 mmol) was added. The mixture was stirred for 1 h at -78 °C, for 1 h at -40 °C and for 1 h at room temperature. The reaction was quenched with sat. aq. NH4CI solution and extracted into DCM (2x). The combined org. phases were washed with brine, dried with sodium sulfate, filtered, and concentrated under reduced pressure. Purification by recrystallization (EtOAc I hexane) afforded the title compound (6.6 g, 47 % yield).

[0884] LC-MS (method 2): Rt= 1.19 min; MS (ESIpos): m / z = 354 [M+H]+

[0885] Intermediate 80

[0886] Tert-butyl (2-{2-(difluoromethyl)-6-[(1R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyl}ethyl)carbamate

[0887]

[0888] The reaction was performed in 3 reaction vessels in equal amounts. (S2S)-N-{(1R)-1-[2-Bromo-3-(difluoromethyl)phenyl]ethyl}-2-methylpropane-2-sulfinamide (1.36 g, 3.84 mmol), potassium {2-[(tert-butoxycarbonyl)amino]ethyl}(trifluoro)borate(1-) (1.93 g, 7.68 mmol), APhos Pd G3 (366 mg, 0.576 mmol) and K2CO3 (1.59 g, 11.5 mmol) were suspended in cyclopentyl methyl ether (35 mL) and stirred at 90 °C for 18 hours. Then, additional APhos Pd G3 (366 mg, 0.576 mmol) and water (7.7 mL) were added and stirred at 90 °C for 18 hours. The reaction was cooled to room temperature, diluted with water and extracted into EtOAc. The org. phase was washed with brine, filtered through hydrophobic filter paper and concentrated under reduced pressure. The crude mixture was combined with another reaction mixture (obtained under similar conditions from100 mg (S2S)-N-{(1R)-1-[2-bromo-3-(difluoromethyl)phenyl]ethyl}-2-methylpropane-2-sulfinamide) and purification by flash column chromatography (hexane / EtOAC) afforded the title compound (430 mg, 13 % yield).

[0889] LC-MS (method 2): Rt= 1.28 min; MS (ESIpos): m / z = 420 [M+H]+

[0890] Intermediate 81

[0891] Tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(difluoromethyl)phenyl}ethyl)carbamate

[0892]

[0893] Iodine (73.1 mg, 288 pmol) was added to a mixture of tert-butyl (2-{2-(difluoromethyl)-6-[(1 R)-1-{[(S)-2-methylpropane-2-sulfinyl]amino}ethyl]phenyl}ethyl)carbamate (402 mg, 960 pmol) in THF (5.8 mL) and water (2.9 mL). The reaction mixture was stirred at 50 °C for 5 h. A second batch, prepared in a similar manner with the same starting material (28.0 mg, 66.89 pmol) was added. Saturated aqueous sodium hydrogen carbonate solution was added and the reaction mixtures were extracted with ethyl acetate. The combined organic phases were washed with saturated aqueous sodium thiosulfate solution, dried through a hydrophobic filter and concentrated under reduced pressure. The residue was purified by flash column chromatography (hexane / ethyl acetate, then ethyl acetate / ethanol) to yield the title compound (171 mg, 90 % purity, 51 % yield). LC-MS (method 2): Rt= 1.13 min; MS (ESIpos): m / z = 315 [M+H]+

[0894] Intermediate 82

[0895] Di-tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate

[0896]

[0897] The reaction was performed in a flow reactor.

[0898] Solution 1: Tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}carbamate (160 g, 435 mmol), DMAP (6.9 g, 56.5 mmol) and triethylamine (72.7 mL, 521 mmol) in THF (480 mL).

[0899] Solution 2: Di-tert-butyl dicarbonate (299 mL, 1304 mmol) in THF (320 mL).

[0900] Solution 1 (flowrate = 15 mL / min) and solution 2 (flowrate = 9 mL / min) were pumped to the flow reactor (coiled reactor, PFA, 6.350 mm [1 / 4”], 360 mL, 150 °C, residence time = 15 min). The output mixture was diluted with water and extracted into EtOAc. The org. phase was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (535 g, quantitative yield) as a mixture with di-tert-butyl dicarbonate. The obtained material was used without further purification.

[0901] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.77 (d, 1H), 7.63 (d, 1H), 7.20 (m, 1H), 3.99 (t, 2H), 3.29 (t, 2H), 1.44 (s, 18H).

[0902] Intermediate 83

[0903] Di-tert-butyl {2-[2-formyl-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate

[0904]

[0905] To di-tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (535 g, 1.14 mol) in DMF (5.0 L) were added PdCl2(dppf) (83.6 g, 114 mmol), triethylsilane (83.6 g, 114 mmol) and triethylamine (480 mL, 3.4 mol) at room temperature. The reaction was performed in 5 batches of equal size (five times of 107 g starting material). The reaction mixtures were stirred at 80 °C for 16 hours under an atmosphere of carbon monoxide (50 psi). The reaction mixtures were allowed to cool down to room temperature, then vented to atmospheric pressure. The reaction mixture was diluted with water, extracted with ethyl acetate and filtered through celite. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give 136 g (76 % purity, 22 % yield) of the title compound as a yellow oil and 215 g of recovered di-tert-butyl {2-[2-bromo-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate as a yellow oil.

[0906] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 10.57 (s, 1H), 8.12 (d, 1H), 7.91 (d, 1H), 7.50 (m, 1H), 3.92 (t, 2H), 3.52 (t, 2H), 1.47 (s, 18H).

[0907] Intermediate 84

[0908] Di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate

[0909]

[0910] To a solution of di-tert-butyl {2-[2-formyl-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (42.0 g, 76 % purity, 76.5 mmol) in 1,2-dichloroethane (500 mL) were added copper(ll) sulfate (36.6 g, 229 mmol) and (S2R)-2-methylpropane-2-sulfinamide (27.8 g, 229 mmol) in portions at room temperature. The reaction mixture was stirred at 70 °C for 16 hours. The reaction mixture was allowed to cool down, filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The residue and the residue of a second batch (synthesized in a analogues way from 63.0 g, 151 mmol, of di-tert-butyl {2-[2-formyl-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate) werecombined and purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give 56.0 g (85 % purity, 40 % yield) of the title compound.

[0911] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 9.01 (s, 1H), 8.19 (d, 1H), 7.80 (d, 1H), 7.41 (m, 1H), 3.89 (td, 2H), 3.52-3.37 (m, 2H), 1.43 (s, 18H), 1.30 (s, 9H).

[0912] Intermediate 85

[0913] Di-tert-butyl (2-{2-[(1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6- (trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate

[0914]

[0915] Under an atmosphere of nitrogen at -50 °C, bromo(methyl)magnesium (180 mL, 540 mmol, 3.0 M in 2-methyltetrahydrofuran) was added dropwise to a solution of di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (95.0 g, 98 % purity, 179 mmol) in dichloromethane (1.0 L). The reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was combined with a second batch synthesized in a similar way and scale and purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (116 g, 56 % yield) as a yellow oil.

[0916] LC-MS (method 3): Rt= 0.70 min; MS (ESIpos): m / z = 337 [M-(CO2C4H9)2+3H]+

[0917] Intermediate 86

[0918] Di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate

[0919]

[0920] At room temperature, iodine (15.1 g, 59.7 mmol) was added to a mixture of di-tert-butyl (2-{2-[(1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (116 g, 92 % purity, 199 mmol) in THF (800 mL) and water (400 mL). The reaction mixture was stirred for 3 hours at 50 °C. The reaction mixture was allowed to cool down, diluted with saturated aq. sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated aq. sodium thiosulfate solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (72.0 g, 80% yield) as a yellow solid.

[0921] [a]D20= +10.27° (c = 1, DMSO)

[0922] LC-MS (method 2): Rt= 1.51 min; MS (ESIpos): m / z = 433 [M+H]

[0923] Intermediate 87

[0924] Tert-butyl {(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}carbamate

[0925]

[0926] Tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (1.42 g, 4.27 mmol) and DIPEA (1.10 mL) were dissolved in DCM (100 mL), then di-tert-butyl dicarbonate (980 pL, 4.3 mmol) was added and the mixture was stirred at roomtemperature for 18 hours. The mixture was washed with sat. aq. NaHCO3solution, then brine, and the org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography (hexane / EtOAc) afforded the title compound (1.73 g, 87 % yield).

[0927] LC-MS (method 2): Rt= 1.44 min; MS (ESIpos): m / z = 433 [M+H]+

[0928] Intermediate 88

[0929] Tert-butyl (R)-(2-(1-aminoethyl)-4-chloro-6-(trifluoromethyl)phenethyl)carbamate

[0930]

[0931] A solution of tert-butyl {(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}carbamate (750 mg, 1.73 mmol) and bis(pinacolato)diboron (440 mg, 1.73 mmol) in THF (30 mL) was purged with argon. Then, (1,5-cyclooctadiene)(methoxy)iridium(l) dimer (17.2 mg, 26.0 pmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (14.0 mg, 52.0 pmol) were added and the reaction mixture was purged for 10 min with argon and then stirred at 80 °C overnight. The reaction mixture was allowed to cool down and concentrated under reduced pressure. The residue was dissolved in methanol (22.5 mL) and copper(ll) chloride (699 mg, 5.20 mmol) and water (22.5 mL) were added. The reaction mixture was stirred at 90 °C overnight. The reaction mixture was allowed to cool down, basified with saturated aqueous sodium hydrogen carbonate solution, diluted with ethyl acetate and water, and the layers were separated. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by flash column chromatography (hexane / ethyl acetate, then ethyl acetate / ethanol) to yield the title compound (81.0 mg, 13 % yield) which was used in the next step without further purification.

[0932] LC-MS (method 2): Rt= 1.32 min; MS (ESIpos): m / z = 367 [M+H]+

[0933] Intermediate 89

[0934] 3-Bromo-5-fluoro-2-iodobenzoic acid

[0935]

[0936] To a solution of 2-amino-3-bromo-5-fluorobenzoic acid (200 g, 855 mmol) in water (1000 mL) and acetonitrile (500 mL) was added aq. hydrochloric acid (400 mL, 12 M, 4.8 mol) slowly at 0 °C. The reaction mixture was stirred for 10 min. Then, sodium nitrite (64.9 g, 940 mmol) in water (400 mL) was added at 0 °C and the reaction mixture was stirred for 45 min at 0 °C. Then, an aqueous solution of sodium iodide (220 g, 1.11 mol) in water (600 mL) was added and the reaction mixture was stirred for 16 hours at 25 °C. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with saturated aqueous sodium thiosulfate solution and brine, then dried over sodium sulfate, filtered and concentrated under reduced pressure to give 268 g (86 % purity, 78 % yield) of the title compound as a yellow solid which was used in the next step without further purification.

[0937] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.64 (m, 1H), 7.52 (d, 1H).

[0938] Intermediate 90

[0939] (3-Bromo-5-fluoro-2-iodophenyl)methanol

[0940]

[0941] The reaction was performed in a flow reactor.

[0942] Solution 1: 3-Bromo-5-fluoro-2-iodobenzoic acid (243 g, 86 % purity, 606 mmol) in 2-methyl tetrahydrofuran (2.43 L).

[0943] Solution 2: Borane tetrahydrofuran complex (1.21 L, 1.0 M, 1211 mmol).

[0944] Solution 1 (flowrate of 57 mL / min) and solution 2 (flowrate of 33 mL / min) were pumped to the flow reactor (80 °C, residence time 5 min). The output solution was collected in a vessel containing methanol at 0 °C. The quenched solution was heated at 75 °C for 16 hours, then cooled to room temperature and concentrated under reduced pressure. Purification by trituration (TBME) afforded the title compound (190 g, 94 % yield).1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.39 (dd, 1 H), 7.27 (d, 1 H), 4.74-4.65 (m, 2H), 2.28-2.17 (m, 1H).

[0945] Intermediate 91

[0946] 3-Bromo-5-fluoro-2-iodobenzaldehyde

[0947]

[0948] A mixture of (3-bromo-5-fluoro-2-iodophenyl)methanol (190 g, 99 % purity, 568 mmol) and manganese(IV) oxide (247 g, 2.84 mol) in chloroform (2.0 L) was stirred at 45 °C for 16 hours. The solid was filtered off and the filtrate was concentrated under reduced pressure to provide 182 g (95 % purity, 92 % yield) of the title compound as a yellow solid which was used in the next step without further purification.

[0949] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 10.06 (m, 1H), 7.70 (dd, 1H), 7.56 (d, 1H).

[0950] Intermediate 92

[0951] 1 -Bromo- 3-(difluoromethyl)-5-fluoro-2-iodobenzene

[0952]

[0953] To a solution of 3-bromo-5-fluoro-2-iodobenzaldehyde (182 g, 95 % purity, 526 mmol) in dichloromethane (2.0 L) was added diethylaminosulfur trifluoride (83 mL, 630 mmol) slowly at 0 °C. The reaction mixture was stirred at 25 °C for 16 hours. The reaction mixture was quenched with saturated aq. sodium bicarbonate solution at 0 °C and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was triturated with methyl tert-butyl ether to give 150 g (95 % purity, 77 % yield) of the title compound as a yellow solid which was used without further purification in the next step.

[0954] 1H NMR (400 MHz, CDCI3) 6 [ppm] = 7.70 (dd, 1H), 7.26 (dd, 1H), 6.72 (t, 1H).Intermediate 93

[0955] 1 -Bromo- 3-(difluoromethyl)-2-[(E)-2-ethoxyethenyl]-5-fluorobenzene

[0956]

[0957] A mixture of 1-bromo-3-(difluoromethyl)-5-fluoro-2-iodobenzene (50.0 g, 95 % purity, 135 mmol), 2-[(E)-2-ethoxyethenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (40.2 g, 203 mmol), PdCl2(dppf) (9.90 g, 13.5 mmol) and potassium carbonate (56.1 g, 406 mmol) in 1,4-dioxane (900 mL) and water (300 mL) was degassed and purged with nitrogen three times. The reaction mixture was stirred at 70 °C for 16 hours under an atmosphere of nitrogen. The reaction mixture was allowed to cool down, diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield 29.0 g (92 % purity, 67 % yield) of the title compound as a yellow oil.

[0958] LC-MS (method 3): Rt= 0.64 min; MS (ESIpos): m / z = 295 [M+H]+

[0959] Intermediate 94

[0960] [2-Bromo-6-(difluoromethyl)-4-fluorophenyl]acetaldehyde

[0961]

[0962] Aqueous hydrochloric acid (290 mL, 4.0 M, 1.2 mol) was added to a solution of 1-bromo-3-(difluoromethyl)-2-[(E)-2-ethoxyethenyl]-5-fluorobenzene (29.0 g, 92 % purity, 90.4 mmol) in acetonitrile (290 mL) and the reaction mixture was stirred for 16 hours at 65 °C. The reaction mixture was allowed to cool down, quenched with saturated aq. sodium bicarbonate solution and extracted with ethyl acetate. The organic phase waswashed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 27.0 g (88 % purity, 98 % yield) of the title compound as a yellow solid which was used in the next step without further purification.

[0963] 1H NMR (400 MHz, DMSO-d6) 5 [ppm] = 9.70 (s, 1H), 7.88 (dd, 1H), 7.54 (dd, 1H), 7.15 (t, 1H), 4.16 (s, 2H).

[0964] Intermediate 95

[0965] 2-[2-Bromo-6-(difluoromethyl)-4-fluorophenyl]ethan-1-ol

[0966]

[0967] To a solution of [2-bromo-6-(difluoromethyl)-4-fluorophenyl]acetaldehyde (26.0 g, 88 % purity, 85.7 mmol) in THF (200 mL) was added a solution of sodium tetrahydroborate (3.24 g, 85.7 mmol) in water (20 mL) dropwise at 0 °C and the reaction mixture was stirred at 25 °C for 2 hours. The reaction mixture was poured into sat. aq. ammonium chloride solution slowly and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 22.0 g (99 % purity, 94 % yield) of the title compound as a white solid which was used in the next step without further purification.

[0968] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 7.46 (dd, 1H), 7.33 (dd, 1H), 7.02 (t, 1H), 3.89 (t, 2H), 3.14 (t, 2H).

[0969] Intermediate 96

[0970] Di-tert-butyl {2-[2-bromo-6-(difluoromethyl)-4-fluorophenyl]ethyl}-2-imidodicarbonate

[0971]

[0972] To a solution of 2-[2-bromo-6-(difluoromethyl)-4-fluorophenyl]ethan-1-ol (22.0 g, 99 % purity, 80.9 mmol) and di-tert-butyl 2-imidodicarbonate (21.1 g, 97.1 mmol) in THF (500 mL) was added triphenylphosphine (25.5 g, 97.1 mmol). Then, diisopropyl azodicarboxylate (19.6 g, 97.1 mmol) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to give 12.0 g (98 % purity, 31 % yield) of the title compound as a white solid.

[0973] LC-MS (method 3): Rt= 0.73 min; MS (ESIpos): m / z = 355.9 [M-(C4H9)2+3H]+

[0974] Intermediate 97

[0975] Di-tert-butyl {2-[2-(difluoromethyl)-4-fluoro-6-formylphenyl]ethyl}-2-imidodicarbonate

[0976]

[0977] To di-tert-butyl {2-[2-bromo-6-(difluoromethyl)-4-fluorophenyl]ethyl}-2-imidodicarbonate (12.0 g, 98 % purity, 25.1 mmol) in DMF (200 mL) were added PdCl2(dppf) (5.51 g, 7.53 mmol), triethylsilane (12 mL, 75 mmol) and triethylamine (11 mL, 75 mmol) at room temperature. The reaction mixture was stirred at 80 °C for 16 hours under an atmosphere of carbon monoxide (45 psi). The reaction mixture was allowed to cool down, vented to atmospheric pressure, diluted with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to give 4.50 g (78 % purity, 33 % yield) of the title compound as a colorless oil.

[0978] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 10.45 (m, 1H), 7.71 (dd, 1H), 7.59 (dd, 1H), 7.10 (t, 1H), 3.82 (t, 2H), 3.39 (t, 2H), 1.50 (s, 18H).

[0979] Intermediate 98

[0980] Di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(difluoromethyl)-4-fluorophenyl]ethyl}-2-imidodicarbonate

[0981]

[0982] To a mixture of di-tert-butyl {2-[2-(difluoromethyl)-4-fluoro-6-formylphenyl]ethyl}-2-imidodicarbonate (3.50 g, 78 % purity, 6.54 mmol) and (S2R)-2-methylpropane-2-sulfinamide (1.59 g, 13.1 mmol) in 1,2-dichloroethane (40 mL) was added caesium carbonate (4.26 g, 13.1 mmol) at room temperature. The reaction mixture was stirred at 60 °C for 16 hours. The reaction mixture was allowed to cool down, diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give 2.35 g (99 % purity, 68 % yield) of the title compound as a white solid.

[0983] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 1.29 (s, 9 H) 1.46 (s, 18 H) 3.27 - 3.36 (m, 2 H) 3.80 (t, 2 H) 7.06 (t, 1 H) 7.49 (dd, 1 H) 7.82 (dd, 1 H) 8.94 (m, 1 H).

[0984] Intermediate 99

[0985] Di-tert-butyl (2-{2-[(1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6-(difluoromethyl)-4-fluorophenyl}ethyl)-2-imidodicarbonate

[0986]

[0987] Under an atmosphere of nitrogen at -60 °C bromo(methyl)magnesium (7.4 mL, 22 mmol, 3.0 M in 2-methyltetrahydrofuran) was added dropwise to a solution of di-tert-butyl {2-[2-({[(R)-tert-butylsulfinyl]imino}methyl)-6-(difluoromethyl)-4-fluorophenyl]ethyl}-2-imidodicarbonate (2.35 g, 99 % purity, 4.47 mmol) in dichloromethane (100 mL). Thereaction mixture was stirred at 0 °C for 2 hours. The reaction mixture was quenched with saturated aq. ammonium chloride solution and extracted with ethyl acetate. The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give 1.55 g (96 % purity, 62 % yield) of the title compound as a yellow oil.

[0988] LC-MS (method 3): Rt = 0.61 min; MS (ESIpos): m / z = 437 [M-CO2C4H9+2H]+

[0989] Intermediate 100

[0990] Tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(difluoromethyl)-4-fluorophenyl}ethyl)carbamate

[0991]

[0992] To a solution of di-tert-butyl (2-{2-[(1R)-1-{[(R)-tert-butylsulfinyl]amino}ethyl]-6-(difluoromethyl)-4-fluorophenyl}ethyl)-2-imidodicarbonate (1.85 g, 99 % purity, 4.20 mmol) in THF (40 mL) and water (40 mL) was added iodine (639 mg, 2.52 mmol) at 25 °C. The reaction mixture was heated to 50 °C for 2 hours. The reaction mixture was diluted with sat. aq. NaHCOs solution and sodium thiosulfate solution (1:1). The aq. phase was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound as a yellow solid (893 mg, 95% purity, 61% yield).

[0993] LC-MS (method 2): Rt= 1.15 min; MS (ESIpos): m / z = 333 [M+H]+

[0994] Intermediate 101

[0995] Di-tert-butyl (2-{2-[(1RS)-2,2-difluoro-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (mixture of diastereomers)

[0996]

[0997] To a solution of di-tert-butyl {2-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (10.0 g, 95 % purity, 18.2 mmol) and caesium fluoride (6.10 g, 40.1 mmol) in THF (80 mL) was added (difluoromethyl)(trimethyl)silane (22.7 g, 182 mmol)) at 0 °C. The mixture was stirred at 50 °C for 16 hours under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (4.10 g, 90% purity, 35% yield) as a mixture of diastereomers.

[0998] LC-MS (method 3): Rt = 0.66 min; MS (ESIpos): m / z = 373 [M-(CO2C4H9)2+3H]+

[0999] Intermediate 102

[1000] Di-tert-butyl (2-{2-[(1S)-2,2-difluoro-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6- (trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate

[1001]

[1002] Tert-butyl (tert-butoxycarbonyl)(2-(1-(((R)-tert-butylsulfinyl)amino)-2,2-difluoroethyl)-6-(trifluoromethyl)phenethyl)carbamate (4.10 g, 90 % purity, 6.44 mmol) was separated by preparative SFC (Instrument: Waters 80Q SFC; Column: Phenomenex-Cellulose-2 (250 mm*30 mm, 10 pm); Mobile Phase: Phase A for supercritical carbon dioxide, Phase B for methanol (0.1% ammonia water); Isocratic elution: 35% Phase B (65% Phase A); flow: 60mL / min; cycle time: 3.5 minutes; Back Pressure: 100 bar to keep the carbon dioxide in supercritical flow; temperature: room temperature; detector: UV 220 nm) to give tert-butyl (tert-butoxycarbonyl)(2-((S)-1-(((R)-tert-butylsulfinyl)amino)-2,2-difluoroethyl)-6-(trifluoromethyl)phenethyl)carbamate (stereoisomer 1, first eluting, SFC retention time:1.46 min) as a white solid (2.20 g, 99% purity, 59% yield) and tert-butyl (tert-butoxycarbonyl)(2-((R)-1-(((R)-tert-butylsulfinyl)amino)-2,2-difluoroethyl)-6- (trifluoromethyl)phenethyl)carbamate (stereoisomer 2, second eluting, SFC retention time: 1.69 min) as a white solid.

[1003] LC-MS (method 3): Rt = 0.66 min; MS (ESIpos): m / z = 373 [M-(CO2C4H9)2+3H]+

[1004] Intermediate 103

[1005] Di-tert-butyl (2-{2-[(1S)-1-amino-2,2-difluoroethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate

[1006]

[1007] A solution of acetyl chloride (820 pL, 12 mmol) in dioxane (1.6 mL) was added to methanol (8 mL) dropwise at 0 °C and stirred at 20 °C for 0.5 hour. In a separate flask, di-tert-butyl (2-{2-[(1S)-2,2-difluoro-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (2.20 g, 3.84 mmol) was dissolved in 1,4-dioxane (20 mL) and the first solution was added dropwise at rt. The reaction mixture was stirred at 20 °C for 1 hour. The reaction mixture was diluted with sat. aq. sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated aq. sodium thiosulfate solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (petroleum ether / ethyl acetate) to give the title compound (1.15 g, 95% purity, 61% yield).

[1008] LC-MS (method 2): Rt= 1.48 min; MS (ESIpos): m / z = 469 [M+H]+

[1009] Intermediate 104

[1010] [2-Bromo-6-(trifluoromethyl)phenyl]acetaldehyde

[1011]

[1012] The reaction was performed in a flow reactor.

[1013] Solution 1: [2-Bromo-6-(trifluoromethyl)phenyl]acetonitrile (90.0 g, 99 % purity, 337 mmol) in DCM (900 mL).

[1014] Solution 2: DIBAL-H in toluene (510 mL, 1.0 M, 510 mmol).

[1015] Solution 1 (flowrate = 20.5 mL / min) and solution 2 were pumped (flowrate = 11.5 mL / min; the pump was started 2 min after solution 1) to a static mixer (stainless steel, 4.76 mm [3 / 16”], 0.93 mL volume), leading to the flow reactor (PFA, coils reactor, 3.175 mm [1 / 8”], 21 mL volume, 0 °C) with a residence time of 2 minutes. The output solution was quenched with sat. aq. Rochelle’s salt sol. and stirred for 1 hour. The mixture was extracted into EtOAc, and the org. phase was washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (90.0 g, 82 % purity, 82 % yield).

[1016] 1H NMR (400 MHz, CDCl3) 6 [ppm] = 9.75 (s, 1H), 7.84 (d, 1H), 7.70 (d, 1H), 7.30 (m, 1H), 4.16 (s, 2H).

[1017] Intermediate 105

[1018] (S2R)-N-{2-[2-Bromo-6-(trifluoromethyl)phenyl]ethylidene}-2-methylpropane-2-sulfinamide

[1019]

[1020] To a mixture of [2-bromo-6-(trifluoromethyl)phenyl]acetaldehyde (90.0 g, 82 % purity, 276 mmol) in titanium tetraisopropoxide (820 mL, 2.8 mol) was added (S2R)-2-methylpropane-2-sulfinamide (67.0 g, 553 mmol) and the mixture was stirred at 80 °C for 16 h. The mixture was diluted with sat. aq. sodium bicarbonate sol., filtered and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (87.0 g, 85 % purity, 72 % yield).

[1021] LC-MS (method 3): Rt= 0.63 min; MS (ESIpos): m / z = 370 [M+H]

[1022] Intermediate 106

[1023] (S2R)-N-{(2S)-1-[2-Bromo-6-(trifluoromethyl)phenyl]propan-2-yl}-2-methylpropane-2-sulfinamide

[1024]

[1025] To a solution of (S2R)-N-{2-[2-bromo-6-(trifluoromethyl)phenyl]ethylidene}-2-methylpropane-2-sulfinamide (87.0 g, 85 % purity, 200 mmol) in DCM (500 mL) was added methylmagnesium bromide (330 mL, 3.0 M in Et20, 1000 mmol) at -40 °C. The reaction mixture was stirred at rt for 16 h, diluted with sat. aq. NH4CI sol. and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (48.0 g, 96 % purity, 60 % yield) as yellow oil.

[1026] LC-MS (method 3): Rt= 0.59 min; MS (ESIpos): m / z = 387 [M+H]

[1027] Intermediate 107

[1028] (2S)-1-[2-Bromo-6-(trifluoromethyl)phenyl]propan-2-amine - hydrogen chloride (1 / 1)

[1029]

[1030] A solution of (S2R)-N-{(2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-yl}-2-methylpropane-2-sulfinamide (48.0 g, 96 % purity, 119 mmol) in HCI (350 mL, 2.0 M in 1,4-dioxane, 700 mmol) was stirred at rt for 2 h. The reaction mixture was concentrated under reduced pressure and the residue was purified by trituration with methyl tert-butyl ether (50 mL), followed by recrystallization from EtOH to yield the title compound (28.0 g, 99 % purity, 73 % yield).

[1031] LC-MS (method 3): Rt= 0.40 min; MS (ESIpos): m / z = 282 [M+H]+

[1032] Intermediate 108

[1033] Tert-butyl {(2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-yl}carbamate

[1034]

[1035] To a solution of (2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-amine-hydrogen chloride (1 / 1) (28.0 g, 99 % purity, 87.0 mmol) and di-tert-butyl dicarbonate (38.0 g, 174 mmol) in DCM (250 mL) and MeOH (250 mL) was added triethylamine (30 mL, 220 mmol) and the mixture was stirred at rt for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (32.0 g, 99 % purity, 95 % yield).

[1036] LC-MS (method 3): Rt= 0.67 min; MS (ESIpos): m / z = 325 [M-C4H9+2H]+

[1037] Intermediate 109

[1038] Tert-butyl {(2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-yl}{[2- (trimethylsilyl)ethoxy]methyl}carbamate

[1039]

[1040] To a solution of tert-butyl {(2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-yljcarbamate (32.0 g, 99 % purity, 82.9 mmol) in DMF (800 mL) was added NaH (9.95 g, 60 % in mineral oil, 249 mmol) at 0 °C and the mixture was stirred at 0 °C for 30 min. Then, [2-(chloromethoxy)ethyl](trimethyl)silane (41.5 g, 249 mmol) was added at 0 °C and the resulting mixture was stirred at 60 °C for 16 h. The mixture was poured into sat. aq. NH4CI sol. slowly under nitrogen atmosphere at 0 °C and extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / EtOAc) to yield the title compound (31.0 g, 84 % purity, 61 % yield) which was used in the next step without further purification.

[1041] LC-MS (method 3): Rt= 0.87 min; MS (ESIpos): m / z = 536.0 [M+Na]+

[1042] Intermediate 110

[1043] Tert-butyl {(2S)-1-[2-ethenyl-6-(trifluoromethyl)phenyl]propan-2-yl}{[2- (trimethylsilyl)ethoxy]methyl}carbamate

[1044]

[1045] To a mixture of tert-butyl {(2S)-1-[2-bromo-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate (25.0 g, 84 % purity, 41.0 mmol) and potassium ethenyl(trifluorido)borate(1-) (8.23 g, 61.5 mmol) in 1,4-dioxane (180 mL) and water (60 mL) was added XPhos Pd G4 (3.53 g, 4.10 mmol) and Na2COs (13.0 g, 123 mmol) and the mixture was stirred at 80 °C for 16 h. The mixture was diluted with water andextracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (18.2 g, 76 % purity, 73 % yield) which was used in the next step without further purification.

[1046] 1H NMR (400 MHz, DMSO-d6) 6 [ppm] = 7.82 (d, 1H), 7.69 - 7.61 (m, 1H), 7.50 - 7.33 (m, 1 H), 7.27 - 6.95 (m, 1 H), 5.88 - 5.67 (m, 1 H), 5.45 - 5.32 (m, 1 H), 4.69 - 4.62 (m, 2H), 4.55 - 4.40 (m, 1H), 3.64 - 3.48 (m, 2H), 3.24 - 2.98 (m, 2H), 1.41 - 1.13 (m, 12H), 0.82 -0.85 (m, 2H), -0.02 (s, 9H).

[1047] Intermediate 111

[1048] Tert-butyl {(2S)-1-[2-formyl-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate

[1049]

[1050] Through a solution of tert-butyl {(2S)-1-[2-ethenyl-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate (18.2 g, 76 % purity, 30.1 mmol) in dichloromethane (400 mL) was bubbled ozone at -78 °C. Once the solution turned blue, ozone addition was stopped. Nitrogen was passed through the solution until the blue colour disappeared. The mixture was allowed to warm to room temperature and flushed with nitrogen for 15 min. Then, anhydrous DMSO (22 mL, 300 mmol) was added and the mixture warmed to room temperature and stirred for 16 h. The mixture was concentrated under reduced pressure to yield the title compound (16.5 g, 83 % purity, 99 % yield) which was used in the next step without further purification.

[1051] LC-MS (method 3): Rt= 0.76 min; MS (ESIpos): m / z = 484.2 [M+Na]+

[1052] Intermediate 112Tert-butyl {(2S)-1-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate

[1053]

[1054] To a mixture of tert-butyl {(2S)-1-[2-formyl-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate (16.5 g, 83 % purity, 29.7 mmol) and (S2R)-2-methylpropane-2-sulfinamide (7.19 g, 59.3 mmol) in 1,2-dichloroethane (200 mL) was added caesium carbonate (19.3 g, 59.3 mmol) and the mixture was stirred at 60 °C for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (12.0 g, 95 % purity, 68 % yield).

[1055] LC-MS (method 3): Rt= 0.81 min; MS (ESIpos): m / z = 587 [M+Na]+

[1056] Intermediate 113

[1057] Tert-butyl [(2S)-1-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6-(trifluoromethyl)phenyl}propan-2-yl]{[2-(trimethylsilyl)ethoxy]methyl}carbamate

[1058]

[1059] To a solution of tert-butyl {(2S)-1-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]propan-2-yl}{[2-(trimethylsilyl)ethoxy]methyl}carbamate (12.0 g, 95 % purity, 20.2 mmol) in dichloromethane (400 mL) was added methylmagnesiumbromide (34 mL, 3.0 M in Et20, 100 mmol) at -60 °C and the mixture was stirred at 0 °C for 16 h. The mixture was quenched with sat. aq. ammonium chloride sol. and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to yield the title compound (5.50 g, 99 % purity, 46 % yield).

[1060] LC-MS (method 3): Rt= 0.79 min; MS (ESIpos): m / z = 603 [M+Na]+

[1061] Intermediate 114

[1062] Tert-butyl [(2S)-1-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}propan-2-yl]carbamate

[1063]

[1064] Tert-butyl [(2S)-1-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}ethyl]-6- (trifluoromethyl)-phenyl}propan-2-yl]{[2-(trimethylsilyl)ethoxy]methyl}carbamate (5.50 g, 99 % purity, 9.37 mmol) was dissolved in THF (100 mL) and water (100 mL), then iodine (1.43 g, 5.62 mmol) was added at room temperature and the reaction mixture was stirred at 50 °C for 24 hours. The reaction mixture was cooled to room temperature and diluted with a 1: 1 mixture of sat. aq. NaHCOs sol. and sat. aq. Na2S2O3sol. and extracted into EtOAc. The org. phase was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by flash column chromatography (petroleum ether / EtOAc) afforded the title compound (1.10 g, 96 % purity, 33 % yield).

[1065] LC-MS (method 3): Rt= 0.75 min; MS (ESIneg): m / z = 345.3 [M-H]’

[1066] Intermediate 115

[1067] Ethyl 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate

[1068]

[1069] General Procedure A was used - Ethyl 4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate (120 mg, 418 pmol), PyBOP (326 mg, 627 pmol), DIPEA (220 pL, 1.3 mmol), di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (217 mg, 501 pmol), and DMF (3.2 mL) afforded the title compound (360 mg, quant.).

[1070] LC-MS (method 2): Rt= 1.64 min; MS (ESIpos): m / z = 703 [M+H]+

[1071] Intermediate 116

[1072] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1073]

[1074] General Procedure B was used - Ethyl 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate (360 mg, 513 pmol), THF (1.6 mL),and aq. lithium hydroxide solution (1.3 mL, 1.0 M, 1.3 mmol) afforded the title compound (300 mg, 87% yield).

[1075] LC-MS (method 2): Rt= 0.96 min; MS (ESIneg): m / z = 673 [M-H]’

[1076] Intermediate 117

[1077] Lithium (R)-4-((1-(2-(2-aminoethyl)-3-(trifluoromethyl)phenyl)ethyl)amino)-6- (trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate

[1078]

[1079] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylic acid (300 mg, 445 pmol) was suspended in dioxane (1.9 mL). HCI (2.2 mL, 4.0 M in dioxane, 8.9 mmol) was added, followed by THF (1.5 mL), then stirred at room temperature for 18 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in THF (1.5 mL) and aq. lithium hydroxide solution (1.6 mL, 1.0 M, 1.6 mmol) was added and the mixture was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure. The resulting residue was triturated with MTBE to afford the title compound (240 mg, quant.) which was used in the next step without any further purification.

[1080] LC-MS (method 2): Rt= 0.74 min; MS (ESIneg): m / z = 472 [M-Li]’

[1081] Intermediate 118

[1082] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-methoxyquinazoline-2-carboxylate

[1083]

[1084] General Procedure A was used - Ethyl 4-hydroxy-6-methoxyquinazoline-2-carboxylate (360 mg, 1.45 mmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6- (trifluoromethyl)phenyl}ethyl)carbamate (459 mg, 1.38 mmol), PyBOP (1.08 g, 2.07 mmol), DBU (620 pL), and DMF (10 mL) afforded the title compound (364 mg, 45% yield).

[1085] LC-MS (method 2): Rt= 1.41 min; MS (ESIpos): m / z = 563 [M+H]+

[1086] Intermediate 119

[1087] (R)-4-((1-(2-(2-((Tert-butoxycarbonyl)amino)ethyl)-3-(trifluoromethyl)phenyl)ethyl)amino)-6-methoxyquinazoline-2-carboxylic acid

[1088]

[1089] General Procedure B was used - Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxyquinazoline-2-carboxylate (362 mg, 643 pmol), THF (11 mL), and aq. lithium hydroxide solution (1.3 mL, 1 M, 1.3 mmol) afforded the title compound (465 mg, quant.). LC-MS (method 2): Rt= 0.80 min; MS (ESIpos): m / z = 535M+H]+Intermediate 120

[1090] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxyquinazoline-2-carboxylic acid — hydrogen chloride (1 / 1)

[1091]

[1092] General Procedure C was used - (R)-4-((1-(2-(2-((tert-butoxycarbonyl)amino)ethyl)-3-(trifluoromethyl)phenyl)ethyl)amino)-6-methoxyquinazoline-2-carboxylic acid (498 mg, 580 pmol), THF (6 mL), and HCI (1.5 mL, 4 M in dioxane) afforded the title compound (457 mg, quant.).

[1093] LC-MS (method 2): Rt= 0.74 min; MS (ESIpos): m / z = 435 [M+H]+

[1094] Intermediate 121

[1095] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6,7-dimethoxyquinazoline-2-carboxylate

[1096]

[1097] General Procedure A was used - Ethyl 4-hydroxy-6,7-dimethoxyquinazoline-2-carboxylate (500 mg, 1.80 mmol) and tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (569 mg, 1.71 mmol), PyBOP (1.34 g, 2.57 mmol), DBU (770 pL), and DMF (15 mL) afforded the title compound (728 mg, 68% yield).

[1098] LC-MS (method 2): Rt= 1.38 min; MS (ESIpos): m / z = 593 [M+H]+Intermediate 122

[1099] (R)-4-((1-(2-(2-((Tert-butoxycarbonyl)amino)ethyl)-3- (trifluoromethyl)phenyl)ethyl)amino)-6,7-dimethoxyquinazoline-2-carboxylic acid

[1100]

[1101] General Procedure B was used - Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6,7-dimethoxyquinazoline-2-carboxylate (725 mg, 1.22 mmol), THF (15 mL), and aq. lithium hydroxide solution (1.8 mL, 1 M, 1.8 mL) afforded the title compound (805 mg, quant.). LC-MS (method 2): Rt= 0.81 min; MS (ESIpos): m / z = 565 [M+H]+

[1102] Intermediate 123

[1103] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6,7-dimethoxyquinazoline-2-carboxylic acid — hydrogen chloride (1 / 1)

[1104]

[1105] General Procedure C was used - (R)-4-((1-(2-(2-((tert-butoxycarbonyl)amino)ethyl)-3-(trifluoromethyl)phenyl)ethyl)amino)-6,7-dimethoxyquinazoline-2-carboxylic acid (805 mg, 87 % purity, 1.22 mmol), THF (12 mL), and HCI (3.1 mL, 4 M in dioxane) afforded the title compound (730 mg, quant.).

[1106] LC-MS (method 2): Rt= 0.72 min; MS (ESIpos): m / z = 465 [M+H]+Intermediate 124

[1107] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylate

[1108]

[1109] General Procedure A was used - Ethyl 4-oxo-6-(trifluoromethoxy)-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (294 mg, 970 pmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (293 mg, 882 pmol), DIPEA (380 pL, 2.2 mmol), PyBOP (688 mg, 1.32 mmol), DMF (9.8 mL) afforded the title compound (449 mg, 99% purity, 74% yield).

[1110] LC-MS (method 2): Rt= 1.47 min; MS (ESIpos): m / z = 618 [M+H]+

[1111] Intermediate 125

[1112] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1113]

[1114] General Procedure B was used - Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylate (447 mg, 724 pmol), THF (2.9 mL), water (1.8 mL), aq. LiOH sol. (930 pL, 2 M, 1.8 mmol) afforded the title compound (438 mg, quant.).

[1115] LC-MS (method 1): Rt= 1.36 min; MS (ESIpos): m / z = 590 [M+H]+

[1116] Intermediate 126

[1117] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1118]

[1119] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylic acid (436 mg, 740 pmol), 1,4-dioxane (4 mL), MeCN (2 mL), HCI (1.8 mL, 4.0 M in dioxane, 7.4 mmol) afforded the title compound (406 mg, quant.).

[1120] LC-MS (method 1): Rt= 0.91 min; MS (ESIpos): m / z = 490 [M+H]+

[1121] Intermediate 127

[1122] Ethyl 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylate

[1123]

[1124] General Procedure A was used - Ethyl 4-hydroxy-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylate (200 mg, 696 pmol), di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (361 mg, 836 pmol), PyBOP (544 mg, 1.04 mmol), DIPEA (360 pL, 2.1 mmol), DMF (5.4 mL) afforded the title compound (530 mg, quant.).

[1125] LC-MS (method 2): Rt= 1.67 min; MS (ESIpos): m / z = 703 [M+H]+

[1126] Intermediate 128

[1127] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylic acid

[1128]

[1129] General Procedure B was used - Ethyl 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylate (530 mg, 755 pmol), THF (2.4 mL),aq. lithium hydroxide solution (1.9 mL, 1.0 M, 1.9 mmol) afforded the title compound (450 mg, 88% yield).

[1130] LC-MS (method 2): Rt= 0.95 min; MS (ESIneg): m / z = 672 [M-H]’

[1131] Intermediate 129

[1132] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6- (trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1133]

[1134] General Procedure C was used - 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylic acid (250 mg, 371 pmol), 1,4-dioxane (1.6 mL), HCI (1.9 mL, 4.0 M in dioxane, 7.4 mmol) were used. Purification by trituration with TBME afforded the title compound (200 mg, quant.).

[1135] LC-MS (method 2): Rt= 0.82 min; MS (ESIpos): m / z = 474 [M+H]+

[1136] Intermediate 130

[1137] Ethyl 6-bromo-4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-7-fluoroquinazoline-2-carboxylate

[1138]

[1139] General Procedure A was used - Ethyl 6-bromo-7-fluoro-4-hydroxyquinazoline-2-carboxylate (290 mg, 90 % purity, 827 pmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (250 mg, 752 pmol), DIPEA (330 pL, 1.9 mmol), PyBOP (587 mg, 1.13 mmol), and DMF (8 mL) afforded the title compound (509 mg, quant.).

[1140] LC-MS (method 2): Rt= 1.51 min; MS (ESIpos): m / z = 629 [M+H]+

[1141] Intermediate 131

[1142] 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-7-fluoroquinazoline-2-carboxylic acid

[1143]

[1144] General Procedure B was used - Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-7-fluoroquinazoline-2-carboxylate (500 mg, 794 pmol), THF (5 mL), water (2 mL), LiOH (47.6 mg, 1.99 mmol) afforded the title compound (448 mg, 94% yield).

[1145] LC-MS (method 2): Rt= 0.88 min; MS (ESIneg): m / z = 599 [M-H]’

[1146] Intermediate 132

[1147] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromo-7-fluoroquinazoline-2-carboxylic acid — hydrogen chloride (1 / 1)

[1148]

[1149] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-7-fluoroquinazoline-2-carboxylic acid (445 mg, 740 pmol), 1,4-dioxane (4 mL), HCI (1.8 mL, 4.0 M in dioxane, 7.4 mmol) afforded the title compound (410 mg, quant.).

[1150] LC-MS (method 2): Rt= 0.80 min; MS (ESIneg): m / z = 499 [M-H]’

[1151] Intermediate 133

[1152] Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)quinazoline-2-carboxylate

[1153]

[1154] General Procedure A was used - ethyl 6-bromo-4-hydroxyquinazoline-2-carboxylate (98.3 mg, 331 pmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6- (trifluoromethyl)phenyl}ethyl)carbamate (100 mg, 301 pmol), PyBOP (235 mg, 451 pmol), DIPEA (130 pL, 750 pmol), and DMF (1 mL) afforded the title compound (163 mg, 89 % yield).

[1155] LC-MS (method 2): Rt= 1.47 min; MS (ESIpos): m / z = 611 [M+H]+

[1156] Intermediate 1346-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)quinazoline-2-carboxylic acid

[1157]

[1158] General Procedure B was used - ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)quinazoline-2-carboxylate (160 mg, 262 pmol), lithium hydroxide (15.7 mg, 654 pmol), water (650 pL), and THF (2.0 mL) afforded the title compound (149 mg, 98%).

[1159] LC-MS (method 2): Rt= 0.88 min; MS (ESIpos): m / z = 583 [M+H]+

[1160] Intermediate 135

[1161] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromoquinazoline-2-carboxylic acid — hydrogen chloride (1 / 1)

[1162]

[1163] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)quinazoline-2-carboxylic acid (145 mg, 249 pmol), hydrogen chloride (1.6 mL, 4.0 M in 1,4-dioxane, 6.2 mmol), and MeCN (3.0 mL) afforded the title compound (175 mg, quantitative yield). LC-MS (method 2): Rt= 0.77 min; MS (ESIpos): m / z = 483 [M+H]+

[1164] Intermediate 136Ethyl 6-bromo-4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]-1,1-difluoroethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate

[1165]

[1166] General Procedure A was used - tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}-2,2-difluoroethyl)carbamate (300 mg, 814 pmol), ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (243 mg, 814 pmol), PyBop (578 mg, 1.11 mmol), and DIPEA (320 pL, 1.9 mmol) in DMF (10 mL) afforded the title compound (270 mg, 51% yield).

[1167] LC-MS (method 2): Rt= 1.39 min; MS (ESIneg): m / z = 646 [M-H]’

[1168] Intermediate 137

[1169] 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]-1,1 -difluoroethyl}- 3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1170]

[1171] General Procedure B was used - ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]-1,1-difluoroethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido [3,4-d]pyrimidine-2-carboxylate (270 mg, 416 pmol), aq. lithium hydroxide sol. (830 pL, 1.0 M, 830 pmol), and THF (5.0 mL) afforded the title compound (262 mg, 99% yield). LC-MS (method 2): Rt= 0.81 min; MS (ESIneg): m / z = 618 [M-H]⁻Intermediate 138

[1172] 4-({(1R)-1-[2-(2-Amino-1,1-difluoroethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1173]

[1174] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]-1,1-difluoroethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (260 mg, 419 pmol), HCI (420 pL, 4.0 M in 1,4-dioxane, 1.7 mmol), and THF (20 mL) afforded the title compound (237 mg, 96% yield).

[1175] LC-MS (method 2): Rt= 0.69 min; MS (ESIpos): m / z = 520 [M+H]+

[1176] Intermediate 139

[1177] Ethyl 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylate

[1178]

[1179] General Procedure A was used - ethyl 4,6-dichloropyrido[3,2-d]pyrimidine-2-carboxylate (282 mg, 1.04 mmol), di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6- (trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (448 mg, 1.04 mmol), DIPEA (360 pL, 2.1 mmol), DMF (11 mL) afforded the title compound (538 mg, 78% yield).

[1180] LC-MS (method 2): Rt= 1.63 min; MS (ESIpos): m / z = 668 [M+H]+Intermediate 140

[1181] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylic acid

[1182]

[1183] General Procedure B was used - ethyl 4-({(1 R)-1 -[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylate (57.0 mg, 85.3 pmol), lithium hydroxide (110 pL, 4.0 M in water, 430 pmol), and THF (350 pL) afforded a mixture of the title compound and the corresponding mono-Boc derivative (51.0 mg). The mixture was used for the following step.

[1184] LC-MS (method 2): Rt= 0.95 min; MS (ESIpos): m / z = 640 [M+H]+

[1185] Intermediate 141

[1186] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1187]

[1188] General Procedure C was used - A mixture of 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylic acid (30.9 mg, 48.2 pmol) and 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,2-d]pyrimidine-2-carboxylic acid (26.1 mg, 48.2 pmol), hydrogen chloride (240 pL, 4.0 M in 1,4-dioxane, 960 pmol), and THF (620 pL) afforded the title compound (41.0 mg, quantitative yield).

[1189] LC-MS (method 2): Rt= 0.82 min; MS (ESIpos): m / z = 440 [M+H]+

[1190] Intermediate 142

[1191] Ethyl 4- ({( 1 R)-1 -[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(1, 1 -difluoroethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate

[1192]

[1193] General Procedure A was used - di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(1,1-difluoroethyl)phenyl}ethyl)-2-imidodicarbonate (2.00 g, 4.67 mmol), ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (1.53 g, 5.13 mmol), PyBop (3.64 g, 7.00 mmol), and DIPEA (2.0 mL, 12 mmol) in DMF (40 mL) afforded the title compound (2.37 g, 72% yield).

[1194] LC-MS (method 2): Rt= 1.56 min; MS (ESIpos): m / z = 708 [M+H]+

[1195] Intermediate 143

[1196] 4-({(1 R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3-(1,1-difluoroethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid

[1197]

[1198] General Procedure B was used - ethyl 4-({(1 R)-1 -[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(1,1-difluoroethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate (2.37 g, 3.34 mmol), lithium hydroxide sol. (6.7 mL, 1.0 M in water, 6.7 mmol), and THF (50 mL) afforded the title compound (2.25 g) as a mixture of bis-boc and mono-boc product. The mixture was used in the next step without further purification

[1199] LC-MS (method 2): Rt= 0.93 min; MS (ESIneg): m / z = 678 [M-H]’

[1200] Intermediate 144

[1201] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(1,1-difluoroethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1202]

[1203] General Procedure C was used - A mixture of 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(1,1-difluoroethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid and 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(1,1-difluoroethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (2.25 g, 3.34 mmol), hydrogen chloride (8.3 mL, 4.0 M in 1,4-dioxane, 33 mmol), and THF (60 mL) afforded the title compound (1.78 g, 99% yield). LC-MS (method 2): Rt= 0.73 min; MS (ESIneg): m / z = 478 [M-H]’Intermediate 145

[1204] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (difluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate

[1205]

[1206] General Procedure A was used - tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(difluoromethyl)phenyl}ethyl)carbamate (155 mg, 493 pmol), ethyl 6-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (123 mg, 493 pmol), PyBop (385 mg, 740 pmol), and 1,8-Diazabicyclo(5.4.0)undec-7-en (220 pL, 1.5 mmol) in DMF (4.7 mL) afforded the title compound (176 mg, 59% yield).

[1207] LC-MS (method 2): Rt= 1.29 min; MS (ESIpos): m / z = 546 [M+H]+

[1208] Intermediate 146

[1209] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-3- (difluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid

[1210]

[1211] General Procedure B used - ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate (175 mg, 90 % purity, 289 pmol), lithium hydroxide sol. (720 pL, 1.0 M in water, 720 pmol), and THF (1.2 mL) afforded the title compound (129 mg, 78% yield).

[1212] LC-MS (method 2): Rt= 0.78 min; MS (ESIpos): m / z = 518.5 [M+H]+

[1213] Intermediate 147

[1214] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(difluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1215]

[1216] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid (128 mg, 247 pmol), hydrogen chloride (1.2 mL, 4.0 M in 1,4-dioxane, 4.9 mmol) in 1,4-dioxane (1.3 mL) and acetonitrile (520 pL) afforded the title compound (129 mg, quant.). LC-MS (method 2): Rt= 0.63 min; MS (ESIpos): m / z = 418 [M+H]+

[1217] Intermediate 148

[1218] Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (difluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate

[1219]

[1220] General Procedure A was used - tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(difluoromethyl)phenyl}ethyl)carbamate (52.7 mg, 168 pmol), ethyl 6-bromo-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (50.0 mg, 168 pmol), PyBop (131 mg, 252 pmol), and 1,8-diazabicyclo(5.4.0)undec-7-en (75 pL, 500 pmol) in DMF (1.6 mL) afforded the title compound (71.0 mg, 68% yield).

[1221] LC-MS (method 2): Rt= 1.34 min; MS (ESIpos): m / z = 594 [M+H]+

[1222] Intermediate 149

[1223] 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1224]

[1225] General Procedure B was used - ethyl 6-bromo-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (1.38 g, 90 % purity, 2.1 mmol), lithium hydroxide (5.2 mL, 1.0 M in water, 5.2 mmol), and THF (8.5 mL) afforded the title compound (1.1 g, 87% yield).LC-MS (method 2): Rt= 0.79 min; MS (ESIpos): m / z = 566 [M+H]+

[1226] Intermediate 150

[1227] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(difluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1228]

[1229] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (1.13 g, 2.00 mmol), hydrogen chloride (10 mL, 4.0 M in 1,4-dioxane, 40 mmol) in 1,4-dioxane (10 mL) and acetonitrile (4.2 mL) afforded the title compound (1.18 g, quant.).

[1230] LC-MS (method 2): Rt= 0.68 min; MS (ESIpos): m / z = 466 [M+H]+

[1231] Intermediate 151

[1232] Ethyl 6-bromo-4-({(1R)-1-[2-{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}-3- (trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate

[1233]

[1234] General Procedure A was used - ethyl 6-bromo-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (1.06 g, 3.57 mmol), tert-butyl [(2S)-1-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}propan-2-yl]carbamate (1.24 g, 3.57 mmol), PyBOP (2.79 g), DBU (1.6 mL) in DMF (32 mL) gave the title compound (2.12 g, 94 % purity, 98 % yield).LC-MS (method 1): Rt= 1.47 min; MS (ESIpos): m / z = 628 [M+H]+

[1235] Intermediate 152

[1236] 6-Bromo-4-({(1R)-1-[2-{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1237]

[1238] General Procedure B was used - ethyl 6-bromo-4-({(1R)-1-[2-{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate (2.12 g, 3.38 mmol), aq. LiOH sol. (8.5 mL, 1.0 M, 8.5 mmol) in THF (15 mL) gave the title compound (1.67 g, 96 % purity, 79 % yield).

[1239] LC-MS (method 1): Rt= 1.29 min; MS (ESIneg): m / z = 596 [M-H]’

[1240] Intermediate 153

[1241] 4-{[(1R)-1-{2-[(2S)-2-Aminopropyl]-3-(trifluoromethyl)phenyl}ethyl]amino}-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid-hydrogen chloride (1 / 1)

[1242]

[1243] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{(2S)-2-[(tert-butoxycarbonyl)amino]propyl}-3-(trifluoromethyl)phenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (1.67 g, 2.79 mmol), HCI (11 mL, 4.0 M in 1,4-dioxane) in 1,4-dioxane (15 mL) yielded the title compound (1.54 g, quant.) after trituration with MTBE.LC-MS (method 1): Rt= 0.81 min; MS (ESIneg): m / z = 498 [M-H]’

[1244] Intermediate 154

[1245] (9S, 15R)-2-Bromo-4,9, 15-trimethyl-11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1246]

[1247] General Procedure E was used - (9S,15R)-2-bromo-9,15-dimethyl-11-(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (500 mg, 1.04 mmol), nitromethane (560 pL, 10 mmol), DBU (310 pL, 2.1 mmol) in DMSO (9.0 mL) yielded the title compound (4.20 mg, 1 % yield).

[1248] LC-MS (method 1): Rt= 1.18 min; MS (ESIpos): m / z = 494.2 [M+H]+

[1249] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.933 (0.91), 0.951 (0.41), 1.228 (0.42), 1.274 (5.40), 1.290 (5.40), 1.617 (5.34), 1.634 (5.32), 2.518 (2.66), 2.523 (1.73), 2.734 (16.00), 2.777 (0.40), 2.815 (0.59), 2.845 (0.45), 3.372 (0.83), 3.384 (0.60), 5.178 (0.75), 5.184 (0.76), 5.196 (0.76), 5.202 (0.74), 5.623 (0.46), 5.635 (0.54), 5.649 (0.46), 7.228 (0.92), 7.247 (2.06), 7.266 (2.84), 7.290 (1.58), 7.430 (1.91), 7.432 (2.24), 7.449 (1.71), 7.452 (1.67), 7.501 (1.83), 7.518 (1.60), 8.449 (5.14), 9.506 (1.68), 9.512 (1.64).

[1250] Intermediate 155

[1251] (15R)-2-Bromo-11-(difluoromethyl)-15-methyl-9,10,15,16-tetrahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1252]

[1253] General Procedure D was used - 4-({(1R)-1-[2-(2-aminoethyl)-3- (difluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1) (1.16 g, 2.31 mmol), N, N-diisopropylethylamine (1.2 mL, 6.9 mmol) in DMF (209 mL), and HATU (965 mg, 2.54 mmol) in DMF (209 mL) afforded the title compound (327 mg, 32% yield).

[1254] LC-MS (method 2): Rt= 1.05 min; MS (ESIpos): m / z = 448 [M+H]+

[1255] Intermediate 156

[1256] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylate

[1257]

[1258] General Procedure A was used - ethyl 6-chloro-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (694 mg, 2.74 mmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (1.00 g, 3.01 mmol), DIPEA (950 pL, 6.84 mmol), PyBOP (2.14 g, 4.10 mmol), DMF (22 mL) afforded the title compound (1.01 g, 65% yield).

[1259] LC-MS (method 2): Rt= 1.42 min; MS (ESIneg): m / z = 566 [M-H]’

[1260] Intermediate 157

[1261] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylic acid

[1262]

[1263] General Procedure B was used - ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylate (350 mg, 616 pmol), LiOH (36.9 mg, 1.54 mmol), THF (2.5 mL), water (1.5 mL). The crude reaction mixture was purified by preparative HPLC purification (acidic method) to afford the title compound (196 mg, 59% yield).

[1264] LC-MS (method 2): Rt= 0.83 min; MS (ESIpos): m / z = 540 [M+H]+

[1265] Intermediate 158

[1266] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1267]

[1268] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylic acid (192 mg, 356 pmol), HCI (4.0 M in 1,4-dioxane, 2.7 mL), MeCN (2.0 mL) afforded the title compound (205 mg, quantitative yield).

[1269] LC-MS (method 2): Rt= 0.71 min; MS (ESIpos): m / z = 440 [M+H]+

[1270] Intermediate 159Ethyl 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate

[1271]

[1272] General Procedure A was used - ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (1.50 g, 5.03 mmol), di-tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (2.18 g, 5.03 mmol), PyBOP (3.93 g, 7.55 mmol), DIPEA (2.1 mL), DMF (39 mL) afforded the title compound (3.14 g, 88% yield).

[1273] LC-MS (method 2): Rt= 1.68 min; MS (ESIpos): m / z = 712 [M+H]+

[1274] Intermediate 160

[1275] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid

[1276]

[1277] General Procedure B was used - ethyl 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate (3.14 g, 4.40 mmol), LiOH sol. (27 mL, 1.0 M in water, 27 mmol), THF (80 mL) afforded the title compound (3.08 g, quantitative yield).

[1278] LC-MS (method 2): Rt= 0.92 min; MS (ESIpos): m / z = 684 [M+H]+

[1279] Intermediate 161

[1280] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1281]

[1282] General Procedure C was used - 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid (3.08 g, 4.41 mmol), HCI (41 mL, 4.0 M in dioxane, 170 mmol), MeCN (85 mL) afforded the title compound (3.15 g, quantitative yield).

[1283] LC-MS (method 2): Rt= 0.71 min; MS (ESIpos): m / z = 484 [M+H]+

[1284] Intermediate 162

[1285] Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3- (trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate

[1286]

[1287] General Procedure A was used - tert-butyl (2-{2-[(1R)-1-aminoethyl]-4-chloro-6- (trifluoromethyl)phenyl}ethyl)carbamate (80.0 mg, 218 umol), ethyl 6-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (59.8 mg, 240 pmol), DBU (98 pL), PyBop (170 mg, 327 pmol), DMF (2.7 mL) afforded the title compound (105 mg, 81% yield). LC-MS (method 2): Rt= 1.44 min; MS (ESIpos): m / z = 598 [M+H]+

[1288] Intermediate 163

[1289] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-5-chloro-3- (trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid

[1290]

[1291] General Procedure B was used - ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate (105 mg, 176 pmol), LiOH sol. (220 pL, 2.0 M in water, 440 pmol), THF (5 mL) afforded the title compound (103 mg, quantitative yield).

[1292] LC-MS (method 2): Rt= 0.87 min; MS (ESIpos): m / z = 570 [M+H]+

[1293] Intermediate 164

[1294] 4-({(1R)-1-[2-(2-Aminoethyl)-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1295]

[1296] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid (103 mg, 181 pmol), HCI (450 pL, 4.0 M in dioxane, 1.8 mmol), dioxane (3 mL). The reaction mixture was diluted with toluene and concentrated under reduced pressure to afford the desired compound (3.15 g, quantitative yield).

[1297] LC-MS (method 2): Rt= 0.76 min; MS (ESIpos): m / z = 470 [M+H]+

[1298] Intermediate 165

[1299] Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)-5-fluorophenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate

[1300]

[1301] General Procedure A was used - Ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (759 mg, 2.55 mmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(difluoromethyl)-4-fluorophenyl}ethyl)carbamate (846 mg, 2.55 mmol), PyBop (1.99 g, 3.82 mmol), DIPEA (1.3 mL, 7.6 mmol), DMF (15 mL) afforded the title compound (1.38 g, 80% yield). LC-MS (method 2): Rt= 1.37 min; MS (ESIpos): m / z = 612 [M+H]+

[1302] Intermediate 166

[1303] 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)-5-fluorophenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1304]

[1305] General Procedure B was used - Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)-5-fluorophenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate (1.35 g, 2.20 mmol), LiOH sol. (2.8 mL, 2.0 M in water, 5.5 mmol), THF (27 mL) afforded the title compound (1.28 g, 99% yield).

[1306] LC-MS (method 2): Rt= 0.79 min; MS (ESIpos): m / z = 584 [M+H]+

[1307] Intermediate 167

[1308] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(difluoromethyl)-5-fluorophenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid

[1309]

[1310] General Procedure C was used - 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(difluoromethyl)-5-fluorophenyl]ethyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (1.28 g, 2.19 mmol), HCI (5.5 mL, 4.0 M in dioxane, 22 mmol), dioxane (20 mL). Purification by HPLC (basic method) yielded the desired compound (655 mg, 62% yield).

[1311] LC-MS (method 2): Rt= 0.71 min; MS (ESIpos): m / z = 484 [M+H]+

[1312] Intermediate 168Ethyl 4-({(1S)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]- 2,2-difluoroethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate

[1313]

[1314] General Procedure A was used - Ethyl 6-bromo-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (668 mg, 2.24 mmol), di-tert-butyl (2-{2-[(1S)-1-amino-2,2-difluoroethyl]-6-(trifluoromethyl)phenyl}ethyl)-2-imidodicarbonate (1.05 g, 2.24 mmol), PyBop (1.75 g, 3.36 mmol), DBU (1.0 mL, 6.7 mmol), DMF (21 mL) afforded the title compound (648 mg, 28% purity, 11% yield). The obtained material was used directly in the next step without further purification.

[1315] LC-MS (method 2): Rt= 1.63 min; MS (ESIpos): m / z = 748 [M+H]+

[1316] Intermediate 169

[1317] 4-({(1S)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]-2,2-difluoroethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid

[1318]

[1319] General Procedure B was used - Ethyl 4-({(1S)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]-2,2-difluoroethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylate (684 mg, 28 % purity, 256 µmol), LiOH sol. (640 µL, 1.0 M in water, 640 µmol) and THF (1 mL) afforded the title compound (600 mg, 30% purity, 98% yield). The obtained material was used directly in the next step without further purification.

[1320] LC-MS (method 2): Rt= 0.91 min; MS (ESIneg): m / z = 720 [M-H]’

[1321] Intermediate 170

[1322] 4-({(1S)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]-2,2-difluoroethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid

[1323]

[1324] General Procedure C was used - 4-({(1S)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]-2,2-difluoroethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid (600 mg, 833 µmol), HCI (4.2 mL, 4.0 M in dioxane, 17 mmol), dioxane (4.4 mL), MeCN (1.7 mL). Purification by HPLC (basic method) yielded the desired compound (125 mg, 25% yield).

[1325] LC-MS (method 2): Rt= 0.72 min; MS (ESIpos): m / z = 520 [M+H]+

[1326] Intermediate 171

[1327] Ethyl 4-({(1 R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-8-methyl-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate

[1328]

[1329] General Procedure E: Ethyl 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate (625 mg, 891 µmol) in DMSO (5.4 mL), DBU (400 µL, 2.7 mmol) and nitromethane (290 µL, 5.3 mmol). The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with DCM and washed with water. The org. phase was filtered through hydrophobic filter paper and concentrated under reduced pressure. Purification by flash column chromatography gave the desired product (538 mg, 84 % yield).

[1330] LC-MS (method 2): Rt= 1.72 min; MS (ESIpos): m / z = 717 [M+H]+

[1331] Intermediate 172

[1332] 4-({(1R)-1-[2-{2-[Bis(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-8-methyl-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine- 2-carboxylic acid

[1333]

[1334] General Procedure B - Ethyl 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-8-methyl-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylate (583 mg, 815 µmol), LiOH sol. (2.0 mL, 1.0 M in water, 2.0 mmol) in THF (2.6 mL) afforded the title compound (570 mg, quantitative yield).

[1335] LC-MS (method 2): Rt= 0.94 min; MS (ESIneg): m / z = 687 [M-H]’

[1336] Intermediate 173

[1337] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-8-methyl-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1338]

[1339] General Procedure C - 4-({(1R)-1-[2-{2-[bis(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-8-methyl-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine-2-carboxylic acid (570 mg, 829 µmol), HCI (4.1 mL, 4.0 M, 17 mmol) in 1,4-dioxane (3.5 mL) and THF (2.3 mL) was stirred for 2 h at rt. The reaction mixture was concentrated under reduced pressure and suspended in MTBE. The resulting solid was filtered and washed with MTBE to afford the desired compound (480 mg, quantitative yield).

[1340] LC-MS (method 2): Rt= 0.77 min; MS (ESIpos): m / z = 488 [M+H]+

[1341] Intermediate 174

[1342] Ethyl 4-({(1 R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3- (trifluoromethyl)phenyl]ethyl}amino)-6-[1-(difluoromethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylate

[1343]

[1344] General Procedure A was used - Ethyl 6-[1-(difluoromethyl)cyclopropyl]-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (275 mg, 889 µmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (296 mg, 889 µmol), DBU (400 µL, 2.7 mmol), PyBOP (694 mg, 1.33 mmol) in DMF (9.6 mL) afforded the title compound (374 mg, 67% yield).

[1345] LC-MS (method 2): Rt= 1.48 min; MS (ESIpos): m / z = 624 [M+H]+

[1346] Intermediate 175

[1347] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-(difluoromethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1348]

[1349] General Procedure B - Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-(difluoromethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylate (370 mg, 593 µmol), NaOH (740 µL, 2.0 M, 1.5 mmol) in THF (6.2 mL) afforded the title compound (337 mg, 95% yield).LC-MS (method 2): Rt= 0.87 min; MS (ESIpos): m / z = 596 [M+H]+

[1350] Intermediate 176

[1351] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-(difluoromethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1352]

[1353] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-(difluoromethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid (335 mg, 562 µmol), HCI (1.4 mL, 4.0 M in 1,4-dioxane, 5.6 mmol) in MeCN (4.1 mL) and 1,4-dioxane (4.1 mL) was stirred at rt overnight. The reaction mixture was diluted with toluene and concentrated under reduced pressure (3x) to afford the desired compound (346 mg, quantitative yield).

[1354] LC-MS (method 2): Rt= 0.78 min; MS (ESIpos): m / z = 496 [M+H]+

[1355] Intermediate 177

[1356] Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3- (trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate

[1357]

[1358] General Procedure A was used - Tert-butyl (2-{2-[(1R)-1-aminoethyl]-4-chloro-6-(trifluoromethyl)phenyl}ethyl)carbamate (80.0 mg, 218 µmol), ethyl 6-methoxy-4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine-2-carboxylate (59.8 mg, 240 µmol), PyBOP (170 mg, 327 µmol), DBU (98 µL, 654µmol) in DMF (2.7 mL) afforded the desired product (105 mg, 81% yield).

[1359] LC-MS (method 2): Rt= 1.44 min; MS (ESIpos): m / z = 598 [M+H]+

[1360] Intermediate 178

[1361] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid

[1362]

[1363] General Procedure B was used - Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylate (105 mg, 176 µmol), aqueous LiOH sol. (220 µL, 2.0 M, 440 µmol) in THF (5 mL) afforded the desired product (103 mg, quantitative yield).LC-MS (method 2): Rt= 0.87 min; MS (ESIpos): m / z = 570 [M+H]+

[1364] Intermediate 179

[1365] 4-({(1R)-1-[2-(2-Aminoethyl)-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1)

[1366]

[1367] General Procedure C was used - 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-5-chloro-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxypyrido[3,4-d]pyrimidine-2-carboxylic acid (103 mg, 181 µmol), HCI (450 µL, 4.0 M in 1,4-dioxane, 1.8 mmol) in 1,4-dioxane (3 mL) afforded the desired compound (106 mg, quantitative yield).

[1368] LC-MS (method 2): Rt= 0.76 min; MS (ESIpos): m / z = 470 [M+H]+

[1369] Intermediate 180

[1370] Tert-butyl (2-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}propyl]-6- (trifluoromethyl)phenyl}ethyl)carbamate

[1371]

[1372] To a solution of di-tert-butyl {2-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6-(trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate (4.90 g, 9.32 mmol) in THF (50 mL) was added ethylmagnesium bromide (16 mL, 3.0 M in THF, 47 mmol) dropwise at -78 °C. The mixture was stirred at 25 °C for 2 hours, then quenched with water and extracted with EtOAc. The org. phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude mixture wascombined with another crude batch (obtained under similar conditions from 5.0 g di-tert-butyl {2-[2-({[(R)-2-methylpropane-2-sulfinyl]imino}methyl)-6- (trifluoromethyl)phenyl]ethyl}-2-imidodicarbonate) and purified by flash column chromatography (petroleum ether / ethyl acetate) which yielded the title compound (1.14 g, 94 % purity, 13 % yield).

[1373] LC-MS (method 3): Rt= 0.61 min; MS (ESIpos): m / z = 451.2 [M+H]+

[1374] Intermediate 181

[1375] Tert-butyl (2-{2-[(1R)-1-aminopropyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate

[1376]

[1377] To a mixture of tert-butyl (2-{2-[(1R)-1-{[(R)-2-methylpropane-2-sulfinyl]amino}propyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (6.41 g, 94 % purity, 13.4 mmol) in water (10 mL) and THF (30 mL) was added iodine (679 mg, 2.67 mmol) and the mixture was stirred at 50 °C for 16 h. The mixture was diluted with saturated aq. sodium bicarbonate solution and extracted with ethyl acetate. The organic phase was washed with saturated aq. sodium thiosulfate solution, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate, then ethyl acetate / methanol) to yield the title compound (3.18 g, 97 % purity, 67 % yield).

[1378] LC-MS (method 3): Rt= 0.46 min; MS (ESIpos): m / z = 347.2 [M+H]+

[1379] Intermediate 182

[1380] Ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]propyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate

[1381]

[1382] General Procedure A was used - ethyl 6-bromo-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (1.72 g, 5.78 mmol), tert-butyl (2-{2-[(1R)-1-aminopropyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (2.42 g, 91 % purity, 6.36 mmol), pyBOP (4.51 g, 8.67 mmol) and DIPEA (2.5 mL, 14 mmol) in DMF (44 mL) yielded the title compound (3.23 g, 89 % yield).

[1383] LC-MS (method 2): Rt= 1.48 min; MS (ESIpos): m / z = 629 [M+H]+

[1384] Intermediate 183

[1385] 6-Bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]propyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1386]

[1387] General Procedure B was used - ethyl 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]propyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylate (3.23 g, 5.16 mmol), LiOH (309 mg, 12.9 mmol) in THF (21 mL) and water (13 mL) yielded the title compound (3.08 g, 90 % purity, 90 % yield). LC-MS (method 2): Rt= 0.89 min; MS (ESIpos): m / z = 600 [M+H]+

[1388] Intermediate 1844-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]propyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid-hydrogen chloride (1 / 1)

[1389]

[1390] General Procedure C was used - 6-bromo-4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]propyl}amino)pyrido[3,4-d]pyrimidine-2-carboxylic acid (1.00 g, 1.67 mmol) and HCI (4.2 mL, 4.0 M in 1,4-dioxane, 17 mmol) in MeCN (15 mL) yielded the title compound (1.05 g, quant.).

[1391] LC-MS (method 2): Rt= 0.77 min; MS (ESIpos): m / z = 498 [M+H]+

[1392] Intermediate 185

[1393] (15R)-11-(Difluoromethyl)-13-fluoro-4,15-dimethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)- 9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1394]

[1395] A mixture of (15R)-2-bromo-11-(difluoromethyl)-13-fluoro-4,15-dimethyl-9, 10, 15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2, 6, 9]benzotriazacyclotridecin-7(8H)-one (35.0 mg, 72.9 µmol), 4,4,6-trimethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)-1,3,2-dioxaborinane (18 µL, 87 µmol), Pd(dppf)Cl2(11.3 mg, 14.6 pmol) and Cs2CO3(71.2 mg, 219 pmol) in 1,4-dioxane (1.2 mL) and water (300 pL) was stirred at 45 °C overnight. The mixture was diluted with DCM and MeOH, filtered and a small spatula of citric acid was added. Themixture was concentrated under reduced pressure and purification by flash column chromatography (DCM / EtOH) yielded the title compound (33 mg, 91 % yield).

[1396] LC-MS (method 2): Rt= 1.31 min; MS (ESIpos): m / z = 496.3 [M+H]+

[1397] Intermediate 186

[1398] Trifluoroacetic acid-(15R)-2-(azetidin-3-yl)-4,15-dimethyl-11-(trifluoromethyl)- 9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (1 / 1)

[1399]

[1400] To a solution of tert-butyl 3-[(15R)-4,15-dimethyl-7-oxo-11-(trifluoromethyl)-7,8,9,10,15,16-hexahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-2-yl]azetidine-1-carboxylate (63.0 mg, 113 pmol) and Et3SiH (1.8 pL) in DCM (3.7 mL) was added TFA (87 pL, 1.1 mmol) and the mixture was stirred at rt overnight. The mixture was concentrated under reduced pressure to yield the title compound (74.6 mg, quant.) which was used in the next step without further purification.

[1401] LC-MS (method 2): Rt= 1.02 min; MS (ESIneg): m / z = 455 [M-H]’

[1402] Intermediate 187

[1403] (15R)-15-Methyl-2-(2-oxopiperazin-1-yl)-11-(trifluoromethyl)-9, 10, 15, 16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1404]

[1405] A solution of tert-butyl 4-[(15R)-15-methyl-7-oxo-11-(trifluoromethyl)-7,8,9,10,15,16-hexahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-2-yl]-3-oxopiperazine-1 -carboxylate (60.0 mg, 102 pmol) and HCI (260 pL, 4.0 M in 1,4-dioxane, 1.0 mmol) in 1,4-dioxane (2.5 mL) was stirred at rt overnight. The mixture was basified with aq. ammonia sol. (25%) and concentrated under reduced pressure. Purification by HPLC (basic method) yielded the title compound (14.1 mg, 28 % yield).

[1406] LC-MS (method 2): Rt= 0.90 min; MS (ESIpos): m / z = 486 [M+H]+

[1407] Intermediate 188

[1408] (15R)-2-(3,3-dimethyl-2-oxopiperazin-1-yl)-15-methyl-11-(trifluoromethyl)-9, 10, 15, 16-tetrahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one — hydrogen chloride (1 / 1)

[1409]

[1410] T ert-butyl 2,2-dimethyl-4-[(15R)- 15-methyl-7-oxo-11 -(trifluoromethyl)-7,8,9, 10,15,16-hexahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-2-yl]-3-oxopiperazine-1 -carboxylate (12.5 mg, 20.4 pmol) was dissolved in 1,4-dioxane (490 pL), then 4 M HCL in 1,4-dioxane (51 pL, 200 pmol) was added and the reaction mixture was stirred at 50 °C for 18 hours. The mixture was cooled to room temperature and concentrated under reduced pressure to afford the title compound (14.0 mg, quantitative yield). The obtained material was used without further purification.

[1411] LC-MS (Method 2): Rt= 0.98 min; MS (ESIpos): m / z = 514 [M+H]+

[1412] Intermediate 189

[1413] (15R)-2-(3,3-Dimethyl-2-oxopiperazin-1-yl)-4,15-dimethyl-11-(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one — hydrogen chloride (1 / 1)

[1414]

[1415] General Procedure C was used - tert-butyl 4-[(15R)-4,15-dimethyl-7-oxo-11-(trifluoromethyl)-7,8,9, 10,15,16-hexahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-2-yl]-2,2-dimethyl-3-oxopiperazine-1-carboxylate (22.5 mg, 35.8 pmol), HCI (90 pL, 4.0 M in 1,4-dioxane, 360 pmol) in 1,4-dioxane (980 pL) afforded the title compound (26 mg, quantitative yield) which was used in the next step without further purification.

[1416] LC-MS (method 2): Rt= 1.02 min; MS (ESIpos): m / z = 528 [M+H]+

[1417] Intermediate 190

[1418] (15R)-15-Methyl-11-(trifluoromethyl)-2-(3,3,3-trifluoroprop-1-en-2-yl)-9,10,15,16-tetrahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1419]

[1420] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (50.0 mg, 107 pmol), 4,4,6-trimethyl-2-(3,3,3-trifluoroprop-1-en-2-yl)-1,3,2-dioxaborinane (28.6 mg, 129 pmol), Cs2CO3(105 mg, 322 pmol) and 1,1-bis(diphenylphosphino)ferrocenedichloropalladium(ll) (16.6 mg, 21.4 pmol) were dissolved in 1,4-dioxane (900 pL) and water (200 pL), placed under argon and heated at 45 °C for 18 hours. The reaction mixture was cooled to room temperature, diluted with DCM and MeOH and filtered through celite. The org. phase was washed with sat. aq. citric acid sol., then concentrated under reduced pressure. Purification by HPLC (basic method) afforded the title compound (25.2 mg, 49 % yield).LC-MS (method 2): Rt= 1.21 min; MS (ESIpos): m / z = 482 [M+H]+

[1421] Intermediate 191

[1422] T ert-butyl 2-bromo-5-fluoropyridine-4-carboxylate

[1423]

[1424] To a solution of 2-bromo-5-fluoropyridine-4-carboxylic acid (88.0 g, 400 mmol) in THF (500 mL) and tert-butanol (500 mL) were added di-tert-butyl dicarbonate (105 g, 480 mmol) and 4-(dimethylamino)pyridine (24.4 g, 200 mmol) at 20 °C and the mixture was stirred at 40 °C for 4 hours. The mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate) to give the title compound (102 g, 90 % purity, 83 % yield).

[1425] LC-MS (method 3): Rt= 0.63 min; MS (ESIpos): m / z = 278.0 [M+H]+

[1426] Intermediate 192

[1427] (15R)-2-[(2RS)-1-{[Tert-butyl(dimethyl)silyl]oxy}propan-2-yl]-15-methyl-11- (trifluoromethyl)-9, 10, 15, 16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (mixture of diastereomers)

[1428]

[1429] (15R)-2-(3-{[Tert-butyl(dimethyl)silyl]oxy}prop-1-en-2-yl)-15-methyl-11 -(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (65.0 mg, 117 pmol) was dissolved in EtOH (1.0 mL) under nitrogen atmosphere. Palladium (6.50 mg, 10 wt% on carbon, 61.1 pmol) was added and the atmosphere was exchanged to hydrogen gas (balloon). The mixture was stirred at RT for 3 hours. The atmosphere was exchanged to nitrogen and the mixture was filtered. The solvent wasevaporated to give the title compound (73 mg, quant.) which was used without any further purification.

[1430] LC-MS (Method 2): Rt= 1.49 min; MS (ESIpos): m / z = 560 [M+H]+

[1431] Intermediate 193

[1432] 4-({(1R)-1-[2-(2-Aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-(hydroxymethyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid hydrogen chloride (1 / 2)

[1433]

[1434] 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl}amino)-6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid (1.60 g, 1.97 mmol) was dissolved in MeCN (19 mL) at RT. HCI (4.9 mL, 4.0 M in dioxane, 20 mmol) was added and the mixture was stirred at RT for 8 hours. All volatiles were evaporated to give the title compound (1.22 g, quant.) which was used without any further purification.

[1435] LC-MS (Method 2): Rt= 0.69 min; MS (ESIpos): m / z = 476.5 [M+H]+

[1436] Intermediate 194

[1437] (15R)-2-(3-{[Tert-butyl(dimethyl)silyl]oxy}prop-1-en-2-yl)-15-methyl-11 -(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1438]

[1439] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (234 mg, 502 pmol) was dissolved in DMF (4 mL). Tert-butyl(dimethyl){[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)prop-2-en-1-yl]oxy}silane (165 mg, 552 pmol) and PdCl2(dppf) (18.4 mg, 25.1 pmol) were added, followed by potassium carbonate (208 mg, 1.51 mmol). The atmosphere was exchanged to argon and the mixtue was stirred at 80 °C for 3 days. The mixture was diluted with water. The aq. phase was extracted with EtOAc. The org. phase was washed with brine and dried. The solvent was evaporated and the residue was purified by flash column chromatography on silica gel using a mixture of hexane and EtOAc as eluent to give the title compound (148 mg, 53% yield).

[1440] LC-MS (Method 2): Rt= 1.54 min; MS (ESIpos): m / z = 558.7 [M+H]+

[1441] Intermediate 195

[1442] 4-({(1R)-1-[2-{2-[(Tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl} amino)-6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylic acid

[1443]

[1444] Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl]ethyl} amino)-6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylate (1.64 g, 1.95 mmol) was dissolved in THF (27 mL) at RT under argon atmosphere. Sodium hydroxide (2.4 mL, 2.0 M in water, 4.9 mmol) was added and the mixture was stirred overnight. The mixture was diluted with water and EtOAc. The pH value was adjusted to approx. 3 to 4 by addition of aq. HCI (2 M). The aq. phase was extracted with EtOAc, the combined org. phase was dried and the solvent was evaporated to give the title compound (1.61 g, quant.) which was used without any further purification.

[1445] LC-MS (Method 2): Rt= 1.24 min; MS (ESIpos): m / z = 814 [M+H]+

[1446] Intermediate 196

[1447] Ethyl 4-({(1R)-1-[2-{2-[(tert-butoxycarbonyl)amino]ethyl}-3-(trifluoromethyl)phenyl] ethyl}amino)-6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyrido[3,4-d]pyrimidine-2-carboxylate

[1448]

[1449] Ethyl 6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate (1.76 g, 3.34 mmol), tert-butyl (2-{2-[(1R)-1-aminoethyl]-6-(trifluoromethyl)phenyl}ethyl)carbamate (1.11 g, 3.34 mmol) and PyBOP (2.60 g, 5.00 mmol) were dissolved in DMF (31 mL) and stirred for 5 minutes at RT. DBU (1.5 mL, 10 mmol) was added and the mixture was stirred at RT overnight. The mixture was diluted with EtOAc and water. The aq. phase was extracted with EtOAc, the combined org. phase was dried and the solvent was evaporated. The residue was purified by flash column chromatography on silica gel using a mixture of hexane and EtOAc as eluent to give the title compound (1.64 g, 58% yield).

[1450] LC-MS (Method 1): Rt= 1.83 min; MS (ESIpos): m / z = 842 [M+H]+Intermediate 197

[1451] Ethyl 6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-4-hydroxypyrido[3,4-d]pyrimidine-2-carboxylate

[1452]

[1453] Ethyl ({6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-4-carbamoylpyridin-3-yl}amino)(oxo)acetate (3.06 g, 5.61 mmol) was dissolved in EtOH (220 mL) and cooled to 0 °C under argon atmosphere. Sodium ethoxide (2.3 mL, 21 wt% in EtOH, 6.2 mmol) was added and the mixture was allowed to warm to RT and stirred for 30 min. The pH value was adjusted to approximately 4 to 5 by addition of HCI (4 M in dioxane). All volatiles were evaporated and the residue was purified by flash column chromatography on silica gel using a mixture of DCM and EtOH as eluent to give the crude title compound. The crude material was triturated with a mixture of hexane and EtOAc (7 / 3). The solids were collected by filtration and then dried to give the title compound (1.76 g, 59% yield). LC-MS (Method 1): Rt= 1.65 min; MS (ESIpos): m / z = 528.5 [M+H]+

[1454] Intermediate 198

[1455] Ethyl ({6-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]-4-carbamoylpyridin-3-yl}amino)(oxo)acetate

[1456]

[1457] 5-Amino-2-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyridine-4-carboxamide (2.50 g, 5.61 mmol) was dissolved in DCM (50 mL) under argon atmosphere. Pyridine(0.91 mL) was added and the mixture was cooled to 0 °C. Ethyl chloro(oxo)acetate (940 pL, 8.4 mmol) was added and the mixture was allowed to warm to RT and stirred for 2 hours. The mixture was diluted with water and DCM. The aq. phase was extracted with DCM and the combined org. phase was dried. The solvent was evaporated to give the title compound (3.54 g, quant.) which was used without any further purification. LC-MS (Method 1): Rt= 1.57 min; MS (ESIpos): m / z = 546.5 [M+H]+

[1458] Intermediate 199

[1459] 5-Amino-2-[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]pyridine-4-carboxamide

[1460]

[1461] 5-Amino-2-[1-(hydroxymethyl)cyclopropyl]pyridine-4-carboxamide (3.36 g, 16.2 mmol) and imidazole (2.21 g, 32.4 mmol) were dissolved in DMF (50 mL) under argon atmosphere and cooled to 0 °C. A solution of tert-butyl(chloro)diphenylsilane (5.1 mL, 19 mmol) in DMF (10 mL) was added dropwise. The mixture was allowed to warm to RT and stirred for 1.5 hours. Water was added and the mixture was extracted with EtOAc. The org. phase was dried and the solvent was evaporated. The residue was purified by flash coulmn chromatography on silica gel using a mixture of hexane and EtOAc as eluent to give the title compound (6.91 g, 96% yield).

[1462] LC-MS (Method 1): Rt= 1.30 min; MS (ESIpos): m / z = 447 [M+H]+

[1463] Intermediate 200

[1464] 5-Amino-2-[1-(hydroxymethyl)cyclopropyl]pyridine-4-carboxamide

[1465]

[1466] To a solution of 2-[1-(hydroxymethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl] amino}pyridine-4-carboxamide (20.0 g, 95% purity, 58.04 mmol) in dichloromethane(150 mL) was added trifluoroacetic acid (150 mL) dropwise at 20 °C. After stirring at 20 °C for 16 hours, the mixture was concentrated in vacuo, adjusted to pH = 11 with aq.

[1467] 1 M sodium hydroxide solution and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (petroleum etherethyl acetate = 1:0 to 0:1, then ethyl acetate: methanol = 1:0 to 1:1) and further triturated with ethyl acetate (50 mL) to give the title compound (3.66 g, 98% purity, 30% yield) as a yellow solid. LC-MS (Method 3): Rt= 0.388 min; MS (ESIpos): m / z = 208.3 [M+H]+

[1468] Intermediate 201

[1469] 2-[1-(Hydroxymethyl)cyclopropyl]-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxamide

[1470]

[1471] To a solution of methyl 1-(4-carbamoyl-5-{[(4-methoxyphenyl)methyl]amino}pyridin-2-yl)cyclopropane-1-carboxylate (180.0 g, 90% purity, 455.83 mmol) in tetrahydrofuran (3 I) was added hydrido(diisobutyl)aluminium (1 mol / L in toluene, 1.37 L, 1.37 mol) dropwise at 0 °C. After stirring at 20 °C for 16 hours under nitrogen atmosphere, the mixture was quenched with sodium potassium tartrate solution and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (petroleum ether: ethyl acetate = 1:0 to 0:1) to give the title compound (64.0 g, 95% purity, 41% yield) as a yellow solid.

[1472] 1H NMR (400 MHz, DMSO-d6) 6 [ppm] = 8.14 (s, 1H), 7.94 (s, 1H), 7.80 (t, 1H), 7.52 (s, 1H), 7.41 (s, 1H), 7.26 (d, 2H), 6.89 (d, 2H), 4.59 (t, 1H), 4.35 (d, 2H), 3.72 (s, 3H), 3.70 (d, 2H), 0.93-0.87 (m, 2H), 0.78-0.72 (m, 2H).

[1473] Intermediate 202

[1474] Methyl 1-(4-carbamoyl-5-{[(4-methoxyphenyl)methyl]amino}pyridin-2-yl)cyclopropane-1-carboxylate

[1475]

[1476] To a mixture of activated zinc powder in tetrahydrofuran (4550 mL) were added iodine (186 mg, 0.74 mmol) and methyl 1 -bromocyclopropane- 1 -carboxylate (789.13 g, 4.41 mol) under nitrogen atmosphere at 20 °C and the reaction mixture was stirred at 50 °C for 16 hours (zinc reagent solution). To a solution of 2-bromo-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxamide (260.0 g, 95% purity, 734.70 mmol), 1,2,3,4,5-pentaphenyl-1'-(di-t-butylphosphino)ferrocene (CTC-Q-PHOS) (41.77 g, 58.78 mmol) and Pd2(dba)3(26.91 g, 29.39 mmol) in tetrahydrofuran (500 mL) was added (1-(methoxycarbonyl)cyclopropyl)zinc(ll) bromide (zinc reagent solution) at room temperature and the resulting mixture was stirred for 16 hours. The mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was triturated with ethyl acetate (500 mL), filtered and the filter cake was dried in vacuo to give the title compound (36.0 g, 95% purity, 13% yield) as a yellow solid. The filtrate was concentrated in vacuo and purified by flash column chromatography on silica gel (petroleum ether: ethyl acetate = 10:1 to 2:1) to give the title compound (218.0 g, 90% purity, 75% yield) as a brown solid.

[1477] 1H NMR (400 MHz, DMSO-d6) 6 [ppm] = 8.24-8.05 (m, 2H), 7.98 (s, 1H), 7.55 (s, 1H), 7.53 (s, 1H), 7.28 (d, 2H), 6.91 (d, 2H), 4.38 (d, 2H), 3.73 (s, 3H), 3.55 (s, 3H), 1.46-1.36 (m, 2H), 1.31-1.23 (m, 2H).

[1478] Intermediate 203

[1479] 2-Bromo-5-{[(4-methoxyphenyl)methyl]amino}pyridine-4-carboxamide

[1480]

[1481] To a solution of 2-bromo-5-fluoropyridine-4-carboxamide (182.00 g, 831.00 mmol) in dimethyl sulfoxide (2.00 L) were added 1-(4-methoxyphenyl)methanamine (171.00 g, 1.25 mol) and N, N-diisopropylethylamine (434.2 mL, 2.49 mol) at 20 °C. After stirring at90 °C for 16 hours, the mixture was diluted with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was triturated with ethyl acetate (100 mL), filtered and the filter cake was dried in vacuo. The filtrate was concentrated in vacuo and the residue was purified by flash column chromatography on silica gel (petroleum ether: ethyl acetate = 10:1 to 0:1), which was combined with the filter cake to give the title compound (260.0 g, 95% purity, 88% yield) as a brown solid.

[1482] LC-MS (Method 3): Rt= 0.475 min; MS (ESIpos): m / z = 336.0 [M+H]+EXPERIMENTAL SECTION - Examples

[1483]

[1484] (15R)- 15-Methyl-2, 11 -bis(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1485]

[1486] General Procedure D was used - HATU (283 mg, 745 pmol), CH2CI2 (15 mL), lithium (R)-4-((1-(2-(2-aminoethyl)-3-(trifluoromethyl)phenyl)ethyl)amino)-6-(trifluoromethyl)pyrido [3,4-d]pyrimidine-2-carboxylate (190 mg, 373 pmol), DIPEA (320 pL, 1.9 mmol), DMF (6.3 mL), CH2CI2 (11 mL) afforded the title compound (16.0 mg, 9% yield).

[1487] LC-MS (Method 2): Rt= 1.12 min; MS (ESIpos): m / z = 456 [M+H]+

[1488] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.035 (7.19), 1.052 (16.00), 1.070 (7.12), 1.178 (0.43), 1.233 (0.58), 1.627 (6.88), 1.644 (7.09), 1.751 (0.64), 1.907 (0.53), 2.518 (12.28), 2.523 (7.90), 2.686 (0.56), 2.721 (0.49), 2.743 (0.91), 2.776 (0.97), 2.801 (0.55), 2.981 (1.02), 3.248 (0.96), 3.280 (1.11), 3.404 (1.06), 3.422 (2.20), 3.434 (2.20), 3.439 (2.08), 3.451 (2.02), 3.469 (0.75), 4.114 (0.69), 4.143 (0.82), 4.167 (0.66), 4.346 (1.04), 4.359 (1.95), 4.371 (0.95), 6.154 (0.96), 6.171 (1.44), 6.189 (0.95), 7.475 (1.15), 7.494 (2.38), 7.513 (1.44), 7.615 (2.64), 7.632 (1.94), 7.925 (2.29), 7.944 (2.00), 8.307 (0.93), 8.321 (1.14), 8.343 (0.90), 8.851 (5.48), 9.247 (5.95), 9.790 (1.73), 9.808 (1.65).

[1489] Example 2

[1490] (15R)-2-Methoxy- 15-methyl-11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)dibenzo[e,j][1,4,8]triazacyclotridecin-7(8H)-one

[1491]

[1492] General Procedure D was used - HATU (67.2 mg, 177 pmol), DMF (6.5 mL), 4-({(1 R)-1-[2-(2-aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-methoxyquinazoline-2-carboxylic acid (80.0 mg, 147 pmol), DIPEA (128 pL, 740 pmol), DMF (6.5 mL) were used. Purification by HPLC (basic method) followed by prep. TLC afforded the title compound (7.9 mg, 12% yield).

[1493] LC-MS (Method 2): Rt= 1.10 min; MS (ESIpos): m / z = 417 [M+H]+

[1494] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.229 (0.40), 1.614 (3.76), 1.632 (3.82), 2.322 (0.43), 2.327 (0.61), 2.332 (0.44), 2.518 (2.16), 2.523 (1.24), 2.665 (0.92), 2.669 (0.94), 2.673 (0.79), 2.697 (0.52), 3.234 (0.45), 3.266 (0.53), 3.292 (0.43), 3.311 (0.49), 3.395 (0.84), 3.399 (0.87), 3.943 (16.00), 4.192 (0.46), 6.138 (0.54), 6.156 (0.81), 6.174 (0.53), 7.438 (1.13), 7.445 (1.18), 7.461 (1.60), 7.468 (1.47), 7.476 (1.38), 7.497 (0.83), 7.586 (1.52), 7.604 (1.09), 7.692 (2.18), 7.715 (1.81), 7.759 (1.69), 7.766 (1.66), 7.966 (1.26), 7.986 (1.15), 8.088 (0.51), 8.103 (0.66), 8.110 (0.65), 8.124 (0.52), 8.913 (1.03), 8.931 (1.00).

[1495]

[1496] (15R)-2,3-Dimethoxy-15-methyl-11-(trifluoromethyl)-9, 10, 15, 16-tetrahydro-6, 17- (azeno)dibenzo[e,j][1,4,8]triazacyclotridecin-7(8H)-one

[1497]

[1498] General Procedure D was used - HATU (512 mg, 1.35 mmol), DMF (50 mL), 4-({(1R)-1-[2-(2-aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6,7-dimethoxyquinazoline-2-carboxylic acid — hydrogen chloride (1 / 1) (730 mg, 1.22 mmol), DIPEA (2.1 mL, 12 mmol), DMF (50 mL) were used. Purification by flash column chromatography (DCMI EtOH), followed by additional purification by HPLC (basic method) afforded the title compound (42.6 mg, 7% yield).

[1499] LC-MS (Method 2): Rt= 1.08 min; MS (ESIpos): m / z = 447 [M+H]+

[1500] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.602 (4.37), 1.619 (4.43), 2.518 (1.08), 2.522 (0.65), 2.660 (0.71), 2.664 (0.69), 2.669 (0.79), 2.685 (0.45), 2.693 (0.61), 3.227 (0.54), 3.259 (0.56), 3.361 (0.64), 3.381 (0.54), 3.881 (14.80), 3.955 (16.00), 4.162 (0.44), 4.185 (0.53), 4.215 (0.42), 6.116 (0.64), 6.134 (0.96), 6.152 (0.63), 7.190 (6.36), 7.456 (0.71), 7.475 (1.59), 7.495 (0.99), 7.582 (1.81), 7.599 (1.28), 7.693 (4.37), 7.950 (1.48), 7.968 (1.34), 8.041 (0.67), 8.055 (0.84), 8.063 (0.80), 8.077 (0.64), 8.703 (1.29), 8.720 (1.23).

[1501] Example 4

[1502] (15R)- 15-Methyl-2-(trifluoromethoxy)- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1503]

[1504] General Procedure D was used - HATU (351 mg, 922 pmol), CH2CI2 (36 mL) and DMF (9.7 mL), DIPEA (540 pL, 3.1 mmol), 4-({(1R)-1-[2-(2-aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethoxy)pyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1) (404 mg, 768 pmol), CH2CI2 (36 mL) and DMF (10.7 mL) were used. Purification by HPLC (basic method) afforded the title compound (61.0 mg, 17% yield).

[1505] LC-MS (Method 2): Rt= 1.16 min; MS (ESIpos): m / z = 472 [M+H]+

[1506] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.612 (13.30), 1.629 (13.57), 2.336 (0.57), 2.518 (5.32), 2.522 (3.26), 2.678 (0.62), 2.696 (0.93), 2.719 (1.75), 2.728 (1.19), 2.744 (1.23), 2.752 (1.80), 2.777 (0.98), 3.218 (0.76), 3.240 (1.54), 3.271 (1.70), 3.295 (1.32), 3.357 (1.98), 3.378 (1.58), 3.392 (1.01), 4.116 (1.30), 4.140 (1.56), 4.169 (1.24), 6.117 (0.48), 6.135 (1.92), 6.153 (2.92), 6.170 (1.91), 6.186 (0.45), 7.470 (2.11), 7.490 (4.67), 7.509 (2.86), 7.608 (5.28), 7.626 (3.83), 7.918 (4.40), 7.937 (3.99), 8.214 (12.77), 8.259 (1.94), 8.273 (2.43), 8.281 (2.28), 8.295 (1.88), 9.022 (16.00), 9.571 (3.61), 9.589 (3.49).

[1507]

[1508] (15R)- 15-Methyl-2, 11 -bis(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[2,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1509]

[1510] General Procedure D was used - HATU (224 mg, 588 pmol), CH2CI2 (12 mL), 4-({(1R)-1-[2-(2-aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1) (150 mg, 294 pmol), DIPEA (256 pL, 1.47 mmol), CH2CI2 (9 mL) and DMF (5 mL) were used. Purification by HPLC (basic method) afforded the title compound (20.0 mg, 14% yield).

[1511] LC-MS (Method 2): Rt= 1.21 min; MS (ESIpos): m / z = 456 [M+H]+

[1512] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.156 (0.40), 1.232 (0.79), 1.352 (0.52), 1.668 (10.03), 1.685 (10.19), 1.904 (0.41), 2.209 (0.43), 2.383 (0.82), 2.518 (16.00), 2.523 (10.11), 2.679 (2.09), 2.755 (0.72), 2.778 (1.41), 2.812 (1.41), 2.834 (0.80), 2.891 (1.03), 2.956 (0.49), 3.239 (1.31), 3.270 (1.54), 3.381 (1.24), 4.150 (1.02), 4.181 (1.23), 4.202 (0.98), 6.206 (1.43), 6.225 (2.14), 6.243 (1.45), 7.451 (1.69), 7.471 (3.54), 7.491 (2.07), 7.594 (3.95), 7.611 (2.89), 8.219 (3.33), 8.238 (3.07), 8.257 (10.08), 8.267 (1.62), 8.279 (13.13), 8.304 (1.51), 8.413 (5.62), 8.435 (4.17), 9.646 (2.89), 9.665 (2.62).

[1513] Example 6

[1514] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1515]

[1516] General Procedure D was used - 4-({(1R)-1-[2-(2-aminoethyl)-3- (trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1) (1.39 g, 73 % purity, 1.95 mmol), DIPEA (1.4 mL, 7.8 mmol) in DCM (1.0 L) and DMF (200 mL) was added to HATU (1.85 g, 4.87 mmol) in DCM (1.2 L). The crude reaction mixture was directly purified by preparative HPLC purification (basic method) to give the desired compound (492 mg, 54 % yield).

[1517] LC-MS (Method 2): Rt= 1.12 min; MS (ESIpos): m / z = 466 [M+H]+

[1518] 1H-NMR (400 MHz, DMSO-d6) 6 [ppm]: 1.602 (12.68), 1.620 (12.89), 1.751 (14.54), 2.518 (3.45), 2.523 (2.32), 2.693 (0.87), 2.717 (1.66), 2.726 (1.10), 2.741 (1.15), 2.750 (1.69), 2.774 (0.91), 3.211 (0.72), 3.233 (1.47), 3.265 (1.57), 3.289 (1.06), 3.319 (0.68), 3.339 (1.08), 3.353 (1.55), 3.373 (1.53), 3.389 (1.08), 3.410 (0.60), 4.100 (1.25), 4.130 (1.50), 4.152 (1.19), 6.098 (0.46), 6.114 (1.84), 6.131 (2.82), 6.149 (1.80), 6.166 (0.44), 7.468 (2.00), 7.487 (4.44), 7.507 (2.70), 7.608 (4.96), 7.625 (3.65), 7.920 (4.16), 7.939 (3.76), 8.264 (1.79), 8.279 (2.26), 8.286 (2.11), 8.300 (1.74), 8.576 (12.09), 8.966 (16.00), 9.610 (3.29), 9.628 (3.18).

[1519] Example 7

[1520] (15R)-2-Bromo-8, 15-dimethyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1521]

[1522] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (300 mg, 643 pmol) and NaH (56.1 mg, 55 % in mineral oil, 1.29 mmol) in THF (14 mL) were stirred for 30 min at room temperature, lodomethane (80 pL, 1.3 mmol) was added and the reaction mixture was stirred over night at room temperature. Aq. citric acid sol. (0.5 M) was added, and the mixture was extracted with EtOAc (3x), and the combined org. phases were washed with brine, filtered through hydrophobic filter paper, and concentrated under reduced pressure. Purification by flash column chromatography (C^Ch / EtOH) yielded the desired product (21.7 mg, 7% yield).LC-MS (Method 2): Rt= 1.19 min; MS (ESIneg): m / z = 478 [M-H]⁻

[1523] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.797 (0.49), 0.813 (0.52), 0.821 (0.64), 0.850 (0.43), 0.903 (0.61), 1.035 (3.56), 1.052 (6.88), 1.069 (3.40), 1.190 (0.58), 1.230 (1.14), 1.604 (5.14), 1.621 (5.26), 1.907 (2.64), 2.518 (1.77), 2.523 (1.11), 3.090 (16.00), 3.102 (0.76), 3.133 (0.69), 3.140 (0.78), 3.167 (0.84), 3.273 (0.44), 3.294 (0.94), 3.316 (0.90), 3.330 (1.10), 3.410 (2.10), 3.428 (3.98), 3.445 (3.44), 3.463 (1.67), 3.492 (0.62), 4.037 (0.50), 4.062 (0.59), 4.091 (0.43), 6.134 (0.72), 6.152 (1.12), 6.169 (0.71), 7.479 (0.79), 7.499 (1.76), 7.519 (1.07), 7.620 (1.98), 7.636 (1.44), 7.925 (1.62), 7.944 (1.44), 8.546 (5.04), 8.953 (6.21), 8.955 (6.18), 9.563 (1.33), 9.581 (1.27).

[1524] Example 8

[1525] (15R)-2-Bromo-4, 15-dimethyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1526]

[1527] General Procedure E was used - (15R)-2-bromo-15-methyl-11-(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (10.0 mg, 21.4 pmol), nitromethane (12 pL, 210 pmol), and 1,8-diazabicyclo(5.4.0)undec-7-ene (6.40 pL, 42.9 pmol) in DMSO (200 pL) afforded the title compound (2.80 mg, 26% yield).

[1528] LC-MS (Method 2): Rt= 1.19 min; MS (ESIpos): m / z = 480 [M+H]+

[1529] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.547 (0.58), 1.589 (6.02), 1.606 (5.95), 1.727 (0.71), 1.743 (0.56), 1.751 (0.83), 2.323 (0.41), 2.327 (0.57), 2.332 (0.43), 2.523 (1.46), 2.665 (0.58), 2.670 (1.00), 2.673 (1.16), 2.698 (0.56), 2.707 (0.82), 2.744 (16.00), 3.129 (0.54), 3.202 (0.48), 3.226 (0.88), 3.235 (0.84), 3.258 (1.61), 3.282 (1.67), 4.102 (0.56), 4.132 (0.69), 4.156 (0.54), 6.114 (1.32), 6.131 (1.31), 7.458 (0.89), 7.478 (1.98), 7.497 (1.21), 7.598 (2.25), 7.617 (1.64), 7.920 (1.87), 7.940 (1.70), 8.250 (0.79), 8.265 (1.01), 8.272 (0.98), 8.286 (0.80), 8.378 (4.73), 8.575 (0.69).

[1530]

[1531] (15R)-2-Bromo-4-ethyl-15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1532]

[1533] General Procedure E was used - (15R)-2-bromo-15-methyl-11-(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (200 mg, 429 pmol), nitroethane (310 pL, 4.3 mmol), and 1,8-diazabicyclo(5.4.0)undec-7-ene (130 pL, 860 pmol) in DMSO (4 mL) afforded the title compound (201 mg, 95% yield).

[1534] LC-MS (Method 2): Rt= 1.27 min; MS (ESIpos): m / z = 494 [M+H]+

[1535] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.848 (0.68), 0.865 (0.58), 0.903 (0.66), 1.207 (6.36), 1.226 (16.00), 1.244 (6.60), 1.593 (5.76), 1.610 (5.87), 2.083 (2.60), 2.323 (0.54), 2.327 (0.73), 2.332 (0.50), 2.518 (1.80), 2.523 (1.17), 2.665 (0.61), 2.669 (0.87), 2.674 (0.89), 2.679 (1.00), 2.712 (0.82), 2.736 (0.44), 3.149 (0.48), 3.167 (1.08), 3.186 (2.47), 3.201 (2.73), 3.204 (2.99), 3.219 (2.48), 3.238 (1.48), 3.256 (1.08), 3.283 (0.53), 3.374 (0.71), 3.388 (0.51), 4.099 (0.57), 4.125 (0.72), 4.155 (0.54), 6.107 (0.70), 6.124 (1.01), 6.140 (0.66), 7.460 (0.97), 7.480 (2.09), 7.499 (1.26), 7.600 (2.37), 7.618 (1.71), 7.920 (1.95), 7.939 (1.74), 8.086 (1.15), 8.254 (0.89), 8.269 (1.03), 8.278 (1.00), 8.292 (0.83), 8.387 (5.78), 9.454 (1.24), 9.471 (1.15).

[1536] Example 10

[1537] (15R)-2-Bromo-4-(difluoromethyl)-15-methyl-11-(trifluoromethyl)-9,10,15,16-tetrahydro-6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1538]

[1539] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (70.0 mg, 0.150 mmol), zinc bis(difluoromethanesulfinate) (88.7 mg, 0.300 mmol), and (Ir[dF(CF3)ppy]2(dtbpy))PF6 (8.4 mg, 0.008 mmol) were dissolved in DMF (1.40 mL), placed under argon and irradiated with light (427 nm) for 18 hours. The reaction mixture was diluted with water and extracted into DCM (3x). The combined org. phases were dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by HPLC (basic method) afforded the title compound (9.0 mg, 12% yield).

[1540] LC-MS (Method 2): Rt= 1.19 min; MS (ESIpos): m / z = 516 [M+H]+

[1541] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.833 (1.36), 0.850 (3.36), 0.867 (1.14), 1.230 (16.00), 1.451 (0.63), 1.469 (0.53), 1.612 (5.84), 1.629 (6.02), 1.969 (0.81), 1.986 (1.61), 2.005 (1.70), 2.024 (0.92), 2.075 (4.12), 2.523 (2.32), 2.703 (0.42), 2.728 (0.86), 2.761 (0.85), 2.784 (0.45), 3.232 (0.74), 3.263 (0.81), 3.289 (0.71), 3.380 (0.64), 4.081 (0.61), 4.111 (0.76), 4.135 (0.60), 5.310 (0.51), 5.321 (0.92), 5.333 (0.48), 6.160 (0.93), 7.472 (1.03), 7.492 (2.34), 7.512 (1.32), 7.613 (2.70), 7.620 (3.24), 7.630 (1.93), 7.754 (1.08), 7.918 (2.00), 7.938 (1.83), 8.332 (0.80), 8.347 (1.01), 8.354 (0.99), 8.369 (0.78), 8.749 (3.62), 9.770 (1.05).

[1542] Example 11

[1543] (15R)-2-Chloro- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1544]

[1545] General Procedure D was used - 4-({(1R)-1-[2-(2-aminoethyl)-3- (trifluoromethyl)phenyl]ethyl}amino)-6-chloropyrido[3,4-d]pyrimidine-2-carboxylic acid — hydrogen chloride (1 / 1) (202 mg, 424 pmol), DIPEA (220 pL, 1.3 mmol) in DCM (20 mL) and DMF (5.0 mL) was added to HATU (177 mg, 467 pmol) in DCM (15 mL). Purification by HPLC (basic method) afforded the title compound (69.9 mg, 37% yield).

[1546] LC-MS (Method 2): Rt= 1.09 min; MS (ESIneg): m / z = 420 [M-H]-

[1547] 1H-NMR (400 MHz, DMSO-d6) 6 [ppm]: 1.227 (1.65), 1.603 (14.98), 1.620 (15.11), 2.684 (1.28), 2.708 (2.09), 2.741 (2.19), 2.765 (1.16), 3.212 (0.94), 3.234 (1.95), 3.266 (2.12), 3.290 (1.49), 3.377 (1.99), 3.391 (1.32), 4.106 (1.64), 4.130 (2.04), 4.159 (1.54), 6.117 (2.24), 6.134 (3.42), 6.152 (2.23), 7.466 (2.42), 7.486 (5.28), 7.506 (3.28), 7.606 (6.02), 7.624 (4.46), 7.917 (5.06), 7.936 (4.65), 8.252 (2.23), 8.266 (2.86), 8.274 (2.75), 8.288 (2.17), 8.424 (13.95), 8.999 (16.00), 9.550 (4.13), 9.568 (4.07).

[1548] Example 12

[1549] (15R)-2-Chloro-4, 15-dimethyl-11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1550]

[1551] General Procedure E was used - (15R)-2-chloro-15-methyl-1 l-(trifluoromethyl)-9,10,15,16-tetrahydro-6, 17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (59.0 mg, 140 pmol), nitromethane (38 pL, 700 pmol), and 1,8-diazabicyclo(5.4.0)undec-7-ene (42 pL, 280 pmol) in DMSO (1.5 mL) afforded the title compound (38.5 mg, 62% yield).

[1552] LC-MS (Method 2): Rt= 1.17 min; MS (ESIneg): m / z = 434 [M-H]-

[1553] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.229 (0.43), 1.594 (5.55), 1.612 (5.53), 2.075 (0.99), 2.327 (0.53), 2.518 (1.30), 2.523 (0.83), 2.665 (0.56), 2.670 (1.00), 2.673 (1.05), 2.697 (0.50), 2.706 (0.76), 2.731 (0.54), 2.751 (16.00), 3.230 (0.62), 3.262 (0.66), 3.285 (0.44), 3.353 (0.71), 3.375 (0.60), 3.389 (0.40), 4.106 (0.53), 4.136 (0.62), 4.159 (0.49), 6.111 (0.79), 6.129 (1.21), 6.146 (0.77), 7.460 (0.87), 7.480 (1.92), 7.499 (1.17), 7.601(2.15), 7.618 (1.59), 7.920 (1.78), 7.939 (1.61), 8.244 (4.89), 8.257 (0.83), 8.271 (0.98), 8.279 (0.93), 8.293 (0.76), 9.434 (1.50), 9.452 (1.43).

[1554] Example 13

[1555] (15R)-2-Chloro-8, 15-dimethyl-11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1556]

[1557] (15R)-2-Chloro- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17-(azeno)pyrido [4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one (32.0 mg, 75.9 pmol) was dissolved in THF (1.7 mL). NaH (4.30 mg, 55 % in mineral oil, 98.6 pmol) was added at RT and the reaction mixture was stirred for 30 min. lodomethane (7.1 pL, 114 pmol) was added and the mixture was stirred at room temperature overnight. Additional NaH (1.66 mg, 55 % in mineral oil, 37.9 pmol) was added and the mixture was stirred at room temperature for 4 hours. Additional NaH (1.66 mg, 55 % in mineral oil, 37.9 pmol) was added and the mixture was stirred overnight. Additional NaH (1.66 mg, 55 % in mineral oil, 37.9 pmol) was added and the mixture was stirred for 3 hours and then iodomethane (2.4 pL, 37 pmol) was added and the mixture was stirred overnight. The mixture was quenched with aq. citric acid and then diluted with EtOAc. The org. phase was washed with brine and filtered through hydrophobic filter paper. The solvent was concentrated under reduced pressure and the residue was purified by HPLC (basic method) to give the title compound (8 mg, 94% purity, 23% yield).

[1558] LC-MS (Method 2): Rt= 1.19 min; MS (ESIneg): m / z = 434 [M-H]-

[1559] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.606 (5.20), 1.624 (5.21), 2.518 (3.40), 2.523 (2.27), 3.091 (16.00), 3.103 (1.74), 3.131 (0.66), 3.139 (0.72), 3.166 (0.78), 3.298 (0.91), 3.473 (0.52), 3.494 (0.45), 3.785 (0.86), 4.041 (0.48), 4.067 (0.56), 4.097 (0.42), 6.138 (0.72), 6.155 (1.11), 6.173 (0.72), 7.478 (0.77), 7.499 (1.73), 7.518 (1.04), 7.619 (1.94), 7.636 (1.41), 7.928 (1.58), 7.946 (1.41), 8.409 (5.40), 8.411 (5.41), 8.990 (5.89), 8.992 (5.70), 9.557 (1.32), 9.575 (1.24).

[1560]

[1561] (15R)-2-Bromo- 15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro-6, 17- (azeno)dibenzo[e,j][1,4,8]triazacyclotridecin-7(8H)-one

[1562]

[1563] General Procedure D was used - HATU (279 mg, 733 pmol), DCM (50 mL), 4-({(1R)-1-[2-(2-aminoethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromoquinazoline-2-carboxylic acid - hydrogen chloride (1 / 1) (172 mg, 74 % purity, 244 pmol), and DI PEA (430 pL, 2.4 mmol) in DCM (15 mL) and DMF (5 mL) were used. Purification by HPLC (basic method) afforded the title compound (22.2 mg, 19% yield).

[1564] LC-MS (Method 2): Rt= 1.19 min; MS (ESIpos): m / z = 465 [M+H]+

[1565] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 1.227 (0.44), 1.592 (15.83), 1.609 (16.00), 1.751 (0.60), 2.323 (0.93), 2.327 (1.32), 2.332 (0.88), 2.518 (3.38), 2.523 (2.22), 2.646 (1.02), 2.669 (3.36), 2.679 (1.73), 2.703 (2.10), 2.727 (1.15), 3.207 (0.85), 3.230 (1.73), 3.263 (1.86), 3.286 (1.25), 3.356 (2.57), 3.378 (1.93), 3.393 (1.08), 4.130 (1.49), 4.152 (1.79), 4.183 (1.42), 6.119 (2.28), 6.136 (3.43), 6.154 (2.20), 6.172 (0.56), 7.456 (2.44), 7.475 (5.47), 7.495 (3.35), 7.593 (6.15), 7.610 (4.49), 7.692 (12.55), 7.714 (14.67), 7.931 (7.51), 7.936 (7.93), 7.946 (5.37), 7.953 (6.78), 7.958 (7.04), 7.965 (4.81), 8.174 (2.21), 8.188 (2.74), 8.196 (2.60), 8.210 (2.15), 8.639 (9.95), 8.644 (9.80), 9.223 (4.25), 9.241 (4.16).

[1566] Example 15

[1567] (15R)-2-Bromo- 10, 10-difluoro-15-methyl- 11 -(trifluoromethyl)-9, 10,15,16-tetrahydro- 6,17-(azeno)pyrido[4,3-d][2,6,9]benzotriazacyclotridecin-7(8H)-one

[1568]

[1569] General Procedure D was used - HATU (123 mg, 322 pmol) in DCM (20 mL), 4-({(1R)-1-[2-(2-amino-1,1-difluoroethyl)-3-(trifluoromethyl)phenyl]ethyl}amino)-6-bromopyrido[3,4-d]pyrimidine-2-carboxylic acid - hydrogen chloride (1 / 1) (59.8 mg, 107 pmol), and DIPEA (190 pL, 1.1 mmol) in dichloromethane (20 mL) and DMF (4 mL) were used. Purification by HPLC (basic method) afforded the title compound (9.50 mg, 98 % purity, 17 % yield). LC-MS (Method 2): Rt= 1.05 min; MS (ESIpos): m / z = 504 [M+H]+

[1570] 1H-NMR (400 MHz, DMSO-d6) 5 [ppm]: 0.940 (1.01), 0.957 (0.96), 1.232 (0.66), 1.651 (0.43), 1.669 (0.49), 1.706 (12.62), 1.723 (12.83), 1.746 (0.90), 2.518 (8.64), 2.523 (5.29), 2.660 (0.76), 2.686 (0.50), 2.864 (0.54), 2.881 (0.72), 3.696 (0.78), 3.713 (0.95), 3.734 (1.26), 3.742 (1.16), 3.751 (1.19), 3.758 (1.30), 3.779 (0.93), 3.796 (0.80), 5.209 (1.58), 5.224 (1.59), 5.855 (0.51), 5.877 (0.60), 5.906 (0.51), 5.936 (0.50), 5.965 (0.59), 5.995 (0.51), 6.562 (0.40), 7.561 (1.72), 7.580 (4.14), 7.600 (2....

Claims

CLAIMS1. A compound of formula (I)formula (I)in which,X represents N or C-R10, in whichR10represents -H, -F, -Cl, -Br,optionally substituted with 1 or 2 -F; C1-3 alkyl optionally substituted with 1 to 3 -F; C1-3 alkoxy, -OCHF2, -OCF3, -OCH2CHF2, or -OCH2CF3; andY represents C-H, N, or C-F; andR1represents-H; or-F, -Cl, -Br, or -I; orC1-4 alkyl optionally substituted with 1 to 6 -F, or 1 to 2 -OH; orC1-6 alkoxy optionally substituted with 1 to 6 -F, or 1 to 2 -OCH3; or-OCD3; or-OR11a, in whichR11arepresents C3-7 cycloalkyl, C3-6 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the followingsubstituents -F, -CH3, -OCH3, or mixtures thereof; orCs-s heteroaryl optionally substituted with 1 or 2 of the followingsubstituents -F,, C1-3 alkyl, or mixtures thereof, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or-O-CH2-R11b, in whichR11brepresents C3-7 cycloalkyl, or C3-6 heterocyclyl, both optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or-P(=O)R12aR12b, -S(=O)2R12a, in whichR12aand R12bindependently from each other represent C1-3 alkyl,; or in which R12aand R12bin -P(=O)R12aR12btogether with the phosphor atom they are attached to form a 5 or 6 membered ring which can be saturated or unsaturated; oreach R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CI, -CH2I, or -CH2OH; and W represents O, or NR14, in whichR14represents -H, C1-3 alkyl optionally substituted with 1 to 3 -F; orZ represents C(=O), or S(=O)2; andR15a, R15b, R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15a, R15b, R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15a, R15b, R15c, R15d, R15eand R15frepresent -H; orT represents C=O, or S(=O)2; andR16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, 16b, 16c, p16djRl6e, Rl6f 16ganc| Rl6h bounc| to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; andR17represents-CH2-CF3, -CH2-CHF2, -C(=O)O-C(CH3)3; or-NR18aR18b, in whichR18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3, or -C(=O)O-C(CH3)3; orNQ N-R19, in whichR19represents -H, -CH3, -CH2-CHF2, -CH2-CF3, or -C(=O)O-C(CH3)3; orwhichnd R20cindependently from each other represent -H,-CH3, -CHF2, or -CF3; andR2represents -H, -F, -Cl, -CD3, -CHD2, C1-4 alkyl optionallysubstituted with 1 to 3 -F or with 1 -OH;optionallysubstitutedor -C=C-R21in which R21representsR3represents C1-3 alkyl optionally substituted with 1 or 2 -F; -C=CH,p4a p4b independently from each other represent -H, or -F; andR5represents -H, -F, -Cl, -Br, or -CH3; andR6represents -H, -F, -Cl, -Br, C1-3 alkyl optionally substituted with1 to 3 -F;optionally substituted with 1 to 2 -F; -OCHF2, -OCF3, -C=CH, or -C=C-CH3; andR7a, R7bindependently from each other represent -H, -F, or -CH3; and / or p8a p8b represent independently from each other -H, or -CH3; and / orR7aand R8arepresent both -H and R7band R8btogether form a double bond;andR9represents -H, CM alkyl optionally substituted with 1 -OH, -CD3, -CHF2, -CF3, -CH2-CHF2, or -CH2-CF3;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

2. The compound according to claim 1, wherein:X represents N or C-R10, in whichR10represents -H, -F, -Cl, -Br,optionally substituted with 1 or 2 -F; C1-3 alkyl optionally substituted with 1 to 3 -F; C1-3 alkoxy, -OCHF2, -OCF3, -OCH2CHF2, or -OCH2CF3; andY represents C-H, N, or C-F; andR1represents-F, -Cl, -Br, -I; orC1-3 alkyl optionally substituted with 1 to 6 -F; orC1-6 alkoxy optionally substituted with 1 to 6 -F, or 1 to 2 -OCH3; or-OCD3-OR11a, in whichR11arepresents C3-6 cycloalkyl, C3-5 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; orCs-s heteroaryl optionally substituted with 1 or 2 C1-3 alkyl, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or-O-CH2-R11b, in whichR11brepresents C3-7 cycloalkyl, or C3-6 heterocyclyl; or-P(=O)R12aR12b, -S(=O)2R12a, in whichR12aand R12bindependently from each other represent -CH3, -CH2-CH3; or in which R12aand R12bin -P(=O)R12aR12btogether with the phosphor atom they are attached to form a 5 or 6 membered ring which can be saturated or unsaturated; orZ represents C(=O), or S(=O)2; andR15a, R15b, R15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15a, R15b, R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15a, R15b, R15c, R15d, R15eand R15frepresent -H; orT represents C=O, or S(=O)2; andR16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; andR17represents-CH2-CF3, -CH2-CHF2, -C(=O)O-C(CH3)3; or-NR18aR18b, in whichR18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3, -C(=O)O-C(CH3)3; specificR20a, R20band R20cindependently from each other represent -H, -CH3, -CHF2, or -CF3; andR2represents -H, -F, -Cl, -CD3, -CHD2, C1-4 alkyl optionallysubstituted with 1 to 3 -F or withoptionallysubstituted with 1 to 2 -F;, -OCH3, -OCHF2, or-OCF3, -C=C-R21in which R21representsandR3represents C1-3 alkyl optionally substituted with 1 or 2 -F; -C=CH,R4a, R4bindependently from each other represent -H, or -F; andR5represents -H, -F, -Cl, or -CH3; andR6represents -H, -F, -Cl, C1-3 alkyl optionally substituted with 1 to 3-F;optionally substituted with 1 to 2 -F; -OCHF2, -OCF3, -C=CH, or -C=C-CH3; andR7a, R7bindependently from each other represent -H, -F, or -CH3; andR8a, R8brepresents independently from each other -H, or -CH3; andR9represents -H, C1-4 alkyl optionally substituted with 1 -OH,-CD3, -CH2-CHF2, or -CH2-CF3;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

3. The compound according to claim 1 or 2, whereinX represents N or C-R10, in whichR10represents -H, -F, or C1-3 alkyl optionally substituted with 1 to 3 -F; andY represents C-H; andR1represents-Br, -I; orC1-3 alkyl optionally substituted with 1 to 3 -F; orC1-4 alkoxy optionally substituted with 1 to 4 -F, or 1 -OCH3; or-OCD3-0R11a, in whichR11arepresents C3-5 cycloalkyl, C3-4 heterocyclyl, or phenyl all three optionally substituted with 1 to 4 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; orCs-s heteroaryl optionally substituted with 1 or 2 C1-3 alkyl, in which the C1-3 alkyl can optionally be substituted with 1 to 3 -F; or-O-CH2-R11b, in whichR11brepresents C3-4 cycloalkyl, or C3-4 heterocyclyl; orR15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15c, R15d, R15eand R15frepresent -H; orindependently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; and R17represents -H, -CH3, -CH2-CH3,-NR18aR18b, in whichR18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H,-CH3, -CH2-CHF2, -CH2-CF3; specific examples of such ringsR20a, R20band R20cindependently from each other represent -H, -CH3, -CHF2, or -CF3; andR2represents -H, -CD3, -CHD2, C1-4alkyl optionally substituted with1 to 3 -F or with 1optionally substituted with 1 to 2 -F; -OCH3, -OCHF2, -OCF3’, -C CH, or -C C-R21in whichR21representsR3represents C1-2alkyl optionally substituted with 1 or 2 -F; or -C=CH; andR4a, R4brepresent -H; andrepresents -H, or -F; andrepresents -Cl, C1-3 alkyl optionally substituted with 1 to 3 -F;-OCHF2, or -OCF3; andR7a, R7brepresent -H; andrepresents -H; andrepresents -H, -CD3, -CH2-CHF2;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

4. The compound according to claim 1, 2 or 3, wherein:X represents N; andY represents C-H;R1representsC1-3 alkyl optionally substituted with 1 to 3 -F; orC1-4 alkoxy optionally substituted with 1 to 4 -F; or-OCD3-OR11a, in whichR11arepresents C3-4 cycloalkyl, or C3-4 heterocyclyl, both optionally substituted with 1 to 2 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or C3-4 heteroaryl optionally substituted with 1 or 2 of the following substituents -CH3, -CHF2, -CF3, -CH2-CHF2, -CH2-CF3; or-O-CH2- R11b, in whichR11brepresents C3-4 cycloalkyl,; orin whicheach R13independently from each other represents -H, -F, -CH3, -CH2F, -CHF2, -CF3, or -CH2OH; orR15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3and all remaining of R15c, R15d, R15eand R15frepresent -H; ornt independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e,R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; andR17represents-CH2-CF3, -CH2-CHF2; or-NR18aR18b, in whichR18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3,; specific examples of such ringswhich R20a, R20band R20cindependently from each other represent -H, -CH3, -CHF2, or -CF3; andR2represents -H, -CD3, C1-3 alkyl optionally substituted with 1 to 3R3represents C1-2 alkyl optionally substituted with 1 or 2 -F; or -C≡CH; andR4a, R4brepresent -H; andR5represents -H, or -F; andR6represents C1-2 alkyl optionally substituted with 1 to 3 -F;-OCHF2, or -OCF3; andR7a, R7brepresent -H; andR8a, R8brepresents -H; andR9represents -H;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

5. The compound according to claim 1, 2, or 3, whereinY represents C-Hand a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

6. The compound according to claim 1, 2, 3, or 5 whereinR7a, R7brepresent -H; andR8a, R8brepresent -H; andR9represents -H;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

7. The compound according to claim 1, 2, 3, 5, or 6 whereinR1represents C1-3 alkyl optionally substituted with 1 to 3 -F; orC1-4 alkoxy optionally substituted with 1 to 4 -F; or-OCD3and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

8. The compound according to claim 1, 2, 3, 5, or 6 whereinR1represents -OR11a, in whichR11arepresents C3-4 cycloalkyl, or C3-4 heterocyclyl, both optionally substituted with 1 to 2 of the following substituents -F, -CH3, -OCH3, or mixtures thereof; or C3-4 heteroaryl optionally substituted with 1 or 2 of the following substituents -CH3, -CHF2, -CF3, -CH2-CHF2, -CH2-CF3; or-O-CH2-R11b, in whichand a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

9. The compound according to claim 1, 2, 3, 5, or 6 whereineach R13independently from each other represents -H, -F, -CH3,-CH2F, -CHF2, -CF3, or-CH2OHand a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

10. The compound according to claim 1, 2, 3, 5, or 6 whereinR15c, R15d, R15eand R15findependently from each other represent -H, or a maximum of 2 of R15c, R15d, R15eand R15frepresent -CH3 and all remaining of R15c, R15d, R15eand R15frepresent -H; orR16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hrepresent independently from each other -H, -F, -CH3; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to the same atom together with the carbon atom they are attached to form a 3-membered ring; or in which two of R16a, R16b, R16c, R16d, R16e, R16f, R16gand R16hbound to 2 different carbon atoms which are not directly adjacent to each other form a bridge with 1 or 2 bridging carbon atoms; andR17represents -H, -CH3, -CH2-CH3, -CH(CH3)2,-CH2-CF3, -CH2-CHF2;orand a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

11. The compound according to claim 1, 2, 3, 5, or 6 whereinR1represents -NR18aR18b, in whichR18aand R18btogether with the nitrogen atom they are attached to form a 4 to 6 membered saturated or unsaturated ring, in which the 4 to 6 membered ring can comprise 1 additional hetero atom which is selected from nitrogen and oxygen; and in which each carbon atom in the 4 to 6 membered ring can be substituted with =0, or -CH3, or if the carbon atoms are not directly attached to any hetero atom can also be substituted with -OCH3, -F, or -Cl; and in which when the additional heteroatom is nitrogen, the nitrogen can be substituted with one residue selected from -H, -CH3, -CH2-CHF2, -CH2-CF3; specificexamples of such rings includeindependently from each other represent -H, -CH3, -CHF2, or -CF3;and a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a tautomer, or a pharmaceutically acceptable salt of an N-oxide, or a mixture of same.

12. A compound of general formula (I) according to any one of claims 1 to 11 for use in the treatment or prophylaxis of a disease.

13. A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 11 and one or more pharmaceutically acceptable excipients.

14. Use of a compound of general formula (I) according to any one of claims 1 to 11 for the treatment or prophylaxis of a disease.

15. Use according to claim 12, 14 or 16, wherein the disease is a hyperproliferative or genetic disorder, such as cancer, for example.

16. Use of a compound of general formula (I) according to any one of claims 1 to 11 for the preparation of a medicament for the treatment or prophylaxis of a disease.